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Abstract 
The rationale behind this work is the discovery that a number of natural 
bromophenols from algae have antibiotic and antioxidant activities. Most natural 
compounds are based on phenol and catechol. Previous studies by the group 
investigated a novel class of halogenated compounds based on resorcinol dimers which 
showed a relatively high antimicrobial activity. In this work, the structures were 
modified further in order to develop a structure-activity relationship for these systems. 
A novel synthetic approach to brominated resorcinol dimers was developed to 
allow efficient synthesis of the products without chromatographic purification. The 
method was additionally applied to the synthesis of a novel class of tetrameric and 
hexameric derivatives. Halogenation and dehalogenation methods were put in place to 
provide additional variety to the derivatives accessible. A set of simplified structures, 
including benzophenones and xanthones, was also prepared for comparison. 
The polyvalent structure of the tetramers and hexamers was investigated and 
exploited for the synthesis of dendrimeric multicalix[4]arene structures, including an 
octacalix[4]arene presenting thirty two amines, as proof of concept for the development 
of novel dendrimers, and among these new potential transfection agents and DNA 
binding structures. 
The library of compounds thus obtained was screened for its effects on the viability of 
two cancer cell lines, MCF-7 and HL60. The results showed a varied profile, ranging 
from potent antiproliferative activity to compounds with very moderate effects. 
Additionally the potential antioxidant activity of the compounds was investigated with 
two in vitro assays and for their cytoprotective activity on MCF-7 cells. 
  
 iii 
Table of Contents 
 
List of Figures .............................................................................................................viii 
List of Schemes ........................................................................................................... xiv 
List of Tables .............................................................................................................. xvii 
List of Abbreviations .................................................................................................xviii 
Acknowledgments .......................................................................................................... 1 
1. Introduction ............................................................................................................ 2 
1.1 Antimicrobials and resistance .............................................................................. 2 
1.1.1 Drug Targets .................................................................................................. 3 
1.1.2 Modes of Resistance and Transmission ........................................................ 4 
1.1.3 Human Involvement ...................................................................................... 7 
1.2 Bromophenols ...................................................................................................... 7 
1.2.1 Brominated bis-phenols as antimicrobials .................................................... 9 
1.3 Radicals, ROS and oxidative damage ................................................................ 15 
1.3.1 ROS: a brief description .............................................................................. 16 
1.3.2 Cell defence against oxidative stress ........................................................... 18 
1.3.3 Oxidative damage and pathologies.............................................................. 19 
1.3.4 Antioxidants as therapeutic agents .............................................................. 22 
1.4 Brominated bis-phenols as antioxidants ............................................................. 26 
1.5 Previous Work .................................................................................................... 29 
1.6 Aim of the Project .............................................................................................. 30 
2. Dimers and Tetramers .............................................................................................. 31 
2.1 Introduction to Resorcinol and Phloroglucinol Dimers ..................................... 31 
2.2 Introduction to Resorcinol Tetramers................................................................. 32 
2.3 Introduction to Resorcinol Hexamers................................................................. 33 
2.4 Synthesis of dimers ............................................................................................ 34 
 iv 
2.4.1 Synthesis of 4-bromoresorcinol .................................................................. 35 
2.4.2 Synthesis of 2,4-dibromoresorcinol ............................................................ 35 
2.4.3 Synthesis of 2,4-dibromophloroglucinol ..................................................... 35 
2.4.4 Synthesis of phloroglucinol and resorcinol dimers ..................................... 36 
2.4.5 Synthesis of Dimers with Method 2 ............................................................ 39 
2.5 Synthesis of tetramers ........................................................................................ 42 
2.5.1 4-Bromoresorcinol based tetramers ............................................................ 42 
2.5.2 4-Chlororesorcinol based tetramers ............................................................ 44 
2.5.3 By-products of 165 and their equilibrium ................................................... 45 
2.5.4 Method 1 for the synthesis of tetramers ...................................................... 52 
2.5.5 Side reactions and scrambling ..................................................................... 53 
2.5.6 Aldehydes and mixed platforms .................................................................. 56 
2.5.7 Crystallography ........................................................................................... 57 
2.5.8 Dehalogenation of tetramers ....................................................................... 60 
2.5.9 Halogenation of tetramers ........................................................................... 61 
2.5.10 Biaryldicarboxaldehyde-based tetramers .................................................. 62 
2.5.11 Flexible tetramers ...................................................................................... 65 
2.6 Synthesis of hexamers ........................................................................................ 65 
2.7 Conclusions ........................................................................................................ 67 
2.8 Experimental ...................................................................................................... 68 
2.8.1 General ........................................................................................................ 68 
2.8.2 Crystal structure analyses ............................................................................ 68 
2.8.3 Synthesis ...................................................................................................... 71 
3. Bis-phenols, Benzophenones, Xanthones and Xanthenes ...................................... 145 
3.1 Introduction to the structures ............................................................................ 145 
3.1.1 Synthetic approach .................................................................................... 146 
3.2 Synthesis ........................................................................................................... 149 
3.2.1 Synthesis of hydroxy benzophenones ....................................................... 149 
3.2.7 Bromination of benzophenones ................................................................. 161 
 v 
3.2.8 Cyclisation of benzophenones ................................................................... 163 
3.2.9 Bromination of xanthones ......................................................................... 165 
3.2.10 Reduction of benzophenones .................................................................. 166 
3.2.11 Bromination of bis-resorcinols ................................................................ 168 
3.2.12 Reduction of xanthones ........................................................................... 168 
3.3 Conclusions ...................................................................................................... 171 
3.4 Experimental .................................................................................................... 173 
3.4.1 General ...................................................................................................... 173 
3.4.2 Synthesis .................................................................................................... 173 
4. Synthesis of dendrimers ......................................................................................... 188 
4.1 Dendrimers ....................................................................................................... 188 
4.2 Calixarenes ....................................................................................................... 189 
4.3 Previous work ................................................................................................... 190 
4.4 CuAAC, a quick overview ............................................................................... 193 
4.5 Functionalization of the Cores ......................................................................... 195 
4.5.2 Test of click reaction ................................................................................. 199 
4.5.3 Synthesis of a hindered model compound ................................................. 202 
4.5.4 Synthesis of a clickable tetra-amino calixarene ........................................ 204 
4.5.5 Synthesis of a functionalised dendrimer ................................................... 206 
4.6 Conclusions ...................................................................................................... 208 
4.7 Experimental .................................................................................................... 209 
4.7.1 General ...................................................................................................... 209 
4.7.2 Synthesis .................................................................................................... 210 
5. Biological evaluation .............................................................................................. 221 
5.1 MTS assay ........................................................................................................ 221 
5.1.1 Cell Lines .................................................................................................. 222 
5.2 Screening .......................................................................................................... 222 
5.2.1 Comparison of MCF-7 and HL60 ............................................................. 223 
5.2.2 Structures with low toxicity ...................................................................... 225 
 vi 
5.2.3 Evaluation of tetramers ............................................................................. 226 
5.2.4 Antiproliferative compounds as potential anticancer agents? ................... 228 
5.3 Imaging ............................................................................................................. 229 
5.4 Conclusions ...................................................................................................... 231 
5.5 Experimental .................................................................................................... 233 
5.5.1 Cell culture ................................................................................................ 233 
5.5.2 Proliferation assay ..................................................................................... 233 
5.5.3 Fluorescence Imaging ............................................................................... 234 
6. Antioxidant activity ................................................................................................ 235 
6.1 Choice of the assay ........................................................................................... 235 
6.1.1 Inhibition of induced lipid auto-oxidation ................................................ 236 
6.1.2 ORAC, TRAP and PABA assays .............................................................. 236 
6.1.3 Ferric Reducing Ability of Plasma (FRAP) assay .................................... 237 
6.1.4 Cupric reducing Antioxidant Capacity (CUPRAC) assay ........................ 238 
6.1.5 Total Phenols Assay .................................................................................. 238 
6.1.6 2,2-Diphenyl-1-picrylhydrazyl (DPPH) radical Scavenging Capacity assay
 ............................................................................................................................ 239 
6.1.7 Trolox Equivalent Antioxidant Capacity (TEAC) assay ........................... 240 
6.1.8 In Vivo Cell Protection Assay ................................................................... 241 
6.2 Results and Discussion ..................................................................................... 241 
6.2.1 DPPH assay ............................................................................................... 241 
6.2.2 TEAC assay ............................................................................................... 253 
6.3 Biological evaluation of protective activity ..................................................... 270 
6.4 Conclusions ...................................................................................................... 273 
6.5 Experimental .................................................................................................... 275 
6.5.1 DPPH assay ............................................................................................... 275 
6.5.2 TEAC assay ............................................................................................... 275 
6.5.3 Cell culture ................................................................................................ 275 
6.5.4 MTS with tert-butyl hydroperoxide .......................................................... 276 
 vii 
7. Conclusions and future work .................................................................................. 277 
8. References .............................................................................................................. 279 
 viii 
List of Figures 
Figure 1. Major classes of antibiotics with a representative example ............................ 2 
Figure 2. Antibiotic targets1 ........................................................................................... 3 
Figure 3. Resistance mechanisms ................................................................................... 5 
Figure 4. Natural bromophenols (1-59)16-29 ................................................................... 9 
Figure 5. Isocitrate lyase (ICL) and tricarboxylic acid cycle (TCA) cycles ................ 10 
Figure 6. Classic ICL inhibitors ................................................................................... 11 
Figure 7. Natural brominated bis-phenols tested by Xu et al.18 ................................... 11 
Figure 8. Natural and synthetic brominated bis-phenols tested by Oh et al.23 ............. 12 
Figure 9. Potent chlorinated bis-phenol ....................................................................... 13 
Figure 10. Bromophenols as isocitrate lyase inhibitors.38 For each column, ICL 
inhibition increases going downwards. ........................................................................ 13 
Figure 11. Oxidative stress and its involvement in neurodegeneration and 
carcinogenesis.49 ........................................................................................................... 20 
Figure 12. Example of DNA modification.42,53 ............................................................ 21 
Figure 13. Vitamin E and Trolox. ................................................................................ 22 
Figure 14. Examples of different polyphenols. ............................................................ 23 
Figure 15. Examples of catalytic antioxidants. ............................................................ 23 
Figure 16. beta-Carotene. ............................................................................................. 24 
Figure 17. Ubiquinone. ................................................................................................. 25 
Figure 18. Natural compounds involved in Nrf2 regulation. ....................................... 25 
Figure 19. Bromophenols with antioxidant activity and their reaction with DPPH radical
 ...................................................................................................................................... 26 
Figure 20 Brominated mono and bis-phenols with radical scavenging activity .......... 26 
Figure 21. Brominated mono- and bis-phenols with radical scavenging activity27,28 .. 27 
Figure 22. Halophenols as antioxidants and cytoprotective agents71 ........................... 28 
Figure 23. Brominated bis-phenols with a side chain72................................................ 29 
Figure 24. Previous and current work examples. ......................................................... 31 
Figure 25. Tetramer with a central phenyl ring. ........................................................... 32 
Figure 26. Biaryl and flexible tetramers. ...................................................................... 33 
Figure 27. Hexamers. ................................................................................................... 33 
Figure 28. Long range coupling of the bridge in 131. .................................................. 38 
 ix 
Figure 29. Set of dimers. Black structures: obtained as pure compounds. Red structures: 
reaction leads to mixtures of products. Blue structures: a solvent or reagent could not 
be removed completely. ............................................................................................... 40 
Figure 30. NMR of 153, with the signals of toluene highlighted. Recorded in DMSO-d6 
at 400 MHz. .................................................................................................................. 41 
Figure 31. NMR of 156 and presence of aldehyde. Recorded in DMSO-d6 at 400 MHz.
 ...................................................................................................................................... 42 
Figure 32. NMR of 158. Recorded in DMSO-d6 at 400 MHz. .................................... 43 
Figure 33. 1H NMRs of 165 (a), 164 (b) and 163 (c). All spectra were recorded in 
DMSO-d6 at 400 MHz. ................................................................................................. 45 
Figure 34. Structures of 165, 166 and 167. .................................................................. 46 
Figure 35. 1H-NMR of 167 (DMSO-d6 at 400 MHz). .................................................. 46 
Figure 36. 13C-NMR of 167. Recorded in DMSO-d6 at 400 MHz. .............................. 47 
Figure 37. Structure of 166, minimised with GAFF force field and rendered in UCSF 
Chimera. ....................................................................................................................... 47 
Figure 38. 1H-NMR of 166. Recorded in DMSO-d6 at 400 MHz. ............................... 48 
Figure 39. 13C-NMR of 166. Recorded in DMSO-d6 at 400 MHz. .............................. 48 
Figure 40. Crystal structure of 166. Top, a single molecule of 166 hydrogen bonded 
with a diethyl ether molecule and chain-like arrangement of 166 within the crystal, 
bottom. .......................................................................................................................... 49 
Figure 41. 1H-NMR of the reaction mixture after 6 and 24 hours and spectra of 166 and 
167 as reference compounds. All spectra were recorded in DMSO-d6 at 400 MHz. ... 50 
Figure 42. Reaction of the closed acetal 166 (a) with 4-chlororesorcinol to give 165 (b) 
at 7 and 24 hours showing presence of 167 (c) during the reaction. All spectra were 
recorded in DMSO-d6 at 400 MHz. ............................................................................. 51 
Figure 43. Yield of some compounds with some favourable fragmentation points 
highlighted. ................................................................................................................... 54 
Figure 44. Scrambling of 163 (a) under Method 1 conditions with reference 4-bromo- 
and 4-chlororesorcinol. All spectra were recorded in DMSO-d6 at 400 MHz. ............ 55 
Figure 45. Scrambling of 163 (a) under Method 2 conditions with reference 4-bromo- 
and 4-chlororesorcinol. All spectra were recorded in DMSO-d6 at 400 MHz. ............ 56 
Figure 46. Crystal structures of 163, 164 and 165 and their arrangement within the 
crystal. .......................................................................................................................... 59 
Figure 47. 1H-NMRs of 163 (a) and 183 (b). ............................................................... 61 
Figure 48. 1H-NMR of 217 (a), 218 (b) and 219 (c). ................................................... 67 
 x 
Figure 49. View of a molecule of 163, indicating the atom numbering scheme and 
hydrogen-bonded atoms of neighbouring molecules.  Thermal ellipsoids are drawn at 
the 50% probability level. ............................................................................................ 99 
Figure 50. 163 molecules linked through hydrogen bonds in chains. The oxygen atoms 
of the hydrogen-bonded ether molecules are also included. ...................................... 100 
Figure 51. View of a molecule of 164.  Thermal ellipsoids are drawn at the 50% 
probability level. ......................................................................................................... 103 
Figure 52. Linking, through hydrogen bonds, of the 164 molecules, showing the ladder 
formation and the linking of pairs of ladders about centres of symmetry. ................. 104 
Figure 53. View of a molecule of 165.  Thermal ellipsoids are drawn at the 50% 
probability level. ......................................................................................................... 107 
Figure 54. The molecules are linked through hydrogen bonds in chains (horizontally) 
about centres of symmetry, and in sheets and through methanol bridges. ................. 108 
Figure 55. View of a molecule of 166 and hydrogen-bonded solvent (Et2O) molecule, 
indicating the atom numbering scheme.  Thermal ellipsoids are drawn at the 50% 
probability level. ......................................................................................................... 111 
Figure 56. A chain of hydrogen-bond linked 166 and ether molecules. .................... 111 
Figure 57. Structures described in Chapter 2. ............................................................ 145 
Figure 58. General structures of the compounds presented in Chapter 3. ................. 146 
Figure 59. 1H-NMR and 13C-NMR of 222. ................................................................ 150 
Figure 60. Comparison of the 13C-NMR spectra of 224 (top) and 225 (bottom). ...... 151 
Figure 61. 1H-NMR of 233. ....................................................................................... 156 
Figure 62. 1H-NMR of the fragmentation of 225 (red) and spiking with 2,4-
dimethoxybenzoic acid (blue). ................................................................................... 158 
Figure 63. 1H-NMRs of 220 (top), 241 (middle) and 242 (bottom). .......................... 163 
Figure 64. 1H-NMRs of 220 (top), 243 (bottom). ...................................................... 164 
Figure 65. 1H-NMRs of 245 (A), reaction mixture for 245 before completion (B), 246 
(C) and 244 (D). ......................................................................................................... 165 
Figure 66. 1H-NMR of 248. ....................................................................................... 167 
Figure 67. 1H-NMR of 247 (a), 243 (b), 244 (c), 249 (d), 245 (e) and 250 (f). ......... 170 
Figure 68. 13C-NMR of 247 (bottom) and 243 (top). ................................................. 170 
Figure 69. Structures presented in the previous chapters and considered for the in 
vitro/in vivo testing in the following chapters. ........................................................... 172 
Figure 70. Convergent and divergent synthesis of dendrimers. ................................. 188 
Figure 71. Basic structure of calix[4]arenes and calix[4]resorcinarenes. .................. 189 
 xi 
Figure 72. Conformations of calix[4]arenes. ............................................................. 190 
Figure 73. 21 units multicalixarene built using click chemistry.135 ........................... 192 
Figure 74. Previously investigated resorcinarene-calixarene based multicalixarenes 
(A)136 and current work (B). ....................................................................................... 193 
Figure 75. 1H-NMR of 183 (top), and 255 (bottom). ................................................. 197 
Figure 76. 1H-NMR of 256. ....................................................................................... 198 
Figure 77. 1H-NMR of 257. ....................................................................................... 200 
Figure 78. HSQC of of 257. ....................................................................................... 201 
Figure 79. HMBC of of 257. ...................................................................................... 201 
Figure 80. IR spectra of 259. ...................................................................................... 202 
Figure 81. 1H-NMR of 260. ....................................................................................... 204 
Figure 82.  1H-NMR of 255 (top), 265 (centre) and 264 (bottom). ........................... 207 
Figure 83. 1H-NMR of 266. ....................................................................................... 208 
Figure 84. Proliferation screening against MCF-7 and HL60, at 10 and 100 μM 
concentrations for a three day treatment. Result expressed as percentage against control.
 .................................................................................................................................... 224 
Figure 85. Compounds showing selectivity over the two cell lines. .......................... 225 
Figure 86. Structures displaying low proliferation inhibition. ................................... 226 
Figure 87. Effect of the central core of tetramers on cell viability. ........................... 226 
Figure 88. Effect of the halogen substitution on cell viability. .................................. 227 
Figure 89. Effect of geometry on cell viability. ......................................................... 227 
Figure 90. Effect of the number of monomers on cell viability. ................................ 228 
Figure 91. Tetramers with high anti proliferative activity. ........................................ 228 
Figure 92. Fluorescent compounds for imaging. ........................................................ 229 
Figure 93. Fluorescence microscopy of MCF-7 cell treated with 187 and Hoescht 
33342. ......................................................................................................................... 230 
Figure 94. Fluorescence microscopy of MCF-7 cell treated with either 165, 187 or 143 
and Hoescht 33342. .................................................................................................... 231 
Figure 95. Autoxidation of linoleic acid monitored by UV absorbance. Initiator addition 
at point B, antioxidant addition at point C. ................................................................ 236 
Figure 96. Structure of Trolox. ................................................................................... 237 
Figure 97. UV profile of the progressive conversion of DPPH into DPPHH. ........... 240 
Figure 98. Sample compounds for the initial evaluation of DPPH radical scavenging 
assay. .......................................................................................................................... 242 
 xii 
Figure 99. Time course profiles of the reaction between DPPH (150 µM) and sample 
compounds monitored at 512 nm. .............................................................................. 242 
Figure 100. Comparison between the scavenging effect of two sample compounds and 
the decomposition of DPPH. ...................................................................................... 243 
Figure 101. Compounds for the evaluation of halogen and geometry effects on DPPH 
scavenging activity. .................................................................................................... 245 
Figure 102. Progress of the reaction between DPPH (150 µM) and sample compounds 
(20 µM) monitored at 512 nm. ................................................................................... 246 
Figure 103. DPPH consumed (initial concentration 150 µM) by sample compounds (10 
µM) after 500 minutes. Measures in triplicate and error expressed as standard deviation.
 .................................................................................................................................... 246 
Figure 104. Compound 183. ....................................................................................... 252 
Figure 105. Decomposition of ABTS, starting from two different concentrations. ... 253 
Figure 106. Different families of compounds, each with a representative structure.. 255 
Figure 107. ABTS scavenging activity of compound families’ representative structures.
 .................................................................................................................................... 256 
Figure 108. Xanthones. .............................................................................................. 256 
Figure 109. ABTS scavenging activity of xanthones. ................................................ 257 
Figure 110. Benzophenones. ...................................................................................... 257 
Figure 111. ABTS scavenging activity of benzophenones. ....................................... 258 
Figure 112. Bis-phenols. ............................................................................................ 258 
Figure 113. ABTS scavenging activity of bis-phenols. ............................................. 259 
Figure 114. Dimers with different sidechains. ........................................................... 259 
Figure 115. ABTS scavenging activity of dimers with different sidechains. ............ 260 
Figure 116. Dimers with different halogens. .............................................................. 261 
Figure 117. ABTS scavenging activity of dimers with different halogens at 10 minutes 
and 600 minutes. ........................................................................................................ 261 
Figure 118. Tetramers with different halogens. ......................................................... 262 
Figure 119. ABTS scavenging activity of tetramers with different halogens. ........... 262 
Figure 120. Tetramers with different geometries. ...................................................... 263 
Figure 121. Activity of tetramers with different geometries. ..................................... 264 
Figure 122. Biaryl tetramers and shorter analogues. .................................................. 264 
Figure 123. ABTS scavenging activity of biaryl tetramers and shorter analogues .... 265 
Figure 124. Biaryl tetramers with different halogens. ............................................... 265 
Figure 125. ABTS scavenging activity of biaryl tetramers with different halogens. . 266 
 xiii 
Figure 126. Alkyl linked tetramers. ........................................................................... 266 
Figure 127. ABTS scavenging activity of alkyl linked tetramers. ............................. 267 
Figure 128. Hexamers. ............................................................................................... 267 
Figure 129. ABTS scavenging activity of hexamers. ................................................. 268 
Figure 130. Effect of the bridge substituent in resorcinol dimers. ............................. 268 
Figure 131. Effect of the number of resorcinol units on the activity. ........................ 269 
Figure 132. Effect of the halogen on the activity. ...................................................... 269 
Figure 133. Effect of the geometry of tetramers on the activity. ............................... 269 
Figure 134. Effect of the central linker on the activity of tetramers. ......................... 270 
Figure 135. Assay model. ........................................................................................... 271 
Figure 136. Effect of different tBuOOH concentrations on proliferation. ................. 271 
Figure 137. Structures tested for protective effects. ................................................... 272 
Figure 138. Effect of different compounds (at three different concentrations, each one 
in triplicate), on MCF-7 cells treated with tBuOOH. Error expressed as standard 
deviation. .................................................................................................................... 273 
Figure 139. Lead compounds by Zhao.71 ................................................................... 274 
 
 xiv 
List of Schemes 
Scheme 1. a) Fenton reaction. b) reduction of iron (III) to iron (II). ........................... 17 
Scheme 2. Lipid peroxidation, adapted from Thanan.49 .............................................. 17 
Scheme 3. Detoxification of superoxide and hydrogen peroxide. SOD (superoxide 
dismutase), CAT (catalase), GPX (glutathione peroxidase), GR (glutathione reductase), 
GST (glutathione S-transferase). .................................................................................. 18 
Scheme 4. Catalytic cycle of Ebselen. ......................................................................... 24 
Scheme 5. Retrosynthesis of dimers. ........................................................................... 34 
Scheme 6. Synthesis of 4-bromoresorcinol. ................................................................. 35 
Scheme 7. Synthesis of 2,4-dibromoresorcinol. ........................................................... 35 
Scheme 8. Synthesis of 2,4-dibromophloroglucinol (123). a) Possible routes to 2,4-
dibromophloroglucinol. b) Approach used to synthesise 2,4-dibromophloroglucinol. 36 
Scheme 9. Method 1. .................................................................................................... 37 
Scheme 10. Synthesis of 131. ....................................................................................... 37 
Scheme 11. Synthesis of 132. ....................................................................................... 38 
Scheme 12. Synthesis of 134, 135 and 136. ................................................................. 38 
Scheme 13. Bacci’s synthesis of bis-phenols. .............................................................. 39 
Scheme 14. Synthesis of 140. ....................................................................................... 39 
Scheme 15. Synthesis of 158. ....................................................................................... 43 
Scheme 16. Synthesis of 160 and attempted synthesis of X. ....................................... 44 
Scheme 17. Synthesis of 163, 164 and 165. ................................................................. 44 
Scheme 18. Synthesis of 165 and 166. ......................................................................... 50 
Scheme 19. Equilibrium between 166 and 167. ........................................................... 51 
Scheme 20. Retro-Friedel-Crafts fragmentation. General mechanism (a) and 
fragmentations observed by Bacci76 (b, c). .................................................................. 53 
Scheme 21. Synthesis of 180, 181 and 182. ................................................................. 57 
Scheme 22. Dehalogentation reactions. ....................................................................... 60 
Scheme 23. Halogenation of tetramers......................................................................... 62 
Scheme 24. Suzuki cross –coupling mechanism (a) and formation of an oxo-palladium 
complex (b). Adapted from Lennox.84 ......................................................................... 63 
Scheme 25. Synthesis of 191, 192, 193 and 194. ......................................................... 64 
Scheme 26. Synthesis of 197, 198 and 199. ................................................................. 64 
Scheme 27. Synthesis of flexible tetramers.................................................................. 65 
 xv 
Scheme 28. Synthesis of hexamers. ............................................................................. 66 
Scheme 29. Synthesis of benzophenones according to Hu.98 .................................... 146 
Scheme 30. Synthetic approach towards benzophenones, bis-phenols, xanthones, 
xanthenes and their brominated analogues. ................................................................ 147 
Scheme 31. Bromination of 2,4-dihydroxybenzoic acid and similarity with 
benzophenones. .......................................................................................................... 147 
Scheme 32. Synthesis of 220. ..................................................................................... 149 
Scheme 33. Synthesis of 222. ..................................................................................... 149 
Scheme 34. Synthesis of 225 and 227. ....................................................................... 150 
Scheme 35. Synthesis of 229 and attempted synthesis of 230. .................................. 151 
Scheme 36. Retrosynthesis of 224. ............................................................................ 152 
Scheme 37. Acylation of aromatic compounds with P2O5/SiO2, examples from Zarei.
109
 .................................................................................................................................... 153 
Scheme 38. Synthesis of 225. ..................................................................................... 153 
Scheme 39. Attempted synthesis of 231. ................................................................... 154 
Scheme 40. Acylation of anisole with acetic acid in the presence of methanesulfonic 
acid and graphite reported by Sarvari.114 ................................................................... 154 
Scheme 41. Acylation of 1,3-dimethoxybenzene with 2,6-dimethoxybenzoic acid. . 155 
Scheme 42. Methylation of 220. ................................................................................ 155 
Scheme 43. Synthesis of 233 from 2,6-dimethoxybenzoic acid. ............................... 156 
Scheme 44. Decarboxylation of 2,6-dimethoxybenzoic acid. .................................... 156 
Scheme 45. Acylation of 1,3-dimethoxybenzene with 2,6-dimethoxybenzoic acid, 
halted before rearrangement. ...................................................................................... 157 
Scheme 46. Synthesis of 233 from 1,3-dimethoxybenzene and 2,6-dimethoxybenzoic 
acid and subsequent rearrangement (a). Rearrangement of 225 to give 233 (b). ....... 157 
Scheme 47. Fragmentation of 225. ............................................................................. 157 
Scheme 48. Breakdown of 233 (a) and decarboxylation of 2,4-dimethoxybenzoic acid 
(b). .............................................................................................................................. 158 
Scheme 49. Summary of the reactions involved in the synthesis of 225 and 233. .... 159 
Scheme 50. Attempted synthesis of 231 with methane sulfonic acid and graphite. .. 159 
Scheme 51. Attempted approaches for the synthesis of 231. ..................................... 160 
Scheme 52. Potential alternative approach to the synthesis of 231............................ 160 
Scheme 53. Pettit’s benzophenones synthesis.118 ....................................................... 161 
Scheme 54. Synthesis of 224. ..................................................................................... 161 
Scheme 55. Synthesis of 240 and 241. ....................................................................... 161 
 xvi 
Scheme 56. Synthesis of 241 and 242. ....................................................................... 162 
Scheme 57. Synthesis of 243. ..................................................................................... 163 
Scheme 58. Synthesis of 244 and 245. ....................................................................... 164 
Scheme 59. Synthesis of 245. ..................................................................................... 165 
Scheme 60. Synthesis of 246 (a) and 244 (b). ............................................................ 166 
Scheme 61. Synthesis of 247 described by Shi.100 ..................................................... 166 
Scheme 62. Synthesis of 248. ..................................................................................... 166 
Scheme 63. Different synthetic approaches to 135. ................................................... 167 
Scheme 64. Different synthetic approaches to 136. ................................................... 168 
Scheme 65. Synthesis of 136 by bromination. ........................................................... 168 
Scheme 66. Synthesis of 247. ..................................................................................... 169 
Scheme 67. Synthesis of 249. ..................................................................................... 169 
Scheme 68. Synthesis of 250. ..................................................................................... 169 
Scheme 69. Dendrimers obtained by reaction of activated carboxylic acids and amines.
 .................................................................................................................................... 191 
Scheme 70. Azide-alkyne cycloaddition. ................................................................... 194 
Scheme 71. Mechanism of CuAAC.144 ...................................................................... 195 
Scheme 72. Functionalization of the cores. ................................................................ 196 
Scheme 73. Synthesis of 255. ..................................................................................... 196 
Scheme 74. Synthesis of 256 and its 3D representation (the image is only meant to 
provide a better visualization of the structure, it is not a representative conformation. 
MarvinSketch and UCSF Chimera) ........................................................................... 198 
Scheme 75. Synthesis of test dendrimer 257. ............................................................. 199 
Scheme 76. Synthesis of 259. ..................................................................................... 202 
Scheme 78. Synthesis of 260. ..................................................................................... 203 
Scheme 79. Synthesis of 264. ..................................................................................... 205 
Scheme 80. Synthesis of 266. ..................................................................................... 207 
Scheme 81. Reduction of MTS to its chromogenic formazan derivative. ................. 221 
Scheme 82. Ferric-tripyridyltriazine complex, oxidised and reduced form. .............. 238 
Scheme 83. Synthesis of ABTS+•. .............................................................................. 241 
Scheme 84. HAT and ET reactions shown on eugenol. ............................................. 247 
Scheme 85. Termination reactions for DPPH. ........................................................... 248 
Scheme 86. Reactions of BHT with DPPH. ............................................................... 249 
Scheme 87. Reactions of eugenol with DPPH. .......................................................... 250 
 xvii 
Scheme 88. DPPH mediated cyclization of garcinol. Only the relevant fragment is 
reported.175 .................................................................................................................. 250 
Scheme 89. Proposed reactions for tetramer 163. ...................................................... 251 
Scheme 90. Cyclization to fluorone. .......................................................................... 252 
List of Tables 
Table 1. Reactive oxygen species42 .............................................................................. 15 
Table 2. Comparison of yields of Method 1 and 2 for 107, 111 and 109. ................... 41 
Table 3. Yields of the reaction between 4-haloresorcinols and isomeric benzene 
dicarboxaldehydes under reaction conditions of Method 1 and 2. ............................... 52 
Table 4. Crystal data and structure refinement details for the four compounds 163, 164, 
165 and 166. ................................................................................................................. 70 
Table 5. Reaction conditions for the synthesis of 225. .............................................. 154 
Table 6. Results of the proliferation screening against MCF-7 and HL60, at 10 and 100 
μM concentrations for a three day treatment. Data expressed as percentage of 
proliferation compared to the control. Colour gradient from 0% proliferation (red) to 
white (50%) and blue (100%). ................................................................................... 223 
Table 7. Summary of the scavenging activity of the tested compounds (1 µM), 
expressed as % of ABTS consumed, after 10 minutes and after 10 hours. Colour scale 
ranges from low activity (red) to high activity (blue). NaAsc = Sodium Ascorbate. 254 
 
 xviii 
List of Abbreviations 
AAPH: 2,2'-azobis(2-amidinopropane) dihydrochloride 
ABTS: 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) 
AD: Alzheimer’s disease 
ALS: amyotrophic lateral sclerosis 
AMD: age-related macular degeneration 
ARE: antioxidant response element 




CUPRAC: cupric reducing antioxidant capacity 
DIPEA: diisopropylethylamine 
DPPH: 1,1-diphenyl-2-picrylhyrdazyl 
EPR: electron paramagnetic resonance 
ET: electron transfer 
FRAP: ferric reducing ability of plasma 
GPX: glutathione peroxidase 
GSH: glutathione 
GSSG: glutathione disulphide 
HAT: hydrogen atom transfer 
HD: Huntington’s disease 
HUVEC: human umbilical vein endothelial cells 
ICL: isocitrate lyase 
Keap1: Kelch-like ECH-associated protein 1 
LDL: low-density lipoprotein 
MDR: multi drug resistant 
MIC: minimum inhibitory concentration 
Mtb: Mycobacterium tuberculosis 
MTS: ([3-(carboxymethoxy)phenyl]-3-(4,5-dimethyl-2-thiazolyl)-2-(4-sulfo-phenyl)-
2H-tetrazolium inner salt) 
MTT: (4,5-dimethyl-2-thiazolyl)-3,5-diphenyl-2H-tetrazolium bromide) 
NaAsc: sodium ascorbate 
 xix 
NAD: nicotinamide adenine dinucleotide 
NBS: N-bromosuccinimide 
NOS: nitric oxide synthase 
Nrf2: nuclear factor erythroid 2–related factor 2 
ORAC: oxygen radical absorbance capacity 
PABA: 4-aminobenzoic acid 
PD: Parkinson’s disease 
PDC: pyridinium dichromate 
ROS: reactive oxygen species 
R-PE: R-phycoerythrin 
RT: room temperature 
SAR: structure-activity relationships 
SOD: superoxide dismutase 
TCA: tricarboxylic acid cycle 
TDR: totally drug resistant 
TEA: trimethylamine 
TEAC: Trolox equivalent antioxidant capacity 
TRAP: total peroxyl radical-trapping antioxidant parameter 
UCSF: University iof California, San Francisco
 1 
Acknowledgments 
First of all, I would like to thank Susan Matthews for giving me the opportunity of 
working with her on this project and for her support during the course of my PhD. I 
would also like to thank Maria O’Connell for her supervision and teaching in the 
biology side of the project. I would also like to thank David Hughes for the 
crystallographic analysis of the compounds presented. 
I would like to thank Zoe Waller for her support through the PhD, for believing in my 
skills. Thanks for pushing me forward and improving my teaching skills. 
Colin Macdonald for the help with the NMR, both on the theoretical and the practical 
side of things. 
Stephen Ashworth for the help with kinetics. 
A big thank goes to all my family, who supported me through the (very long) course of 
my studies and had to put up with the distance. 
My partner, Giulia, who has been with me and supported me during happy times and 
also when I was stressed or depressed. 
Simone, Zoe and Qiran, for their friendship and help during the PhD. Anja, Noelia, Ivy, 
Shirley and Patricia for their help in the biology lab and their kind teaching. Jack, 
Antony, Alicia, Magda, Robert, Donald, Anissa, Janet and Jane the students who 
worked with me and bore with my improving and very harsh way of teaching. 
Doroty, Desi, Hanae, Veronica, Melania, Henry, Ana, Luca, Sonia, Dani, Victor, 
Davide, Teresa, Yohan, Laura, Luigi, Paul, Carl and all the people I am sure I forgot to 
add. Thanks for the friendship, shopping, drinks, table football, barbecues and whatnot! 
Mark Searcey, Lesley Howell, and my current lab mates. Thank you for believing in 
me.  
Daniela Barlocco, Stefania Villa, Arianna Gelain, Daniela Masciocchi, Elena Cocchi 
and all the people in Milano, without your help I would have not been able to find a 
PhD in the first place. 
 2 
1. Introduction 
1.1 Antimicrobials and resistance 
Antibiotics are undoubtedly one of the most important scientific achievements of 
the 20th century. Their introduction, beginning in the 30s with sulfonamides and β-
lactams, revolutionised the treatment and prophylaxis of bacterial infections and paved 
the way for considerable medical progress (e.g. surgery and transplants). Following the 
first discoveries, a “golden age” of development led to the main antibiotic families still 
in use today, with the introduction of chloramphenicol, macrolides, tetracyclines, 
quinolones, aminoglycosides and aminocoumarins (Figure 1).1-4 
 
Figure 1. Major classes of antibiotics with a representative example 
 From the 70s, new classes of broad spectrum antibiotics have not been 
commercialised and only a few new compounds have been approved, often developed 
from older discoveries. 
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On the other hand, in 1942, immediately after the first discoveries, the problem 
of resistance emerged. Initially, it appeared a minor concern compared to the fast-paced 
development of new treatments. However, at present, it has become an area of major 
concern. Resistance has been identified for all available classes of compounds and 
multidrug-resistant (MDR) strains have been identified, with extreme cases of totally 
drug resistant (TDR) bacteria also now present.1,3 
1.1.1 Drug Targets 
A range of different type of targets have been successfully exploited by 
antibiotics developed to date (Figure 2). β-Lactams produce their bactericidal effects 
by alteration of the homeostasis of the cell wall, a structure mainly sustained by a 
peptidoglycan composed of alternating N-acetylmuramic acid  and N-
acetylglucosamine. These structures are crosslinked through D-alanine pentapeptides 
protruding from the N-acetylmuramic units. The crosslinking reaction is catalysed by 
transpeptidases, which are the target of β-lactams. These are similar to the enzyme’s 
substrate and irreversibly acylate it, leading to impaired wall synthesis. Without the 
wall, the cell is exposed to an hyperosmotic environment with subsequent cell death.5 
A minor class of antibiotics, glycopeptides (e.g. Vancomycin), produce their activity by 
inhibition of both transglycopeptidases and transpeptidases by mimicking their 
structure.6 The absence of the cell wall in mammals drives the selectivity and the interest 
towards these approaches, and novel molecules, such as cationic peptides, are being 
developed to target this key structure.7,8 
 
Figure 2. Antibiotic targets1 
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  Another important family of targets are DNA gyrase and topoisomerase IV. 
Bacterial DNA is normally a circular, single molecule, which is tightly packed into a 
supercoiled conformation. Access to DNA for replication, transcription and other 
processes, requires intervention of either gyrases or topoisomerases. These enzymes can 
introduce temporary breaks which allow unwinding and thus processing of DNA. By 
inhibiting these enzymes, there is impaired access to the genetic information, which 
leads to rapid death of the cell. These targets are also selective, as humans do not express 
the same types of topoisomerases.6 
 DNA-dependent RNA synthesis can also be targeted. Rifampicin, an antibiotic 
derived from structural modifications of natural metabolites of Nocardia mediterranei, 
is able to inhibit RNA synthesis. Its activity is due to binding within the main channel 
of bacterial DNA-dependent RNA polymerase and subsequent blocking of the 
elongation process of the forming RNA.9 
 Downstream of RNA synthesis, translation can additionally be targeted. 
Different families of antimicrobials can inhibit protein synthesis by interfering with 
different cellular structures. Bacterial ribosomes are different in humans and bacteria, 
and thus a rational target for antibiotics. Aminoglycosides, for example, bind to the 30S 
ribosomal unit and cause mistranslations, leading to the synthesis of nonsense proteins. 
Similarly to aminoglycosides, tetracyclines also bind to the 30S subunit (although other 
binding sites have been suggested to be involved in their action) but produce termination 
of the peptide growth. Macrolides and chloramphenicol, on the other hand, bind to the 
50S subunit and prevent elongation, thus producing their bacteriostatic effect.6 
 Sulfonamides were among the first classes of antimicrobials discovered. They 
have a completely different mode of action, as 4-aminobenzoic acid (PABA) analogues 
they compete for dihydropteroate synthetase, an enzyme involved in folic acid 
synthesis. Differently from humans, who acquire folate through the diet, bacteria need 
to produce it. Folate is necessary for a variety of functions, and is essential for the 
synthesis of thymidine, without which the bacteria cannot multiply. Trimethoprim is 
another antimicrobial agent involved in folic acid metabolism; it acts downstream of 
the sulfonamides, and inhibits the reduction of dihydrofolic acid to tetrahydrofolic acid.6 
1.1.2 Modes of Resistance and Transmission 
 Despite all these different mechanisms of action, bacteria have been able to 
develop a multifaceted array of survival adaptations and mechanisms of resistance for 
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every available antibiotic. Often, a single microorganism displays multiple forms of 
resistance against the same type of antibiotic. 
 
Figure 3. Resistance mechanisms 
As illustrated in Figure 3, the ways in which bacteria exert resistance can be 
classified into four main modes of action: 
- modification of the antibiotic 
- modification of the target 
- gene amplification 
- efflux from the cell3,4 
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A notable example of modification of antibiotics is through hydrolysis. 
Penicillins are substrates of β-lactamase, enzymes produced by the bacteria which 
inactivate the antibiotic by hydrolysis of the β-lactam ring. Macrolides are another 
example of family subject to hydrolytic enzymes. Alternatively, chloramphenicol is 
acetylated by a CoA-dependent chloramphenicol acetyltransferase. Another CoA-
dependent acetyltransferase is responsible for the same transformation of 
aminoglycosides. These are also subject to O-phosphorylation and O-adenylation by 
ATP-dependant phosphotransferases and nucleotidyltransferases respectively.5,10,11 
 Resistance by alteration of the target has spread to most classes of 
antimicrobials. It involves a change in the target of the antibiotic, for example a residue 
mutation in the sequence of an enzyme, which retains its activity while reducing the 
affinity for the antimicrobial. A single amino acid mutation in dihydropteroate synthase 
can lead to resistance, as in the case of specific Escherichia coli strains. In other species, 
e.g. Staphylococcus haemolyticus and aureus, multiple mutations cause resistance to 
the sulfonamides. Base repeats leading to modified tertiary structures have also been 
linked to altered response in Streptococcus pneumoniae. Quinolones, macrolides, 
aminoglycosides and β-lactams are other major examples of antimicrobials which can 
incur a resistance by alteration of the target.1,12  
 Gene amplification produces overexpression of either the target protein or other 
systems involved in resistance (e.g. efflux pumps), thus reducing the effect of the 
antimicrobial. Sulfonamides and trimethoprim, for example, are susceptible to this type 
of resistance.3,13 Efflux pumps externalise solutes from the cytosol of the bacteria, 
effectively decreasing their intracellular concentration, with obvious consequences in 
the case of antibiotics. These systems become relevant when they are overexpressed 
(which can be substrate-induced) and/or mutated, thus increasing their effectiveness. 
The pumps can be specific for a substrate or be associated with multi drug resistance.13 
Increased efflux and its consequent reduction of intracellular xenobiotic can facilitate 
the development of resistance either directly, by a combined effect with other resistance 
mechanisms, or indirectly by enhancement of gene transfer and recombination, partly 
by activation of the SOS response, radical mediated damage and subsequent repair 
mechanisms.3,14 
 The genes responsible for resistance can be transmitted both vertically, by 
multiplication of the microorganism, and horizontally, by exchange of genetic 
information from one cell to another, thus maximising the potential of diffusion. 
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Horizontal gene transfer comprises a complex set of regulated functions, involving 
mobile genetic elements. Plasmids are probably the most relevant vectors, but viruses, 
transposons, integrons and naked DNA have been involved with resistance.3,15 
1.1.3 Human Involvement 
 Human activities have a great impact on development and maintenance of 
antibiotic resistance. Although misuse or abuse of antimicrobials for treatment or 
prophylaxis in humans is often perceived as a main factor in promoting and maintaining 
selection of resistant strains, there are many other factors to be accounted for. Treatment 
of household pets has to be considered as well, especially with the animal being in close 
contact with humans. Antibiotics are used in animal prophylaxis and treatment, and 
have also been used for growth production. Aquaculture and agriculture also take 
advantage of antibacterial products. Finally, cleaning products and research also 
contribute to resistance development.3 
1.2 Bromophenols 
Nature provides an incredibly varied range of substances, often with complex 
structures and different biological activities. Therefore, medicinal chemists frequently 
take inspiration from natural compounds. The idea behind this project comes from a 
group of brominated phenols isolated from red algae, which were harvested in the seas 
of China, Korea and Japan. 
Figure 4 shows a set of representative bromophenols (1-59). These compounds 
were isolated from four families of red algae: 
- Rhodomela (confervoides,16-20 larix21) 
- Odonthalia (corymbifera22,23) 
- Symphyocladia (latiscula24-26) 
- Polysiphonia (urceolata,27-29 lanosa30) 
These organisms all have a vanadium bromoperoxidase, a vanadate dependant 
enzyme, which is responsible for the synthesis of a profuse number of brominated 
substances.31 These products are involved in defence (antimicrobial and feeding-
deterrent activities),22,31,32 signaling31 and scavenging H2O2 during oxidative stress.
33 
The colour of the algae itself is due to a cuticle composed of polymerised 
bromophenols.33  
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The structures presented in Figure 4 are, for the most part, based on brominated 
catechols and present redundant side chains, especially alcohols, ethers, aldehydes, 
acids and esters. A small number of derivatives coupled with amino acids (22, 23, 33, 
48, 56)17,19,26 or nucleosides (24)19 have also been discovered. Most of the isolated 
compounds are based on mono- and diaryl-bromophenols, only a few examples of tri- 
and tetra-aryl structures are currently known.34 
Of particular interest in this project are brominated bis-phenols such as 27-34, 
produced by dimerisation of brominated catechols and extensively studied for their 
activities as antioxidants and antimicrobials (isocitrate lyase inhibitors). These 
compounds also present an interesting inhibitory activity against aldose reductase,25 α-
glucosidase34 and tyrosine phosphatase 1B,35 hence they possess a potential antidiabetic 
activity. Natural bis-phenols with these properties and their respective synthetic 
derivatives, already reported, will be individually discussed in the following sections.   
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Figure 4. Natural bromophenols (1-59)16-29 
1.2.1 Brominated bis-phenols as antimicrobials 
Some of the isolated and synthesised brominated phenols and their dimerised 
derivatives have displayed activity against a range of bacteria and fungi. Whilst the 
mechanism of action is not fully clear, isocitrate lyase (ICL) has been identified as a 
potential target.36  
1.2.1.1 Isocitrate Lyase 
Isocitrate lyase is present in bacteria, fungi, some protists and plants. It is part 
of the glyoxylate cycle and mediates the conversion of isocitrate to succinate and 
glyoxylate (Figure 5). It is an anaplerotic path in the tricarboxylic acid cycle (TCA) 
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and allows the microorganism to assimilate 2-carbon compounds for catabolic reactions 
such as carbohydrate synthesis, bypassing the following limiting steps (mediated by 
isocitrate dehydrogenase and α-ketoglutarate dehydrogenase). Mammals do not have 
ICL, thus it represents an interesting, selective, target for the development of new 
antibiotics and biological tools.18,37-39  
 
Figure 5. Isocitrate lyase (ICL) and tricarboxylic acid cycle (TCA) cycles 
 The role of ICL is critical in Mycobacterium tuberculosis (Mtb). The pathogen, 
which expresses two isoforms, ICL1 and ICL2, is dependent on their activity, notably 
during lung infection and within macrophages. Previous studies proved that deletion of 
both enzymes impairs intracellular replication of the pathogen and leads to its 
elimination from the lungs of mice.40  
Since the identification of ICL as target, a number of inhibitors have been 




Figure 6. Classic ICL inhibitors 
Classic inhibitors are substrate analogues, 3-nitropropionate, itaconate and 3-
bromopyruvate (Figure 6). These are toxic compounds, they are aspecific and interact 
with other enzymes of the previously described cycles. 3-Bromopyruvate is also an 
alkylating agent. Their use is limited to that of tools to investigate the activity of the 
enzyme and 3-nitropropionate is usually exploited as a positive control for ICL 
inhibition. The large number of inhibitors discovered up to now have very different 
structures, and they are of both natural and synthetic origin. However, none of these 
compounds have been brought forward to clinical trials. Reviewing ICL inhibitors is 
beyond the scope of this thesis and, for a comprehensive review of these, we recommend 
the recent “Potential Inhibitors for Isocitrate Lyase of Mycobacterium tuberculosis and 
Non-M. tuberculosis: A Summary”, BioMed Research International (2015), by Lee.39 
1.2.1.2 Natural and synthetic bromophenols as antimicrobials 
In 2003 Xu et al.18 reported the antimicrobial activity of a small set of natural 
brominated bis-phenols, shown in Figure 7. These were tested against different strains 
of Gram positive and Gram negative bacteria: Pseudomonas aeruginosa, Escherichia 
coli, Staphylococcus aureus and Staphylococcus epidermidis. 
  
Figure 7. Natural brominated bis-phenols tested by Xu et al.18 
The compounds display highest activity in the Staphylococcus family, with 30 and 25 
showing the strongest inhibition, and are almost inactive against Escherichia coli. The 
only conclusion about the structure activity relationship is limited to compounds 29-31: 
the optimal length of -R, for the activity against Staphylococcus, is one carbon.  
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 In 2008 Oh et al.23 described the antibacterial and antifungal activities of some 
natural bromophenols and synthetic derivatives (Figure 8 – note: some compounds 
were previously discussed but the data cannot be related to that of Xu et al. because the 
strains and methods used are different). Concerning the antifungal activity, the natural 
compound 27 exhibited potent inhibition in all the four strains tested (Candida albicans, 
Aspegillus fumigatus, Trichophyton rubrum, Trichophyton mentagrophytes) with a 
minimum inhibitory concentration (MIC) two- to fourfold lower than the reference, 
Amphotericin B. Any change to the structure caused marked loss of activity, for 
example its regioisomer 68 and the derivatives with different numbers of hydroxyl 
groups are inactive. 
 
Figure 8. Natural and synthetic brominated bis-phenols tested by Oh et al.23 
The antimicrobial activity was tested against six strains of bacteria: 
Staphylococcus aureus, Bacillus subtilis, Micrococcus luteus, Proteus vulgaris, 
Salmonella typhimurium and Escherichia coli. E. coli showed resistance to all tested 
compounds. Molecules 64 and 65 can inhibit the growth of all the other strains and show 
a potent activity, especially the latter, whose MIC is comparable to that of Ampicillin. 
Analysing compounds 63-65, it is interesting to note that the activity increases when 
the number of bromine atoms increases; the same trend can be observed for compounds 
60 and 71 (which is a strong inhibitor). Surprisingly, and for unknown reasons, 
compound 62 is completely inactive. 
In 2009 and 2010 the same research group published two more papers on the 
subject. The first one considers, for the most part, chlorinated compounds.41 A notable 
structure presented in this work is 69 (Figure 9): it is roughly two times more potent 
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than ampicillin (although, as seen with most molecules with this backbone, it is inactive 
against E. coli). This result suggests that the halogen is playing an important role in 
activity and merits further investigation. 
The second report38 focused on brominated derivatives and, in addition to the 
previous antibacterial and antifungal activities, presents specific information about ICL 
inhibition. The tested compounds are shown in Figure 10. 
  
Figure 10. Bromophenols as isocitrate lyase inhibitors.38 For each column, ICL inhibition increases 
going downwards. 
All tested compounds, with the exception of the non-brominated 77 and 81, 
show strong inhibition of ICL, with potency similar or higher than the reference, 3-
nitropropionate. Compound 73 is the most active compound with an IC50 20 times lower 
than the reference. The structure-activity relationships (SAR) for ICL inhibition that 
can be obtained from this work can be summarised as follows: 
- the activity increases when the number of halogens increases (Figure 10), 
similarly to that seen for the antibacterial activity of compounds 63-65 
(Figure 8). 
- the benzophenone derivatives are more effective than their reduced 
counterparts (71-73 vs. 70, 27). 
 
Figure 9. Potent chlorinated bis-phenol 
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- on the contrary, replacement of the methylene bridge with an ether causes a 
small reduction of activity. 
- in the case of the ethers, changing the length of the bridge has little effect on 
the activity. 
Despite the positive results for the inhibition of ICL, none of the new 
compounds show interesting activity when tested in vitro. Compound 27 is still the most 
potent: this result shows the importance of balancing enzyme-based and whole-
organism studies to enable evaluation of the cell penetrating effects of new 
compounds.38  
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1.3 Radicals, ROS and oxidative damage 
“A free radical is defined as any atom or molecule that contains unpaired 
electrons and has independent existence (hence, the term free).”42 Bearing unpaired 
electrons translates into high reactivity. For this reason, radicals are usually short lived 
and tend to react, in a biological context, with different structures, ranging from 
membranes to DNA. 
Oxygen- and nitrogen-centred radicals are often associated with closely related 
and highly reactive non-radical species and are often collectively termed Reactive 
Oxygen Species (ROS). The most important species are illustrated in Table 1.42 
Radicals Non-radicals 
Superoxide (O2-) Hydrogen peroxide (H2O2) 
Hydroperoxyl (HOO•) Alkyl hydroperoxides (LOOH) 
Peroxyl (LOO•) Singlet oxygen (1O2) 
Alkoxyl (LO•) Ozone (O3) 
Hydroxyl (HO•) Hypochlorous acid (HOCl) 
Nitric oxide (NO•) Peroxynitrite (ONOO-) 
Nitrogen dioxide (NO2•)  
Table 1. Reactive oxygen species42 
The concept of oxidative stress was originally defined by Helmut Sies as “an 
imbalance between oxidants and antioxidants in favour of the oxidants, potentially 
leading to damage”.42 Cells are normally able to maintain an equilibrium between the 
production and the removal of radicals, and partially repair the damage caused by their 
activity. Alterations of these homeostasis processes have been identified in a number of 
pathological conditions.42,43 
Although radicals and the concept of oxidative stress are normally associated 
with cellular damage and pathological processes, it is important to remember that 
radicals are also involved in physiological processes. This consideration highlights the 
delicate equilibrium and the controversy that may arise in the evaluation of the activity 
of antioxidants, normally considered as protective agents but whose activity may 
reverse under different conditions.42,44-46 
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1.3.1 ROS: a brief description 
ROS generation is an intertwined, non-linear process. These species are 
produced through a number of different processes and their reactions can lead to other 
ROS. 
Superoxide radicals are mainly, but not exclusively, produced in the 
mitochondria through their electron transport system. They are also generated by 
autoxidation of small molecules (e.g. cysteine) and Fe2+ and its complexes. Cytochrome 
P450, cyclooxygenases and lipoxygenases are also among the enzymes able to produce 
this species. Superoxide is an interesting type of radical as it can either act as oxidising 
(e.g. NADH to NAD+) or reducing (e.g. Fe3+ to Fe2+) agent. Although its reaction with 
DNA, lipids and proteins is not biologically significant, its protonated form 
(hydroperoxyl radical, HOO•) and the intermediates of its reaction with Fe3+ can directly 
induce lipid peroxidation.42,47 
Superoxide is also a source of singlet oxygen and H2O2 by spontaneous 
dismutation. In the case of hydrogen peroxide, the conversion can also be catalysed by 
the enzymatic activity of superoxide dismutase (SOD), one of the enzymes involved in 
maintaining the cellular balance of oxidative species. Superoxide is also a source of 
peroxynitrite, which is produced by its reaction with nitric oxide.42,47,48 
Singlet oxygen is another important oxidant as it can directly oxidise guanine 
residues of nucleic acids, polyunsaturated fatty acids, and amino acids.42,48 
Hydrogen peroxide, also generated for the major part from superoxide radicals, 
is a poor oxidant, compared to its precursor, and is targeted by detoxification 
mechanisms, such as catalases, completing the activity of superoxide dismutase. 
Nonetheless, its activity must not be underestimated, its stability and permeability 
allows diffusion and subsequent action at other sites than its origin.42,47 
The effect of hydrogen peroxide is mediated by hydroxyl radicals (HO•) which 
are produced by interaction with transition metals (predominantly Cu+ and Fe2+). The 
reaction between these two species has become widely known as the Fenton reaction 
(Scheme 1, a).42,47 
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Scheme 1. a) Fenton reaction. b) reduction of iron (III) to iron (II). 
 It has to be noted that reconversion of Fe3+ to Fe2+ can be mediated by either 
superoxide radical or by other reducing agents, such as ascorbate. It is now evident how 
a reducing agent, widely considered as protective, can exert a pro-oxidant activity, 
allowing the cycle to continue. The reaction also provides a means to produce hydroxyl 
radicals in situ for model studies.42,48 
 Hydroxyl radicals are extremely reactive, do not exclude almost any substrate, 
and often display rates of reaction above 2×109 M-1s-1, which means the availability of 
a substrate and diffusion rate of the radical are the limiting steps of the reaction. They 
are therefore involved in lipid peroxidation, protein, DNA, RNA and carbohydrate 
damage.42 
 Alkyl hydroperoxides (LOOH), alkyl peroxyl (LOO•) radicals and alkoxyl 
radicals (LO•) are generated prevalently during lipid peroxidation processes. It is a chain 
reaction which is initiated by interaction of a polyunsaturated fatty acid with a reactive 
radical, for example a hydroxyl radical (Scheme 2, Initiation). 
 
Scheme 2. Lipid peroxidation, adapted from Thanan.49 
 The reaction of the alkyl radical (L•) with oxygen to give a peroxyl radical 
(LOO•, which can also convert to alkoxyl, LO•) and subsequent regeneration of an alkyl 
radical sustain the reaction chain in a propagation step (Scheme 2, Propagation). 42,49 
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Nitrogen radicals are another relevant group of species. Of these, nitric oxide 
(NO•) is a particularly interesting molecule. It is produced by nitric oxide synthase under 
physiological condition and it is involved in regulation of vascular relaxation, but it is 
also related to inflammation processes. It can be converted to nitrogen dioxide (NO2
•) 
by reaction with oxygen. Rapid reaction with superoxide, on the other hand, generates 
peroxynitrite (ONOO-) which is a highly toxic non-radical molecule, which can oxidise 
most biological structures.42,49 
1.3.2 Cell defence against oxidative stress 
 All organisms have developed a set of defence mechanisms to prevent, minimise 
and repair the damage caused by ROS. These mechanisms work at different levels and 
are of different nature. 
 Enzymes are a first line of defence. As previously described, superoxide 
dismutase converts superoxide into the less reactive hydrogen peroxide. This product is 
subsequently decomposed by catalase and glutathione peroxidase (GPX, Scheme 3). 
GPX and another enzyme, thioredoxin, can also decompose peroxynitrite. Glutathione 
peroxidase is part of a detoxifying system involving a number of auxiliary enzymes. 
GPX requires reduced glutathione (GSH) for its activity and converts it to the oxidised 
form (GSSG). Glutathione reductase, although not directly involved in ROS 
decomposition, is required to reconvert GSSG to GSH, allowing the cycle to continue. 
This suggests that the enzymes involved in the biosynthesis of GSH are part of the 
mechanism of protection. Glutathione S-transferase is also involved in protection from 
oxidative damage. It can conjugate products of lipid peroxidation, thus contributing to 
detoxification. Cells can overexpress this set of enzymes in response to increased 
oxidative activity as a means of protection.42 
 
Scheme 3. Detoxification of superoxide and hydrogen peroxide. SOD (superoxide dismutase), CAT 
(catalase), GPX (glutathione peroxidase), GR (glutathione reductase), GST (glutathione S-transferase). 
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 An important consideration relevant to these enzymes is their dependence on 
metals. SODs are a diverse family, some are copper and zinc dependent, while others 
require manganese. Iron is required by catalase, while selenium is necessary for GPX. 
Iron and copper, in particular, can turn from pro-oxidants, by catalysing Fenton’s 
reaction, to protective elements as part of detoxifying enzymes. To control the levels of 
metals further, many small molecules and proteins become involved in chelation of 
metals, thus contributing to regulate the oxidative stress related to their activities.42 
 Together with glutathione, other small molecules have antioxidant activity. 
Some of these are produced by the organism as in the case of melanin, which protects 
the skin from ultraviolet radiation. Others are absorbed from the diet, this is the case of 
antioxidant vitamins such as ascorbate, vitamin E and carotenoids. Other substances, 
like plant derived polyphenols, also have antioxidant activity and will be discussed in 
Chapter 1.3.4. 
 A different system involved in controlling the oxidative stress of the cell is 
nuclear factor erythroid 2–related factor (Nrf2) / Kelch-like ECH-associated protein 1 
(Keap1). Keap1 is responsible for controlling the activity of Nrf2, which is normally 
retained in the cytoplasm. As a consequence of increased oxidant stress, alteration of 
cysteine residues impairs the activity of Keap1, and Nrf2 is released. Subsequent 
translocation of Nrf2 into the nucleus and heterodimerization with other transcription 
factors allows binding to Antioxidant Response Element (ARE). Interaction with these 
promoters allows transcription of genes which are responsible for protection against 
antioxidants (SOD, among others) and xenobiotics.50-52 
1.3.3 Oxidative damage and pathologies 
Inflammation and oxidative stress are influenced by a number of environmental 
factors. As previously described, transition metals have pro-oxidant activities, and other 
chemical stimuli can lead to production of radical species. Infectious agents directly 
activate the immune response, a complex series of events which includes production of 
large quantities of radicals by activated phagocytes. Inflammation is a process involved 
in many different conditions, autoimmune pathologies, age related pathologies and 
cancers, for example (Figure 11).45,49 
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Figure 11. Oxidative stress and its involvement in neurodegeneration and carcinogenesis.49 
 Aging and age-related pathologies are linked to environmental factors and 
genetic traits, and are interlinked with inflammation and oxidative stress. Alzheimer’s, 
Parkinson’s and other neurodegenerative diseases have been liked to increased protein 
oxidative damage. Carbonyl proteins derived from oxidative activity of ROS can 
contribute to the insurgence and progress of these pathologies. Their accumulation can 
impair critical cellular functions, such as lysosomal and proteasomal degradation, and 
increase ROS production by damaging mitochondria, for example, which may also 
induce apoptosis. Carbonyl proteins have also been found in protein aggregates 
typically found in synucleinopathies (e.g. Parkinson) and Alzheimer’s disease. 
Increased oxidation of lipids, particularly abundant in neurons, has also been identified 
for most of these age related, neuronal pathologies. DNA damage is particularly 
relevant for the onset of these diseases. It is often strongly correlated with 
environmental factors, in particular exposition to high levels of transition metals. 
Damage to DNA, together with mitochondrial dysfunction, is a relevant step in 
induction of apoptosis.42,49 
Oxidative damage to lipids, proteins and, in particular, DNA, can drive 
mutagenesis and transformation of normal cells into cancer cells. The damage to DNA 
is particularly relevant in the case of nitrogen radicals, generated by inducible nitric 
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oxide synthases, whose expression is stimulated by infectious agents and other agents 
such as asbestos. Infectious agents related to cancer and DNA damage can be either 
bacterial (e.g. Helicobacter pylori), viral (e.g. human papilloma virus and hepatitis 
virus) and others (e.g. Schistosoma haematobium). Hydroxyl radicals are also involved 
in DNA damage (Figure 12). Fenton’s reaction is the major source of this radical, iron 
bound to DNA produces the radical in situ, with consequent hydroxylation of DNA 
bases. Repair mechanisms can attempt to replace the modified bases, however it is an 
error-prone system, which may introduce a wrong base, thus generating a permanent 
mutation.42,49 
 
Figure 12. Example of DNA modification.42,53 
As previously discussed, oxidative stress can play multifaceted roles. Although 
nitrative DNA damage is undoubtedly related to mutagenesis, recent studies have 
highlighted that, in specific cases, progression of cancer can be favoured by 
antioxidants. As the cell, progressively deregulated, tries to cope with increased 
oxidative stress, ROS lose their role as promoters of transformation and become a threat, 
thus inverting the role of a supposedly protective agent.46 
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1.3.4 Antioxidants as therapeutic agents 
 Due to the wide implications of radicals in aetiology and development of a 
number of pathologies, antioxidants have been the subject of extensive studies as 
preventative and therapeutic agents. 
 Antioxidants can be classified into two main categories, direct antioxidants 
which are able to react with radicals to break chain reactions, and indirect antioxidants, 
which do not react with radicals but help the cell to manage oxidative stress.52 
1.3.4.1 Direct antioxidants 
 Phenols, the main subject of this thesis, belong to the category of direct 
antioxidants, together with enzyme mimetics and polyenes. Phenols can also be 
subdivided into monophenols and polyphenols.52 
 Among monophenols (Figure 13) key examples are vitamin E and its related 
tocopherols. Trolox, used as reference for some of the assays presented in this thesis, is 
an analogue of vitamin E. 
 
Figure 13. Vitamin E and Trolox. 
 Studies on the role of vitamin E in Alzheimer’s disease (AD), Parkinson’s 
disease (PD), Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS) gave 
varying results. Whilst vitamin E proved effective in delaying ALS, in the case of AD, 
the results prove contradictory, and there is no clear indication for the use of vitamin E 
supplements. In the other diseases, it appears that it does not provide any beneficial 
effect but in combination with other antioxidants, slowed progression of age-related 
macular degeneration (AMD). On the other hand, potential negative effects of large 




Figure 14. Examples of different polyphenols. 
 Stilbenoids like resveratrol, flavonoids like quercetin and other natural products 
like curcumin belong to the polyphenol group (Figure 14). The compounds synthesised 
during this work also belong to this family. This group of compounds is vast, if we 
consider that more than 8000 flavonoids are currently known. Many of these substances 
enter our diet daily, with flavonoids being probably the most relevant. These 
compounds, on top of their direct radical quenching ability, display metal chelating 
properties (thanks to the catechol and α-hydroxyketone), thus increasing their protective 
ability. Resveratrol and its analogues have been evaluated for their activity, in particular 
with AD, and proved to be an interesting starting point for development of novel 
therapeutic agents. Curcumin, a component of turmeric, has been widely evaluated for 
a number of pathologies. It showed ameliorating effects in cardiovascular diseases, 
where inflammation plays a major role. In atherosclerosis, where oxidation of lipids is 
a critical factor, ischaemia and reperfusion, and other cases, there are significant 
indications of positive effects from treatment with curcumin.59-62 
 
Figure 15. Examples of catalytic antioxidants. 
Ebselen and its analogues belong to a different group of direct antioxidants, and 
display a catalytic activity (Figure 15). Ebselen is converted to its selenol by 
thioredoxin, thioredoxin reductase and GPX. In this form, it reacts quickly with 
hydrogen peroxide, which is decomposed to water, and it is converted to the 
corresponding selenic acid. Upon internal cyclisation and consequent loss of water 
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ebselen is regenerated (Scheme 4). It can also inhibit nitric oxide synthase (NOS) and 
lipooxygenase among other enzymes, with additional antioxidant/anti-inflammatory 
effect. It is a promising agent, with potential activity in reducing oxidative damage 
associated with cardiovascular pathologies, diabetes, asthma and xenobiotic toxicity 
(cis-platin, cadmium, etc).52,63,64 
 
Scheme 4. Catalytic cycle of Ebselen. 
Ebselen is not the only agent with catalytic activity, some manganese complexes 
also display antioxidant activity. Metalloporphyrins, such as the one reported in Figure 
15, display SOD-like and catalase-like activities. 52,64 
 
Figure 16. beta-Carotene. 
The last group of direct antioxidants is constituted by the carotenoids (β-
carotene, Figure 16) and similar polyene structures, commonly found in plants. They 
readily react with singlet oxygen and peroxyl radicals forming stabilised radicals, 
thanks to their highly conjugated structures. Although these compounds display 
therapeutic effects in AD prevention, there is no evidence linking their mechanism of 
action with their antiradical properties. 52  
 25 
1.3.4.2 Indirect antioxidants 
 In contrast to direct antioxidants, these compounds do not react with ROS, but 
support the mechanisms of protection of the cell. 
 
Figure 17. Ubiquinone. 
Quinones and their (poly)prenylated analogues (vitamin K group) are essential 
factors for varied physiological functions. Ubiquinone (Figure 17) is a notable member 
of this group and is involved in the mitochondrial electron transport chain. There are 
indications of potential beneficial effects in treatment of PD, HD and AD. 52,65 
 
Figure 18. Natural compounds involved in Nrf2 regulation. 
 A different type of mechanism is the induction or repression of systems involved 
in oxidative stress protection. This is the case for some nitrone spin labels. Although 
these molecules can indeed react with radicals and form adducts, the initial reason for 
interest in these molecules, they can also induce protective pathways. Interaction with 
the previously described Keap1/Nrf2 path, may produce a similar effect. Any substance 
able to induce Nrf2 activity would lead to translation of antioxidant enzymes, thus 
decreasing oxidative stress. Epigallocatechin and curcumin, which are also a direct 
antioxidants, are examples of natural products able to activate this regulatory pathway 
(Figure 18). In these two cases, Nrf2 activity is induced indirectly through 
phosphorylation by an upstream kinase (protein kinase C delta).52,66,67 
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1.4 Brominated bis-phenols as antioxidants 
 As previously described, mono- and poly-phenols display direct antioxidant 
properties. Halogenated bromophenols belong to this family of compounds. Extracts 
from algae, isolated compounds and synthetic derivatives have been tested both in vitro 
and in vivo to evaluate their potential antioxidant potential. A brief summary of the most 
relevant results is herein presented.  
In 1998, Park reported the antioxidant activity of a methanolic extract of 
Symphyocladia latiuscula.68 Subsequently, the same research group isolated, from the 
same alga, three bromophenols with 1,1-diphenyl-2- picrylhydrazyl (DPPH) radical 
scavenging activity (Figure 19).24 
 
Figure 20 Brominated mono and bis-phenols with radical scavenging activity 
 
Figure 19. Bromophenols with antioxidant activity and their reaction with DPPH radical 
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 In 2007, Duan tested a set of natural bromophenols isolated from Symphyocladia 
latiuscula (Figure 20) for their DPPH radical scavenging activity. The compounds were 
tested against the known antioxidant butylated hydroxytoluene (BHT), showing a 
potency 3.3- to 10-fold higher. From a SAR point of view, in agreement with previous 
observations by Son,69 the activity increases with the number of hydroxyl groups: 87-
90 are more potent than the monophenols 83-86 and 48.70 
 The same research group reported the antioxidant activity of other brominated 
phenols isolated from Polysiphonia urceolata (Figure 21) and confirmed the previous 
observation about the relationship between potency and number of hydroxyl groups 
(Figure 21).27,28 
 
Figure 21. Brominated mono- and bis-phenols with radical scavenging activity27,28 
 Following on from this, Zhao tested a large library of synthetic halophenols as 
antioxidants and cytoprotective agents (Figure 22).71 The compounds were tested for 
their DPPH radical scavenging activity. The chosen set demonstrated the importance of 
the hydroxyl groups for the activity: compounds 96-104b and 96-104d were active and 
most of them showed a potency higher than BHT (up to almost 3-fold for 98b); on the 
contrary, their methoxy analogues (96-104a and 96-104c) did not show any antioxidant 
activity. 
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 The compounds were also evaluated in vivo for their cytoprotective activity 
against H2O2-induced injury in human umbilical vein endothelial cells (HUVEC). Some 
SAR considerations were drawn from the results: 
- the methoxy compounds were not active, the presence of hydroxyl groups is 
necessary 
- the presence of a bromine or chlorine is necessary 
- unlike the radical scavenging activity, the potency in vivo does not increase 
with the number of hydroxyl groups (100b,d, 101b,d are inactive)  
- the position of the halogen can influence the activity (104c, with a chlorine 
in the para position is active, but its regioisomers do not provide protective 
activity)71 
 
Figure 22. Halophenols as antioxidants and cytoprotective agents71 
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1.5 Previous Work 
The work described in this thesis is a continuation of previous work of our 
research group, published in 2011.72 This study led to a set of interesting compounds, 
which are presented in Figure 23. 
 
Figure 23. Brominated bis-phenols with a side chain72 
These new compounds present two main differences with the previous reports: 
they are based on resorcinol instead of catechol and phenol, the main building blocks 
of the natural compounds, and bear a side chain on the methylene bridge. For these 
compounds, the ICL inhibition follows the same trend described by Oh for the 
catechols:38 higher number of halogens, higher potency. This is valid also for the side 
chain and different halogens: the most potent compound of the group is 111 and its 
activity is comparable with that of the natural compound 27. The good activity of these 
compounds shows that resorcinol derivatives can also inhibit ICL and a catechol-based 
structure is not mandatory.  
Compounds 107 and 109 possess high antibacterial activity, especially the latter, 
with an activity comparable to ampicillin. It is relevant to note that, exactly as described 
for ICL inhibition, the potency increases with the number of halogens. 
Regarding the side chain on the bridging carbon, different substitutions lead to 
small variations in activity, indicating the possibility of further development of the 
bridging substituent to improve the receptor binding. 
Also, it is immediately evident that they present four hydroxyl groups each. As 
previously described, these are directly related to the radical scavenging properties of 
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bromophenols and thus these molecules may also present antioxidant behaviour, 
although this has not yet been investigated. 
These compounds are also interesting as they constitute rational building blocks 
toward the synthesis of substituted resorcarenes, an active area of research in the group. 
Cyclisation of two dimers with a differently substituted aldehyde has previously been 
described to obtain resorcarenes with alternating substituents on the bridge,73 providing 
additional interest into these compounds. 
1.6 Aim of the Project 
Following our previous results, the aim of the present work is to prepare new 
families of resorcinol derivatives and investigate their activity as antimicrobials and 
antioxidants. The scope of the SAR of the previously synthesised resorcinol dimers will 
be expanded by variation of the number and type of halogens, the number of monomers 
will be increased to four and six, and simpler structures will also be included for 
comparison (Chapters 2 and 3). In addition, these novel, multivalent structures will be 
exploited as dendrimer cores, to prepare a new class of multicalixarenes (Chapter 4). 
Since most of the compounds have never been prepared before, their 
antiproliferative activity will also be assessed (Chapter 5). Finally, simple antioxidant 
tests will be presented to evaluate potential radical scavenging properties (Chapter 6). 
For simplicity, every chapter will introduce the rationale behind the synthesis or 
assays for the compounds under consideration. 
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2. Dimers and Tetramers 
In this chapter, the synthesis of the first two main families of compounds will 
be presented. The first one, the dimers, is closely related to the compounds previously 
synthesised by our group, while the second is an extension to more complex, tetrameric 
structures. 
2.1 Introduction to Resorcinol and Phloroglucinol 
Dimers 
Similarly to the compounds in our group’s previous report, the dimers family 
consist of a set of bis-phenols with a bridging substituent (Figure 24). However, in this 
case, the compounds prepared bear up to four halogens, in various combinations, and 
these are not limited to bromine. The interest in chlorine lies in its similarity with 
bromine (electronegativity, lipophilicity, sigma-hole), although with a lower molecular 
mass. Chlororesorcinol is also readily available and offer some advantages over 
bromine, relative to its reactivity, as discussed in further chapters. 4-Fluororesorcinol 
based analogues have also been considered due to the low molecular weight and strong 
inductive effect of fluorine. Also, differently from bromine and chlorine, it does not 
present a sigma-hole. 
  
Figure 24. Previous and current work examples. 
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Initially, only the products with 4-hydroxybenzyl and pentyl substituents on the 
bridge were chosen. However, once the synthetic method was refined, allowing easy 
access to more products, other functional groups have been considered. 
In addition, the synthesis of a phloroglucinol-based set was added, allowing 
evaluation of the effect of additional hydroxyl groups. 
2.2 Introduction to Resorcinol Tetramers 
 The basic tetramers synthesised in this work are effectively presenting the same 
bis-resorcinol component twice, arranged around a central phenyl ring (Figure 25). 
Since the sidechain of dimers did not produce great variation in the activity, at least in 
the case of ICL binding,72 it is worth investigating whether a “doubled” structure can 
produce a better result. In the case of the antioxidant activity, since it is correlated with 
the number of available hydroxyl groups, tetrameric structures are expected to offer a 
significant advantage compared to their dimeric analogues. 
 
Figure 25. Tetramer with a central phenyl ring. 
Additionally, since these structures present eight functionalizable hydroxyl 
groups, with a well organised topology, they could also be very interesting as potential 
dendrimer cores, allowing access to differently organised structures. 
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Figure 26. Biaryl and flexible tetramers. 
In addition to the basic tetramers, built around a benzyl group, two additional 
sets of tetramers were planned (Figure 26). Biaryl-tetramers have a similar but longer, 
biaryl central structure, which maintain a certain degree or rigidity. Alternatively, 
flexible tetramers can be prepared by building around an alkyl chain, which allows 
control of the distance between the units and introduces considerable flexibility around 
its centre. 
2.3 Introduction to Resorcinol Hexamers 
 Hexamers are the largest resorcinol-based structures considered (Figure 27). 
They are also the most interesting from the point of view of the raw number of 
functionalizable hydroxyl groups. With twelve anchoring points, uniformly distributed 
around a central phenyl ring, they constitute a very attractive, novel dendrimer core in 
addition to their medicinal chemistry applications. 
 
Figure 27. Hexamers. 
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2.4 Synthesis of dimers 
The synthetic approach for this class was planned based on previous work by 
the group.72 Proceeding by retrosynthesis: for all compounds, the final and crucial step 
of the procedure is the condensation of an aldehyde (which bears the bridging sidechain) 
and the halogenated monomer (resorcinol/phloroglucinol-based) – Scheme 5, a. This 
key step is an acid-catalysed condensation. As subsequently described, it is strongly 
influenced by both the aldehyde and the reactivity of the resorcinol and a number of 
different conditions were investigated. 
 
Scheme 5. Retrosynthesis of dimers. 
Whilst 4-fluoro/chloro/bromo resorcinols are commercially available, synthesis 
of 4-bromoresorcinol (116) is rapid and more cost-effective and was therefore 
employed. However, selective introduction of one bromine atom on activated aromatics 
such as resorcinol and phloroglucinol cannot be achieved directly, while 
polyhalogenation is rapid and leads to complex mixtures. For this reason, in the case of 
4-bromoresorcinol, a carboxylic group is exploited as protecting group (Scheme 5, b), 
and it also reduces the reactivity of the resorcinol, thus allowing access to a 
monosubstituted product which can be conveniently decarboxylated. 
For dibromoresorcinol (119) and mono- (122) and dibromophloroglucinol 
(123), dehalogenation of a fully brominated substrate (124) is more convenient 
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(Scheme 5, c). Synthesis of tribromo-resorcinol/phloroglucinol is rapid and convenient 
thanks to their high reactivity towards bromination. 
2.4.1 Synthesis of 4-bromoresorcinol 
 Synthesis of 4-bromoresorcinol was achieved with a method previously 
employed within the group and based on a work by Sandin (Scheme 6).74 2,4-
Hydroxybenzoic acid is initially brominated to give 117. The product is isolated by 
precipitation and subsequent thermal decarboxylation on the crude material produces 
116 after flash chromatography, with an overall yield of 43%. 
 
Scheme 6. Synthesis of 4-bromoresorcinol. 
2.4.2 Synthesis of 2,4-dibromoresorcinol 
Synthesis of compound 119 from resorcinol also requires two steps. Positions 4 
and 6 are more reactive than position 2; therefore, to synthesise compounds which bear 
a bromine in position 2 such as 119 and 126, complete substitution of all activated 
positions was initially pursued. Subsequently, a debromination approach similar to that 
reported by Kiehlmann75 was used (Scheme 7) to yield the di-substituted compound. 
  
Scheme 7. Synthesis of 2,4-dibromoresorcinol. 
The reaction conditions were not optimised but the chosen strategy offered a 
simple route to the desired products with a yield over two steps of 54% and 10%, for 
119 and 126, respectively. 
2.4.3 Synthesis of 2,4-dibromophloroglucinol 
Due to the strong activating effect of hydroxyl groups, bromination of 
phloroglucinol is fast and proceeds rapidly to the tribrominated product. Therefore, 
monobromo- and dibromo-phloroglucinol can be prepared either by debromination of 
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tribromophloroglucinol or bromination and deprotection of a phloroglucinol derivative 
(Scheme 8, a).75 
 
  
Scheme 8. Synthesis of 2,4-dibromophloroglucinol (123). a) Possible routes to 2,4-
dibromophloroglucinol. b) Approach used to synthesise 2,4-dibromophloroglucinol. 
The debromination approach (Scheme 8, b) was chosen for a number of reasons. 
Firstly, mono- and dibromophloroglucinol can be easily separated by flash 
chromatography. Secondly, debromination can be performed on the crude 
tribromophloroglucinol and thus the procedure allows a simple, quick, two step 
procedure with only a final purification. Thirdly, monobromination of 
trihydroxybenzoic acid (which is also more expensive than phloroglucinol) is not truly 
selective, and the intermediate requires purification, increasing the number of steps 
required. Finally, CS2 is not a convenient solvent, due to its toxicity. 
The chosen procedure allows, in a few hours, the preparation of 123 and 122 
with a yield over two steps of 14% and 12% respectively. Unreacted 124 is easily 
separated by filtration and can be recycled. 
2.4.4 Synthesis of phloroglucinol and resorcinol dimers 
The synthesis of phloroglucinol and resorcinol dimers was investigated 
according to the procedure used by Bouthenet.72 Condensation of halogenated 
resorcinol or phloroglucinol (Scheme 9, Monomer) with an aldehyde was performed 
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in a 1:1 solution of ethanol and 37% hydrochloric acid at 70 °C over three hours 
(Scheme 9). For convenience, this method will be henceforth referred to as Method 1. 
 
Scheme 9. Method 1. 
Compound 131, which is one of the novel dibromoresorcinol-based structures 
required, was chosen to test the reaction (Scheme 10). 4-Hydroxybenzaldehyde (130) 
was selected as condensation partner because the product would give two well defined 
doublets in the 1H-NMR. 
 
Scheme 10. Synthesis of 131. 
The expected compound was obtained, although only traces of product were 
isolated. The NMR data are consistent with the proposed structure. The molecule shows 
a potential plane of symmetry (Figure 28): hydrogens 1, 9 and 10 show three different 
peaks, each one integrating for two hydrogens. As expected, in the 13C-NMR, eleven 
different peaks can be identified. The connectivity to the bridge was confirmed by 
HMBC: 3J couplings were observed between carbon 7 and hydrogens in positions 9 and 
1. 
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Figure 28. Long range coupling of the bridge in 131. 
The same conditions were then tested with 123, however, the reaction did not 
give the expected compound, instead a complex mixture of undefined products was 
obtained (Scheme 11). Given that 4-hydroxybenzaldehyde might not be reactive 
enough and the product may be susceptible to retro Friedel-Crafts reaction, (Chapter 
2.5.5,) dimerization with formaldehyde was considered. It is more reactive than its 
higher analogue, less hindered and not susceptible to electrophilic attack. 
 
Scheme 11. Synthesis of 132. 
In this case, dimerisation of compound 123 with formaldehyde (Scheme 12), 
led to the expected compound, 134, even though the yield is very low (4%). 
Dimerisation with formaldehyde worked with brominated resorcinols as well, allowing 
the preparation of 135 (3%) and 136 (20%).  
 
Scheme 12. Synthesis of 134, 135 and 136. 
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All these reactions provided complex mixtures, with consequently difficult and 
inefficient purification. It has to be noted that TLC/column chromatography on silica 
gel is not particularly suitable for these compounds; firstly, the compounds have a 
significant tendency to tailing, which is slightly controllable by addition of acid. 
Secondly, many products have high absorbance/fluorescence due to their aromatic 
nature, causing difficulties in discriminating relevant products/impurities. Considering 
the fact that reproducibility is also low, finding a new method with larger scope, better 
yields and easier purification was necessary.  
2.4.5 Synthesis of Dimers with Method 2 
Bacci and co-workers reported a method for a two-step synthesis of fluorones 
through bis-phenols. The first condensation (Scheme 13), leading to a bis-resorcinol, 
involves a methanesulfonic acid-catalysed condensation in DCM/diethyl ether, which 
is a less polar system compared to the previously used water/ethanol media.76 
 
Scheme 13. Bacci’s synthesis of bis-phenols. 
This alternative reaction was tested with the synthesis of 140 (Scheme 14). One 
equivalent of aldehyde was condensed with an excess of 4-chlororesorcinol (2.5 
equivalents), using a 1:1 solution of DCM:Et2O with 8% of methanesulfonic acid as 
catalyst. Under these conditions the product was obtained in five hours: NMR of the 
reaction mixture shows only the product and the remaining excess of resorcinol.  
 
Scheme 14. Synthesis of 140. 
The real improvement required for this reaction is the purification. Bacci used 
chromatographic methods, however a more convenient approach was sought. In most 
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cases these products do not precipitate from the reaction mixture and the excess of 
haloresorcinol cannot be removed by extraction. 
In an attempt to avoid flash chromatography, an initial extraction to remove the 
acid and a subsequent crystallisation were attempted. Crystallisation from diethyl ether, 
DCM, methanol, hexane and their combinations could not be achieved, and it was clear 
would require optimisation for every compound. 
Considering that monohalogenated resorcinols are soluble in water, a different 
and less conventional approach was used. The reaction mixture was diluted with diethyl 
ether to reduce its density below that of water and poured on distilled water. The 
multiphasic system was vigorously allowed to stir until the organic solvent evaporated 
completely, producing a solid suspension. The solid was collected on a Büchner  filter 
and washed with further water to give the product. This method allows quick 
purification and removal of residual acid, which is essential to avoid degradation of the 
stored compound. 
Using this method, a first set of dimers was produced (Figure 29, black 
structures). The products were obtained in yields ranging from 18 to 91%, with most 
reaction producing good, higher than 50%, yields. Compound 144 is a special case, it 
requires an additional crystallisation step, as the reaction is not as clean as the others, 
thus lowering the yield considerably. 
 
Figure 29. Set of dimers. Black structures: obtained as pure compounds. Red structures: reaction leads 
to mixtures of products. Blue structures: a solvent or reagent could not be removed completely. 
 The purification method employed, although very convenient and rapid, has a 
simple disadvantage: compounds with relatively good solubility in water provide lower 
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yields. All compounds show a marked tendency to retain water, which cannot be 
completely removed. Quantification of the water was attempted by thermogravimetric 
analysis however the compounds quickly decompose, preventing quantification. 
Calculation of water content was therefore performed indirectly: the product content in 
weighed samples was measured by quantitative NMR and the amount of water was 
obtained by difference. 
 Compared to Method 1, previously used in the group to synthesise 107, 111 and 
109,72 the present approach is more convenient as it avoids purification by flash 
chromatography, allowing immediate access to the products. The yields (Table 2) are 
also superior, except in the case of 109, probably as a consequence of the higher 
solubility provided by the additional phenol. 
Yield Method 1 (%) Method 2 (%) 
107 22 41 
111 36 84 
109 63 34 
Table 2. Comparison of yields of Method 1 and 2 for 107, 111 and 109. 
As discussed in detail (Chapter 2.5.5), dibromoresorcinol requires longer 
reaction times. After ten days it was possible to isolate 154 and 153. However, the 
reaction does not reach completion and removal of the aldehyde is necessary. To do so, 
following precipitation in water, toluene was used to wash the solid product. 
Unexpectedly, compound 153 displayed very high affinity with toluene (Figure 30). 
Repeated washes and co-evaporations with different solvents were not helpful, thus its 
purification was not possible. Chromatographic purification could lead to the pure 
product, however it was not pursued as a number of analogues were already available. 
 
Figure 30. NMR of 153, with the signals of toluene highlighted. Recorded in DMSO-d6 at 400 MHz. 
Compound 156 was also successfully synthesised, however the aldehyde cannot 
be removed from the mixture with toluene. The NMR (Figure 31) respects the canons 
dictated by all the other isolated compounds but the product could not be isolated in 
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pure form with the method in use. Preparative HPLC will have to be considered for its 
isolation, were it necessary. 
 
Figure 31. NMR of 156 and presence of aldehyde. Recorded in DMSO-d6 at 400 MHz. 
 In contrast to those previously described, compounds 152 and 155 led to 
complex mixtures, in which the expected compound could not be clearly identified by 
NMR and purification was not pursued. 
An alternative approach to the synthesis of tetrabrominated dimers would be the 
bromination of their dibrominated precursors by NBS (as in Chapter 2.5.9 for 
tetramers), although this has not been attempted. 
This synthetic approach using methanesulfonic acid as catalyst was extensively 
used throughout the project and, for convenience, will be henceforth referred to as 
Method 2. The effect of the solvent and side reactions leading to complex mixtures, 
together with a comparison between Method 1 and Method 2 will be discussed in 
(Chapter 2.5.5). 
2.5 Synthesis of tetramers 
 As discussed in the introduction to this chapter, to evaluate whether increasing 
the number of halogenated resorcinol units produces better activity, synthesis of 
tetramers was also undertaken. 
2.5.1 4-Bromoresorcinol based tetramers 
Application of Method 2 to the synthesis of tetramers was straightforward. 
Reaction of 1 equivalent of benzene-1,4-dicarboxaldehyde with 4.5 equivalents of 4-
bromoresorcinol led to the expected product, 158,  in 87% yield (Scheme 15). The 
purification of this compound was different from that used for the dimers. The reaction 
mixture was diluted with diethyl ether and left overnight at 4 °C to give large crystals. 
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Identity of the compound was confirmed by NMR and high resolution mass 
spectrometry.  
 
Scheme 15. Synthesis of 158. 
The molecule displays two planes of symmetry and thus the resulting 1H-NMR 
spectrum is simple. Three singlets, at 6.8, 6.5 and 6.5, each assigned an integral of four, 
identify the aromatic hydrogens (Figure 32. b, c, d) and a singlet at 5.7, with an integral 
of two, represents the bridge’s proton (Figure 32. a). Assignments were confirmed by 
HSQC and HMBC. 
 
Figure 32. NMR of 158. Recorded in DMSO-d6 at 400 MHz. 
To obtain the geometrical isomers, required for activity comparison and 
different presentation of hydroxyl groups for dendrimer development, the reaction was 
also performed with benzene-1,3- and benzene-1,2-dicarboxaldehyde (Scheme 16). 
The reaction with benzene-1,3-dicarboxaldehyde (159) readily proceeded to the 
expected product (160) in 61% yield. 
However, under these conditions, the ortho isomer (161) did not lead to the 
expected product and the formation of a complex mixture was observed (Scheme 16). 
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Scheme 16. Synthesis of 160 and attempted synthesis of X. 
For these compounds, crystallisation from organic solvents is not ideal as a final 
purification step. The crystals include the solvent and a small amount of acid which 
shortens the shelf life of the product and has to be removed before testing in biological 
systems or in vitro assays. To obtain an acid-free product without solvents of 
crystallisation, trituration of the product in water is the ideal procedure and was used to 
prepare all samples required for testing. 
2.5.2 4-Chlororesorcinol based tetramers 
To prepare the chloro- substituted analogues, the same reactions were conducted 
using 4-chlororesorcinol. 4-Chlororesorcinol is commercially available and 
inexpensive, allowing scale-up and testing without the need of synthesising 
intermediates (Scheme 17). 
 
Scheme 17. Synthesis of 163, 164 and 165. 
Synthesis of 163 proceeded as expected and provided the product in 87% yield. 
Unexpectedly, 164 did not crystallise in a reproducible way, but the product could be 
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isolated by evaporation on water, as with the dimers. The product can be alternatively 
prepared as described in Chapter 2.5.4. 
Compound 165 behaved rather differently from its analogues. Precipitation of 
the product in large quantities impaired the stirring and progress of the reaction, with 
subsequent formation of a relevant by-product (Chapter 2.5.3). The reaction was 
changed to provide better stirring and the volume of the solvent was also increased. 
Compound 165 was then obtained as a green solid in 94% yield.  
After changing geometry, symmetry is mantained. In all cases, each resorcinol 
monomer is equivalent to the others in the molecule, thus giving two singlets for the 
aromatic hydrogens (Figure 33, 6.6 to 6.2 ppm) and two singlets for the hydroxyl 
groups (above 8.8 ppm). Between 7.2 and 6.6 ppm the peaks of the central ring are 
observed (Figure 33). Between 5.7 and 5.6 ppm the bridge singlet can be identified. 
 
Figure 33. 1H NMRs of 165 (a), 164 (b) and 163 (c). All spectra were recorded in DMSO-d6 at 400 
MHz. 
2.5.3 By-products of 165 and their equilibrium 
 As previously stated, the initial conditions and set-up used for the synthesis of 
165 led to a non-homogeneous mixture. Despite this, isolation of the product by 
filtration led to pure 165, although in poor yields. The reaction was followed by 1H-
NMR to investigate whether it was slower than the previous reactions, potentially as a 
consequence of steric hindrance, and thus to optimise the reaction conditions. The 
aldehyde was quickly and completely consumed, but the presence of an unidentified 
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product was revealed. Since the product of the reaction is solid and insoluble, complete 
isolation of it by filtration was possible. The remaining liquor was slowly evaporated, 
producing crystallisation of the by-product – 166 (Figure 34).  
 
Figure 34. Structures of 165, 166 and 167. 
In order to understand the reaction fully, 167 was synthesised. Phthalaldehyde 
reacted with two equivalents of 4-chlororesorcinol under Method 2 conditions. The 
expected product was isolated by filtration. Interestingly, intermediate 166, also visible 
in the 1H-NMR, was collected by crystallisation of the remaining liquor. 
For aldehyde 167 (Figure 34), three peaks are expected in the low field range 
of the 1H NMR, two for the hydroxyl groups (Figure 35, b, a) and one, at highest ppm, 
for the aldehyde (Figure 35, g). Two singlets identify the hydrogens of the resorcinol 
(Figure 35, e, f). The open aldehyde exerts a strong deshielding effect on the bridge 
(Figure 35, d), causing an upfield shift of about 1.5 ppm, compared to its closed 
analogue. The presence of an aldehyde can also be clearly identified by 13C-NMR: in 
Figure 36, the presence of a peak at 191.7 ppm is a distinctive trait of 167. 
 
Figure 35. 1H-NMR of 167 (DMSO-d6 at 400 MHz). 
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Figure 36. 13C-NMR of 167. Recorded in DMSO-d6 at 400 MHz. 
Considering the distances between the aldehyde and the hydroxyl groups, 
formation of an acetal was a reasonable hypothesis. The structure was drawn and 
minimised with GAFF force field in UCFS Chimera (Figure 37) and displayed 
reasonable angles and bond distances, suggesting that the acetal could be formed.  
 
Figure 37. Structure of 166, minimised with GAFF force field and rendered in UCSF Chimera. 
Results from 1H-NMR proved consistent with the proposed structure. In DMSO-
d6 (Figure 38), compound 166 displays a single peak above 9 ppm, corresponding to 
the hydroxyl groups. Two singlets identify the isolated hydrogens of the resorcinol 
groups (Figure 38, c, e). The position of the bridge is consistent with the other structures 
previously described (Figure 38, f). As expected, the hydrogen of the acetal lies in the 
region of the aromatics, downfield of the bridge Figure 38, d). The connectivity of 166 




Figure 38. 1H-NMR of 166. Recorded in DMSO-d6 at 400 MHz. 
 
Figure 39. 13C-NMR of 166. Recorded in DMSO-d6 at 400 MHz. 
Since 166 has a unique bicyclic structure, crystallisation and X-ray diffraction 
was also used to confirm the structure and verify its topology. As expected from the 
initial modelling, the molecule displays a triplanar structure (Figure 40, top). The 
hydrogens of the hydroxyl groups are the only atoms out of any plane. They act as 
hydrogen bond donors towards a molecule of ether on one side, and towards another 




Figure 40. Crystal structure of 166. Top, a single molecule of 166 hydrogen bonded with a diethyl 
ether molecule and chain-like arrangement of 166 within the crystal, bottom. 
As previously said, using the first method employed to obtain 165, a mixture of 
166 and product was obtained (Scheme 18). Curiously, aldehyde 167 was not isolated 
from the reaction; it is an unexpected result because it is the obvious intermediate in the 
formation of 166.  
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Scheme 18. Synthesis of 165 and 166. 
To investigate this anomaly, phthalaldehyde was treated with two equivalents 
of 4-chlororesorcinol and the reaction was followed by 1H-NMR (Figure 41). Both 167 
and 166 are present in the reaction mixture after 6 and 24 hours; the ratio between the 
two is stable and is 1.6 to 1, respectively (Figure 41). 
 
Figure 41. 1H-NMR of the reaction mixture after 6 and 24 hours and spectra of 166 and 167 as 
reference compounds. All spectra were recorded in DMSO-d6 at 400 MHz. 
 Additionally, reaction of the closed acetal 166 (Figure 42, a) with an excess of 
4-chlororesorcinol led to the expected tetramer, 165 (Figure 42, b). Over the course of 
the reaction, the open aldehyde was also identified by 1H-NMR (Figure 42, c).  
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Figure 42. Reaction of the closed acetal 166 (a) with 4-chlororesorcinol to give 165 (b) at 7 and 24 
hours showing presence of 167 (c) during the reaction. All spectra were recorded in DMSO-d6 at 400 
MHz. 
These results suggest that the acetal is involved in an equilibrium with its 
aldehyde form. During the initial reaction for 165, probably due to the large amount of 
product formed, which tends to bind water effectively, the equilibrium was likely to 
have been pushed towards acetal 166, explaining why aldehyde 167 was not isolated 
(Scheme 19). 
 
Scheme 19. Equilibrium between 166 and 167. 
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2.5.4 Method 1 for the synthesis of tetramers 
 Despite the earlier failures with the use of Method 1 for the synthesis of dimers, 
it was additionally investigated for the synthesis of tetramers. The results are listed in 
Table 3. With 4-bromoresorcinol, only Method 2 provided results. Surprisingly, 
Method 1 produced the expected compounds with good yields in the case of 4-
chloro/fluororesorcinol based tetramers. This was particularly useful in the synthesis of 
164, which did not crystallise as easily as its regioisomers. Isolation of 164 using 
Method 2 required evaporation of ether from a water mixture as seen for the dimers. 
This is not convenient for large scale reactions. With Method 1, evaporation of the 
solvent, resuspension of the solid in water and filtration provides the pure product in 
excellent yields (91%). However, except for the specific case of 164, Method 2 
provides better yields and its scope additionally covers the bromoresorcinol derivatives. 
 
Table 3. Yields of the reaction between 4-haloresorcinols and isomeric benzene dicarboxaldehydes 
under reaction conditions of Method 1 and 2. 
 Fluoro-derivative 168 was prepared to evaluate the effects of fluorine as a 
substituent in the following biological and in vitro studies. Due to the cost of the starting 
material, only one example was prepared and further analogues will be synthesised if 
the substitution proves valuable. As opposed to its chloro- and bromo-analogues, its 
solubility in water is significantly higher and is probably the cause of the poor yield of 
the reaction, especially in the case of Method 1. 
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2.5.5 Side reactions and scrambling 
 The different behaviour of tetramers and dimers towards Method 1 and 2 was 
further investigated. In the presence of strong acids, activated aromatic compounds are 
expected to undergo retro-Friedel-Crafts fragmentation (Scheme 20, a).  
This behaviour was confirmed by Bacci with similar structures (Scheme 20, 
b).76 Formation of highly reactive benzhydryl cations leads to unexpected products and 
polymerisation. In their experiments fluorinated bis-phenols were fragmented in neat 
methanesulfonic acid and the cation trapped using triethylsilane to obtain 175 in 81% 
yield. They also observed fragmentation on the aniline ring under Method 2 conditions 
(Scheme 20, c).  
 
Scheme 20. Retro-Friedel-Crafts fragmentation. General mechanism (a) and fragmentations observed 
by Bacci76 (b, c). 
Their results suggest that fragmentation is the main cause of poor yields and by-
products formation. In light of this, it was interesting to review our previous results. The 
harsh conditions of Method 1 favours formation of by-products: high polarity of the 
solvent stabilises the ionic intermediates, and high temperatures increase the rate of 
fragmentation. Method 2 uses low polarity solvents and lower temperatures. This is 
particularly reflected in the synthesis of dimers, such as 131 (see page 37). 4-
Hydroxybenzaldehyde is activated and prone to retro-Friedel-Crafts (Figure 43). If we 
also consider the fact that dibromoresorcinol is a relatively poor nucleophile, it is easy 
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to expect very low yields (traces in this case). However, with formaldehyde, which is 
more reactive and does not have a side chain susceptible to retro-Friedel-Crafts, 
dibromoresorcinol produces considerably better yields (136, 19.5%). Interestingly, 
when 4-bromoresorcinol reactes with formaldehyde to give 135 (see page 38), the yield 
is again very poor (2.6%), probably as a consequence of the susceptibility to 
protonation. 
 
Figure 43. Yield of some compounds with some favourable fragmentation points highlighted. 
Regarding tetramers, fragmentation by electrophilic addition to the central 
benzene is unlikely, as it is not activated. Therefore, fragmentation can be considered 
as directly dependent on resorcinol substitution.  Chlorine is more electronegative than 
bromine, and the subsequently less electron-rich resorcinol displays slower 
fragmentation rates. This explains the difference between 158 and 163. In fact, only the 
former has been isolated under Method 1 conditions. One would expect even better 
results for fluororesorcinol, however, this cannot be verified by isolated yields as it is 
fairly soluble in water, with consequent product loss during purification. 
 Since Bacci isolated the sideproduct derived from fragmentation of his aniline 
sidechain in the conditions of Method 2, it was relevant to verify whether and to what 
extent chloro and bromoresorcinol were giving fragmentation in the case of our 
tetramers (especially considering that we obtained the pure products without the 
necessity of any chromatographic purification step). 
Compound 163 was reacted with an excess of bromoresorcinol (5 eq) under both 
Method 1 and 2 conditions, for five hours in both cases. The results are presented in 
Figure 44 and Figure 45. It is immediately evident that Method 1 leads to 
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fragmentation (presence of chlororesorcinol in the reaction mixture) and significant 
polymerisation (broad, undefined mounds). Method 2 produces scrambling as well, 
although to an evidently lesser extent. This shows that aldehyde-dimers, like 167, are 
unlikely to be useful for the synthesis of mixed tetramers as scrambling would occur, 
producing complex mixtures of different tetramers. To prepare mixed tetramers, a 
different approach will need to be used and will be discussed in the following paragraph. 
 
Figure 44. Scrambling of 163 (a) under Method 1 conditions with reference 4-bromo- and 4-




Figure 45. Scrambling of 163 (a) under Method 2 conditions with reference 4-bromo- and 4-
chlororesorcinol. All spectra were recorded in DMSO-d6 at 400 MHz. 
2.5.6 Aldehydes and mixed platforms 
 Isolation of a dimer presenting an aldehyde (167) was relevant for the 
preparation of mixed tetramers. Due to the reversibility of the reaction with 
monosubstituted resorcinols, obtaining aldehyde-dimer products was not normally 
possible. To ensure the reaction of only one aldehyde, the less reactive 2,4-
dibromoresorcinol was employed. As expected, its reaction with benzene-1,4-
dicarboxaldehyde produced 180 (Scheme 21). An excess (6 equivalents) of 
dibromoresorcinol was necessary, on top of eight days reaction time. 
Dibromoresorcinol is a very poor nucleophile and it does not appear to be significantly 
affected by retro Friedel-Crafts reactions. On top of this, its product 180 is poorly 
soluble in the reaction mixture, reducing the chances of a potential condensation of the 
second aldehyde and fragmentations. These effects might also be supported by a 
reduced reactivity of the second aldehyde, as a consequence of the electron-
withdrawing effect of carbonyls, condensation of one aldehyde could slightly reduce 
the electrophilicity of the second. 
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Despite the poor solubility of 180, it was possible for this to react with 
monohalogenated resorcinols and prepare the mixed platforms 181 and 182 (Scheme 
21). 
 
Scheme 21. Synthesis of 180, 181 and 182. 
2.5.7 Crystallography 
 As the resorcinol tetramers were novel structures, we envisioned the possibility 
of using them as dendrimer cores and in supramolecular organic-inorganic frameworks, 
in addition to the Medicinal Chemistry applications. Single crystal X-ray diffraction 
was conducted to have absolute confirmation of the identity and further insight into the 
crystal arrangement and geometry/conformation. Structures of 163, 164 and 165 were 
confirmed. All of them present the resorcinol rings on staggered planes. In every case, 
an extensively interconnected hydrogen-bond network leads to column or ladder-like 
structures, with solvent molecules (diethyl ether or methanol) bridging the chains of 
compounds and filling the spaces. 
163 (Figure 46, a) forms columns, with each molecule stacked above the 
previous and hydrogen bonded to it through two hydroxyl groups, O14, O141. The other 
six hydroxyl groups form hydrogen bonds with diethyl ether, which intercalates the 
parallel running chains. 
164 (Figure 46, b) is organised in a ladder-like structures, with two hydroxyl 
groups donating hydrogen bonds to the following molecule. The ladders organise in 
 58 
pairs running alongside, with each tetramer lying about a point of symmetry in respect 
to the one in the adjacent ladder. These double chains are bridged with one another 
through methanol molecules. 
165 (Figure 46, c) displays a similar ladder system, with each molecule stacked 
on the preceding one. In this case, the ladders lie on the same plane and are bound to 
each other by double-bridging methanol molecules. It is interesting to note that the 
hydrogens of the bridge, unlike the other tetramers, are forced to point towards each 
other as a consequence of the steric hindrance. 
 The extensive binding of solvent by the compounds explains the difficulties 
found in removing solvents from the products. Even diethyl ether, per se extremely 
volatile, cannot be removed under high vacuum at 40 °C, which is impressive 
considering that its boiling point is 34.6 °C. Co-evaporation with water, which provides 
stronger hydrogen bonds, allows removal of organic solvents which would not leave 
otherwise. This is a necessary step for those compounds meant for biological testing. 
After a week of drying in the presence of silica gel and high vacuum, the products were 
analysed by quantitative 1H-NMR to obtain exact sample purity, quantification is in any 
case necessary for yield calculation.  
 59 
 






2.5.8 Dehalogenation of tetramers 
 Dehalogenation of tetramers is essential to obtain reference compounds for SAR 
studies. Moreover, these structures are suitable candidates for dendrimer cores. To be 
useful as such, a simple and scalable synthesis would be ideal to obtain the products in 
reasonable amounts for further studies. In previous work by our collaborators in South 
Korea, dehalogenation of bromoresorcinol dimers was obtained through hydrogenation 
in the presence of catalytic amounts of palladium over alumina, in methanol, at room 
temperature.72 The reaction yield is low (21-56%) and purification by RP-HPLC was 
employed. 
The first dehalogenation attempted was the reduction of 158. Palladium over 
carbon was used as catalyst due to its availability and the reaction was conducted in 
methanol at room temperature, however extensive polymerisation was observed. Since 
the reaction leads to hydrobromic acid as side-produc, and the product would be 
expected to be very sensitive to acids (Chapter 2.5.5), it was therefore reasonable to 
see whether a base could scavenge the acid, thus preventing fragmentation. 
Triethylamine was chosen because it is soluble in the reaction conditions and acidic 
water (for purification purposes), and it is not reactive towards the product. As expected, 
with this modification, the reaction led to the pure product, in almost quantitative yields, 
after a simple extraction (Scheme 22). 
 
Scheme 22. Dehalogentation reactions. 
We then investigated the chloro-substituted analogues instead of 
bromoresorcinol-based tetramers, as chlororesorcinol is readily available and cheap, 
allowing the desired scale up. Additionally, 185 is only accessible through its 
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chlororesorcinol-based precursor 165. As expected, chlorine is less reactive and the 
temperature had to be increased slightly to obtain complete dehalogenation. 183 was 
obtained at 40 °C in 96% yield. Probably, as a consequence of steric hindrance, 
reduction of 164 and 165 required a further increase in temperature, the products, 184 
and 185, were obtained at 50 °C in 62% and 69% yield, respectively.  
 Identification of the dehalogenated product, and completion of the reaction, can 
be easily verified by 1H-NMR (Figure 47). The first thing to be noted is that, as one 
would expect, the symmetry observed before is maintained. The singlets belonging to 
the resorcinol are split in doublets (3J and 4J) and a new double doublet (3J, 4J) appears, 
indicating the hydrogen replacing the halogen. This pattern is typical for all non-
halogenated tetramers. 
 
Figure 47. 1H-NMRs of 163 (a) and 183 (b). 
2.5.9 Halogenation of tetramers 
 Since formation of tetramers based on dibromoresorcinol is not possible using 
our first method, due to the fact that the reaction stops at the dimer as in the case of 180, 
an alternative approach was necessary. The work by Das77 was initially considered. The 
author used ammonium acetate to catalyse the selective bromination of phenolic 
compounds by N-bromosuccinimide (NBS). Decomposition of NBS by ammonia leads 
initially to Br2, which is then further reduced by ammonia to HBr.
78 Hydrobromic acid 
polarises the N-Br bond of NBS, facilitating electrophilic substitution  of the aromatic 
compound but, unfortunately, presence of acid would likely lead to fragmentation.  
Since the resorcinols are more reactive than the model compounds used by Dal, 
the reaction was attempted without the catalyst. Compound 158 was dissolved in 
acetonitrile and freshly crystallised NBS was added. Unexpectedly, the reaction 
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produced an immediate precipitation and reached completion in 25 minutes, giving 186 
in 63% yield (Scheme 23). Similarly, 163 and 165 reacted with NBS to obtain 187 and 
188, respectively. Compounds with resorcinol units bearing mixed halogens were thus 
obtained. It has to be noted that these reactions can easily (and very rapidly) produce 
by- products and polymerisation, either as a consequence of acid formation or oxidation. 
For this reason, and with the additional issue of the reduced solubility of the products, 
development of other derivatives was postponed until after results from the biological 
tests on the already available compounds. 
 
Scheme 23. Halogenation of tetramers. 
2.5.10 Biaryldicarboxaldehyde-based tetramers 
 To develop a further set of tetramers with a longer spacer while maintaining a 
(relatively) rigid and defined geometry, biaryldicarboxaldehydes were also considered 
as a bridging unit. To obtain the necessary aldehyde in one step from commercially 
available materials, a classical Suzuki coupling appeared to be the most convenient 
approach and some desired products were already described in the literature.79,80 
Homocoupling reactions are also available,81,82 however they present the significant 
drawback of not allowing access to mixed products in case of further development (on 
top of the increased cost of the boron-based starting material). 
2.5.10.1 Suzuki cross-coupling 
 In 1979, Suzuki and Miyaura reported the palladium-catalysed cross coupling 
of alkenyl/alkynyl halides with alkenylboranes. The reaction has since been developed 
and acquired a major role among the chemical tools available, leading to the award of 
a Nobel Prize to the author (joint with other major contributors to palladium-catalysed 
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cross coupling, R. E. Heck and E. Negishi).83 To date, there are many variations on the 
original theme, the conditions have been improved and the scope of the reaction has 
been considerably extended. 
 
Scheme 24. Suzuki cross –coupling mechanism (a) and formation of an oxo-palladium complex (b). 
Adapted from Lennox.84 
A general mechanism for the reaction is reported in Scheme 24, a. The 
Palladium(0) catalyst reacts with a formally nucleophilic aryl substrate in the Oxidative 
Addition step, leading to a first Palladium(II) complex. Subsequent Transmetalation 
with a formally nucleophilic aryl boron, leads to a second Palladium complex. A last 
step, involving reduction of Pd(II) to Pd(0) and elimination of the cross-coupled product 
regenerated the catalyst bringing the cycle to its beginning. Different organoboron 
reagents have different pathways to undergo the transmetalation step. In the case of 
boronic acids, a base produces an Oxo-Palladium complex which is then able to 
transmetalate, as reported in Scheme 24, b.83-86 
2.5.10.2 Synthesis of biaryl-tetramers 
Aldehyde 191 was prepared in good yields (69%) from palladium-catalysed 
cross coupling of 3-formylphenylboronic acid with 3-bromobenzaldehyde. Despite the 
fact that Kuhnert79 did not specify the procedure used, a tentative method led to the 
product in 69% yield, a result consistent with his 71%. The reaction was conducted in 
DMF-water medium, in the presence of sodium carbonate and [1,1′-
bis(diphenylphosphino)ferrocene] dichloropalladium as catalyst, at 40 °C. The product 
was then purified by column chromatography. Subsequently, Method 2 allowed access 
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to both chloro and bromo-resorcinol based tetramers in excellent yields, 87.5 and 99.5% 
respectively (Scheme 25). Dehalogenation of the product was obtained with the method 
previously described, however the conditions were not yet refined. The reaction was 
carried out at 60 °C instead of 50 °C, probably causing a loss of product and reducing 
the yield (38.8%). 
 
Scheme 25. Synthesis of 191, 192, 193 and 194. 
Similarly to that described above, aldehyde 197 was obtained by the Suzuki 
reaction in high yield (86%). Tetramer 198 was then prepared according to Method 2 
in excellent yield (79%). Subsequent dehalogenation led to the expected molecule (199) 
in 69% yield. 
 
Scheme 26. Synthesis of 197, 198 and 199. 
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2.5.11 Flexible tetramers 
 An additional set of tetramers, presenting two dimers linked by a flexible chain 
of different lengths was also prepared. The linker consists of two 4-
hydroxybenzaldehydes with an alkyl chain bridging the hydroxyl groups. To prepare 
the linker, similarly to the method reported by Narasimha,87 4-hydroxybenzaldehyde 
was reacted with dibromoalkanes of different lengths (two, four and six carbons) in the 
presence of a base and the expected products were obtained in poor to good yields 
(Scheme 27). Subsequent condensation of the aldehyde with 4-chloro/bromoresorcinol 
according to Method 2 led to the expected products in good yields (58-84%). 
 
Scheme 27. Synthesis of flexible tetramers. 
2.6 Synthesis of hexamers 
We also saw the intriguing opportunity of preparing a hexamer, which would 
display twelve available hydroxyl groups. For this, synthesis of 1,3,5-triformylbenzene 
was undertaken. The synthesis was carried out according to the procedure by Kaur 
(Scheme 28).88 Trimesic acid (benzene-1,3,5-tricarboxylic acid) is a cheap and readily 
available starting material. It was converted to its corresponding methyl ester (214) by 
heating at reflux in a solution of sulphuric acid in methanol. The clean product was 
obtained in very good yield (89.5%) after an extraction workup. The following reaction, 
which involves the reduction of the ester to alcohol (215), is the bottleneck of the 
procedure. Despite its acceptable yield (62.5%) it requires a very long reaction time, 
and totally unexpected, an even longer quenching time, far higher than the reported 
procedure. The reduction required three days (instead of four hours) and six equivalents 
of lithium aluminium hydride (instead of three). The author used a 1:1 mixture of celite 
and potassium hydrogensulfate to quench the reaction. Due to unavailability, sodium 
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hydrogensulfate was used instead. To quench the reaction properly, the ratio of 
NaHSO4:celite was increased to 4:1 and the mixture was allowed to stir for 112 hours. 
Using diluted HCl was not a viable option, as it led to a viscous oil and no identifiable 
product. The oxidation of alcohol to aldehyde (216) with PCC proceeded as expected, 
although the yield obtained was lower than the reported one (31% versus 51%). 
 
Scheme 28. Synthesis of hexamers. 
 Synthesis of the hexamers with Method 2 proceeded as expected but the 
reaction time was increased to twenty-four hours to allow completion.  The yields, 
however, were lower than for the tetramers, with only 43% and 54% for bromo and 
chloro-resorcinol based hexamers, respectively.  
Unfortunately, dehalogenation of 218 to 219 did not yield a pure product. The 
expected compound could be clearly identified by 1H-NMR but it was not possible to 
isolate it in a sufficiently pure form (Figure 48, c). Nonetheless, upon propargylation 
of the hydroxyl groups and subsequent purification, the crude can be used for the 
synthesis of a dodecavalent dendrimer core, as described in Chapter 4.5.1. 
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Figure 48. 1H-NMR of 217 (a), 218 (b) and 219 (c). 
From the 1H NMR (Figure 48, a, b), both products present the same features as 
the tetramers, with equivalent hydrogens for all resorcinol units, producing two singlets, 
a singlet for the hydrogens of the core and a final one for the bridge. Two singlets 
represent the two hydroxyl groups. Similarly, as described before, dehalogenation 
produces new peaks and splitting of the pre-existing signals (Figure 48, c). 
2.7 Conclusions 
Two rapid and convenient methods for the synthesis of dimers and tetramers 
have been discussed. Method 2, in particular, allowed access to a large number of 
resorcinol derivatives, with significant improvements over the previously employed 
approach. The scope of the reaction has been extended and the new purification method 
developed, allowed access to the products without requiring chromatography, thus 
permitting large scale reactions. Application and study of Method 2 provided better 
understanding of the limitation of the reaction as a consequence of the fragmentations 
described.  
Study of Method 2 also led to a novel polycyclic structure, 166, previously 
unreported. It is an interesting spinner like structure, which can be interconverted 
between the open and closed conformation. However, similar structures could not be 
identified in the literature and potential biological activities cannot be suggested. 
Three families of novel tetramers have been synthesised and characterised. 
These flexible structures are open to further modifications and, thanks to their well 
organised geometries, are also interesting as dendrimer cores, as discussed in Chapter 
4. 
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Methods for further halogenation and dehalogenation of tetramers have been 
described, to provide access to additional analogues for SAR. In total, 40 structures 
have been added to those previously available, thus extending considerably the 
complexity of the accessible SAR. The library will be evaluated for antimicrobial and 
antioxidant activities with the compounds presented in Chapter 3. 
2.8 Experimental 
2.8.1 General 
All reagents and solvents for synthesis were commercial and used without further 
purification. NMR spectra were recorded at 293 K, unless otherwise stated, using a 400 
MHz Spectrometer. Shifts are calibrated relative to deuterated solvent residual peaks. 
Infrared spectra were recorded using an FT-IR spectrometer with ATR attachment. MS 
were run on an LTQ orbitrap XL and were recorded by the EPSRC Mass Spectrometry 
National facility. Thin-layer chromatography (TLC) was carried out on aluminium 
sheets coated with silica gel 60 F254 (Merck). TLC plates were inspected by UV light 
(λ = 254 nm). Silica gel column chromatography was performed with silica gel Si 60 
(40–63 µm). 
2.8.2 Crystal structure analyses 
Crystal data and results from structure refinement for the four compounds are collated 
in Table 4. Analyses were performed by Dr David Hughes. 
A crystal of each compound was mounted in oil on a glass fibre and fixed in the cold 
nitrogen stream on an Oxford Diffraction Xcalibur-3/Sapphire3-CCD diffractometer, 
equipped with Mo-Kα radiation and graphite monochromator.  Intensity data were 
measured by thin-slice ω- and φ-scans.   
Data were processed using the CrysAlisPro-CCD and –RED89 programs.  The structures 
were determined by the direct methods routines in the SHELXS program90 and refined 
by full-matrix least-squares methods, on F2's, in SHELXL.90   
The non-hydrogen atoms of the principal molecule in each structure were refined with 
anisotropic thermal parameters.  There are solvent molecules (ether and/or methanol) 
in all the crystals; in some cases, 163 and 166, these are fully ordered but, in 164 and 
165, there are disordered with varying degrees of resolution; except for those of low site 
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occupancy (which were refined isotropically), the non-hydrogen atoms were refined 
anisotroically. Generally, the phenolic and hydroxyl hydrogen atoms were identified in 
difference maps and were refined freely; all other hydrogen atoms were added in 
idealised positions and set to ride on the parent carbon atoms. In compound 163, 
however, all the hydrogen atoms were located in difference maps and refined freely.  
Scattering factors for neutral atoms were taken from reference91.  Computer programs 
used in this analysis have been noted above, and were run through WinGX92 on a Dell 
Optiplex GX620 PC at the University of East Anglia. 
  
  
Table 4. Crystal data and structure refinement details for the four compounds 163, 164, 165 and 166.
Compound 163 164 165 166 
Elemental formula C32 H22 Cl4 O8, 6(C4 H10 O) C32 H22 Cl4 O8, ca 7.5(C H4 O) 
C32 H22 Cl4 O8, ca 2(C H4 O), 
ca 5(C4 H10 O) 
C20 H12 Cl2 O4, C4 H10 O 
Formula weight 1121.02 916.61 1111.0 461.32 
Crystal system, space group Monoclinic,  I2/a Triclinic,  P-1 Triclinic,  P-1 Monoclinic,  P21/n 
Unit cell dimensions     
a (Å) 19.5798(5) Å 11.5190(3) 13.6713(5) 12.3214(6) 
b (Å) 10.5855(2) Å 12.8094(5) 13.6859(4) 11.6802(5) 
c (Å ) 30.2255(8) Å 15.5844(4) 15.8507(5) 15.2837(6) 
α (°) 90 79.044(3) 87.748(3) 90 
β (°) 100.449(2) 77.462(2) 71.565(3) 107.433(4) 
γ (°) 90 ° 71.732(3) 84.007(3) 90 
Volume (Å3) 6160.7(3) 2112.99(11) 2798.10(16) 2098.54(16) 
Z, Calculated density (Mg/m3  ) 4,  1.209 2,  1.441 2,  1.319 4,  1.460 
F(000) 2392 962 1184 960 
Absorption coefficient (mm-1 ) 0.251 0.350 0.277 0.345 mm 
Crystal colour, shape pale brown block colourless prism pale yellow prism colourless plate 
Crystal size (mm) 0.36 x 0.24 x 0.18 0.40 x 0.12 x 0.10 0.32 x 0.13 x 0.12 0.12 x 0.10 x 0.05 
Theta range for data collection (°) 3.03 to 27.50 2.99 to 22.49 3.09 to 22.50 3.07 to 25.00 
Completeness to theta-max (%) 99.8 99.2 99.7 99.8 
Max. and min. transmission 1.0 and 0.918 1.0 and 0.935 1.0 and 0.883 1.0 and 0.914 
Reflections collected 50395 20695 30403 29087 
No. of unique reflections, R(int) 7083, 0.040 5493, 0.054 7299, 0.060 3688, 0.071 
No. of 'observed' reflections (I > 2σI) 5801 3401 5321 2842 
Data / restraints / parameters 7083 / 0 / 498 5493 / 0 / 603 7299 / 0 / 768 3688 / 0 / 288 
Goodness-of-fit on F2, S 1.027 1.041 1.046 1.028 
Final R indices ('observed' data) R1 = 0.038, wR2 = 0.093 R1 = 0.074, wR2 = 0.191 R1 = 0.067, wR2 = 0.156 R1 = 0.038, wR2 = 0.078 
Final R indices (all data) R1 = 0.051, wR2 = 0.099 R1 = 0.138, wR2 = 0.240 R1 = 0.095, wR2 = 0.172 R1 = 0.058, wR2 = 0.083 
Largest diff. peak and hole (e.Å-3  ) 0.32 and -0.24 1.11 and -0.37 0.40 and -0.39 0.24 and -0.23 
  





Prepared according the procedure by Sandin,74 with minor modifications. 
A stirring mixture of 2,4-dihydroxybenzoic acid (20 g, 85.83 mmol) in 160 mL of acetic 
acid was heated at 40 °C until complete dissolution of the solid. The solution was cooled 
to 30 °C and a solution of bromine (6.4 mL, 124.9 mmol) in 60 mL of acetic acid was 
added dropwise. The reaction was allowed to stir for one hour and then poured in 1.5 L 
of distilled water. After one night at 4 °C, the crystalline product (117) was collected 
by Büchner filtration. The crude 117 was suspended in distilled water and refluxed for 
36 hours. The solution was cooled at room temperature and extracted with diethyl ether 
(3 x 300 mL). The organic layers were collected, dried over magnesium sulfate and 
evaporated under reduced pressure. The crude material was then purified by flash 
chromatography (30:1, DCM:MeOH) to give 116 as a white solid. 
43% yield. 
MP: 103-104 °C 
1H NMR (400 MHz, DMSO) δ 9.97 (s, 1H), 9.45 (s, 1H), 7.19 (d, J = 8.6 Hz, 1H), 6.43 
(d, J = 2.7 Hz, 1H), 6.18 (dd, J = 8.6, 2.7 Hz, 1H). 
13C NMR (101 MHz, DMSO) δ 157.78, 154.56, 132.67, 108.10, 103.57, 98.09. 
Compound 12075 
 
A solution of bromine (30 mL, 0.58 mol) in 200 mL of DCM was added dropwise to a 
solution of resorcinol (20 g, 0.18 mol) in DCM (200 mL) over 4 hours. The red solution 
was allowed to stir at 40 °C for 64 hours. Excess bromine was removed by bubbling air 
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through the mixture. The solvent was evaporated and the crude material was used 
without any further purification for the synthesis of 119 and 126. 
1H NMR (400 MHz, DMSO) δ 9.98 (s, 2H, ArOH), 7.69 (s, 1H, ArH). 
Compounds 11975 and 12675 
A solution of sodium sulfite (45.79 g, 0.36 mol) in 210 mL of water/MeOH (2:1) was 
added to a allowed to stir mixture of 120 in 240 mL of the same solvent. The reaction 
was allowed to stir until 120 was completely consumed (TLC with DCM, I2 staining). 
The yellow solution was extracted with diethyl ether; the organic layers were collected, 
dried over anhydrous magnesium sulfate and evaporated. Upon flash chromatography 
with DCM, 119 and 126 were isolated as white crystalline solids.  
Compound 119: 
54% yield over two steps. 
MP: 99-100 °C (lit. 92.8-93.7 °C)93 
1H-NMR (400 MHz, DMSO) δ 10.34 (s, 1H, ArOH), 9.55 (s, 1H, ArOH), 7.29 (d, J=8.6, 
1H, ArH), 6.46 (d, J=8.6, 1H, ArH). 
13C-NMR (101 MHz, DMSO) δ 154.92, 151.45, 130.97, 108.73, 100.58, 100.04. 
Compound 126: 
10% yield over two steps. 
1H-NMR (400 MHz, DMSO) δ 9.92 (s, 2H, ArOH), 6.92 (t, J=7.9, 1H, ArH), 6.40 (d, 
J=7.9, 2H, ArH). 
Compound 12475 
 Over one hour, a solution of bromine (6.1 mL, 0.12 mol) in DCM (20 mL) was added 
dropwise to a suspension of phloroglucinol (5 g, 0.04 mol) in 130 mL. Then the mixture 
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was allowed to stir at room temperature for one hour. Upon evaporation under reduced 
pressure of the solvent a solid product was obtained. The crude was used without further 
purification for the synthesis of 123 and 122.  
Compounds 123 and 12275 
 Crude 124 was suspended in a water/methanol solution (38 ml: 76 mL) and allowed to 
stir for 15 minutes. A solution of sodium sulphite (5 g, 0.04 mol) and sodium 
hydrogencarbonate (6.66 g, 0.08 mol) in water (112 mL) was added. The mixture was 
allowed to stir for 3 hours and then quenched with 60 mL of HCl 1.2 M. The solid was 
collected and washed with water to give clean 124, which could be recycled. The water 
was extracted with diethyl ether, and then with ethyl acetate. The organic layers were 
combined, dried over anhydrous magnesium sulfate and evaporated. The crude product 
was purified by flash chromatography using 60:1 DCM/MeOH to elute 123 and then 
55:1 DCM/MeOH for 122. 
Compound 123: 11.8% yield over two steps. 
MP: 165-167 °C 
1H-NMR (400 MHz, DMSO) δ 10.08 (s, 2H, ArOH), 9.21 (s, 1H, ArOH), 6.27 (s, 1H, 
ArH). 
13C NMR (101 MHz, DMSO) δ 154.10, 151.87, 95.44, 89.59. 
IR (νmax, cm-1): 3445, 3387, 1591, 1481, 1435, 1250, 1210, 1158, 1037, 806. 
Compound 122: 14.2% yield over two steps. 
1H-NMR (400 MHz, DMSO) δ 9.69 (s, 2H, ArOH), 9.20 (s, 1H, ArOH), 5.92 (s, 2H, 
ArH). 
13C NMR (101 MHz, DMSO) δ 157.32, 155.41, 94.74, 87.46. 
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Compound 134 
1.5 mL of HCl 37% (aq) were added to a suspension of 123 (0.5 g, 1.44 mmol) and 
formaldehyde (37% in water, 0.68 mmol) in 2 mL of ethanol. The mixture was allowed 
to stir for three hours at 70 °C. Subsequently, the reaction was neutralised with NaHCO3 
and extracted with ethyl acetate. The organic layers were collected, dried over sodium 
sulphate anhydrous and evaporated. The crude material was purified via flash 
chromatography (DCM/MeOH 8:2) to give 134. 
3.7% yield. 
1H-NMR (400 MHz, DMSO) δ 9.85 (b, 4H, ArOH), 9.46 (b, 2H, ArOH), 3.87 (s, 2H, 
Ar2CH2). 





4 mL of HCl 37% (aq) were added to a solution of 116 (1 g, 5.29 mmol) and 
formaldehyde (37% in water, 2.51 mmol) in 8 mL of ethanol. The reaction was allowed 
to stir for 3.5 hours at room temperature. Subsequently, the yellow solution was 
neutralised  with NaHCO3 and extracted with ethyl acetate. The organic layers were 
collected, dried over sodium sulphate anhydrous and evaporated. The crude was 
purified via flash chromatography (DCM/MeOH 20:1) to give 135 as an off white solid. 
2.6% yield. 
1H-NMR (400 MHz, DMSO) δ 9.78 (s, 2H, ArOH), 9.47 (s, 2H, ArOH), 6.93 (s, 2H, 
ArH), 6.50 (s, 2H, ArH), 3.52 (s, 2H, Ar2CH2). 
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13C-NMR (101 MHz, DMSO) δ 155.01, 152.46, 132.80, 119.92, 103.32, 97.65, 27.54 
(Ar2CH2). 
HMBC correlations:  
 
IR (νmax, cm-1): 3491, 3364, 1614, 1597, 1585, 1504, 1484, 1422, 1357, 1317, 1296, 
1266, 1199, 1169, 1136, 1115, 1007, 922, 894, 878, 827, 804. 
 
Compound 13623 
3 mL of HCl 37% (aq) were added to a solution of 119 (1 g, 3.73 mmol) and 
formaldehyde (37% in water, 1.77 mmol) in 4 mL of ethanol. The reaction was allowed 
to stir for 16 hours at 70 °C. Subsequently, the solution was neutralised  with NaHCO3 
and extracted with ethyl acetate. The organic layers were collected, dried over 
anhydrous magnesium sulfate and evaporated. The crude was purified via flash 
chromatography (DCM/ethanol 100:1) to 136 as a light pink solid. 
19.5% yield. 
MP: 215 °C decomposition 
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1H-NMR (400 MHz, DMSO) δ 9.52 (s, 2H, ArOH), 9.27 (s, 2H, ArOH), 7.06 (s, 2H, 
ArH), 3.80 (s, 2H, Ar2CH2). 
13C-NMR (101 MHz, DMSO) δ 151.96, 149.60, 131.29, 121.74, 102.89, 100.89, 29.59 
(Ar2CH2). 
HMBC correlations:  
 
IR (νmax, cm-1): 3474, 3353, 1594, 1569, 1467, 1455, 1428, 1349, 1310, 1250, 1231, 
1204, 1169, 1141, 1033, 922, 894, 871, 834. 
 
Compound 131 
10 mL of HCl 37% (aq) was added to a solution of 119 (1.48 g, 5.52 mmol) and 4-
hydroxybenzaldehyde (0.22 g, 1.8 mmol) in 20 mL of ethanol. The reaction was allowed 
to stir for 3 hours at 70 °C. Subsequently, the solution was neutralised with NaHCO3 
and extracted with ethyl acetate. The organic layers were collected, dried over 
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anhydrous magnesium sulfate and evaporated. The crude was purified via flash 
chromatography (DCM/MeOH gradient: 50:1→20:1) to give a red solid of 131. 
Yield < 1%. 
1H-NMR (400 MHz, DMSO) δ 9.59 (s, 2H, ArOH), 9.30 (s, 1H, ArOH), 9.13 (s, 2H, 
ArOH), 6.78 (d, J=8.6, 2H, ArH), 6.70 (d, J=8.6, 2H, ArH), 6.59 (s, 2H, ArH), 5.87 (s, 
1H, Ar3CH). 
13C-NMR (101 MHz, DMSO) δ 155.78, 151.72, 149.59, 131.95, 130.58, 129.80, 
126.04, 115.17, 103.18, 100.44, 48.57 (Ar3CH). 
Compound 140 
 
0.24 mL of methanesulfonic acid was added to a pre-cooled (0 °C) mixture of hexanal 
(250 mg, 2.5 mmol) and 4-chlororesorcinol (902.1 mg, 6.24 mmol)  in 3 ml of 
Et2O/DCM (1/1, v/v). The reaction vessel was sealed and the reaction allowed to stir 
for 5 h. The resulting mixture was diluted with diethyl ether, poured into distilled water 
and allowed to stir vigorously until a suspension was obtained. The product was 
collected by Büchner filtration, washed with abundant distilled water and dried in a 
desiccator to give a light orange powder. 
Yield: 40% (calculated from NMR to account for solvent of crystallisation) 
MP: 186-188 °C 
1H-NMR (400 MHz, DMSO) δ 9.66 (s, 2H), 9.27 (s, 2H), 6.86 (s, 2H), 6.44 (s, 2H), 
4.26 (t, J = 7.8 Hz, 1H), 1.77 (q, J = 7.8 Hz, 2H), 1.28 – 1.12 (m, 6H), 0.82 (t, J = 7.0 
Hz, 3H). 
13C-NMR (101 MHz, DMSO) δ 154.79, 151.52, 128.85, 123.86, 109.33, 104.10, 36.01, 
33.82, 31.64, 27.71, 22.46, 14.40. 
  




0.64 mL of methanesulfonic acid was added to a pre-cooled (0 °C) mixture of 3-
bromobenzaldehyde (0.315 mL, 2.7 mmol) and 4-chlororesorcinol (976.65 mg, 6.76 
mmol)  in 8 ml of Et2O/DCM (1/1, v/v). The reaction vessel was sealed and the reaction 
allowed to stir for 5 h. The resulting mixture was diluted with diethyl ether, poured into 
distilled water and allowed to stir vigorously until a suspension was obtained. The 
product was collected by Büchner filtration, washed with abundant distilled water and 
dried in a desiccator to give an orange powder. 
Yield: 90.6% (calculated from NMR to account for solvent of crystallisation) 
MP: 230-232 °C 
1H-NMR (400 MHz, DMSO) δ 9.89 (s, 2H), 9.51 (s, 2H), 7.39 (d, J = 7.8 Hz, 1H), 7.24 
(t, J = 7.8 Hz, 1H), 7.07 (s, 1H), 6.97 (d, J = 7.8 Hz, 1H), 6.52 (s, 2H), 6.41 (s, 2H), 
5.69 (s, 1H). 
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13C-NMR (101 MHz, DMSO) δ 154.68, 152.45, 147.26, 131.53, 130.79, 129.96, 
129.25, 128.31, 122.06, 121.95, 109.32, 104.23, 42.20. 
IR (νmax, cm-1): 3439, 1613, 1592, 1504, 1423, 1335, 1234, 1195, 1169, 1118, 1072, 




0.24 mL of methanesulfonic acid was added to a pre-cooled (0 °C) mixture of 
benzaldehyde (250 mg, 2.36 mmol) and 4-chlororesorcinol (851.4 mg, 5.89 mmol)  in 
3 ml of Et2O/DCM (1/1, v/v). The reaction vessel was sealed and the reaction allowed 
to stir for 5.5 h. The resulting mixture was diluted with diethyl ether, poured into 
distilled water and allowed to stir vigorously until a suspension was obtained. The 
product was collected by Büchner filtration, washed with abundant distilled water and 
dried in a desiccator to give an orange powder. 
Yield: 87.2% (calculated from NMR to account for solvent of crystallisation) 
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MP: 105-108 °C 
1H-NMR (400 MHz, DMSO) δ 9.81 (s, 2H), 9.41 (s, 2H), 7.27 (t, J = 7.3 Hz, 2H), 7.17 
(t, J = 7.3 Hz, 1H), 6.96 (d, J = 7.3 Hz, 2H), 6.50 (s, 2H), 6.39 (s, 2H), 5.71 (s, 1H). 
13C-NMR (101 MHz, DMSO) δ 154.66, 152.15, 144.18, 129.98, 129.19, 128.56, 
126.26, 123.01, 109.14, 104.16, 42.25. 
IR (νmax, cm-1): 3584, 3416, 3267, 1617, 1601, 1523, 1493, 1425, 1377, 1338, 1303, 




1.2 mL of methanesulfonic acid was added to a pre-cooled (0 °C) mixture of 2,6-
dichlorobenzaldehyde (500 mg, 2.86 mmol) and 4-chlororesorcinol (1.0325 g, 7.14 
mmol)  in 15 ml of Et2O/DCM (1/1, v/v). The reaction vessel was sealed and the reaction 
allowed to stir for 6 h. The resulting mixture was diluted with diethyl ether, poured into 
distilled water and allowed to stir vigorously until a suspension was obtained. The 
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product was collected by Büchner filtration, washed with abundant distilled water and 
dried in a desiccator to give a pale orange powder. 
Yield: 83% (calculated from NMR to account for solvent of crystallisation) 
MP: 238-240 °C 
1H-NMR (400 MHz, DMSO) δ 9.85 (s, 2H), 9.44 (s, 2H), 7.39 (d, J = 8.0 Hz, 2H), 7.25 
(t, J = 8.0 Hz, 1H), 6.51 (s, 2H), 6.48 (s, 2H), 6.18 (s, 1H). 
13C-NMR (101 MHz, DMSO) δ 154.88, 152.48, 138.93, 135.73, 130.34, 129.89, 
128.93, 119.25, 109.27, 103.82, 41.48. 
IR (νmax, cm-1): 3642, 3520, 3498, 3428, 1612, 1599, 1555, 1502, 1428, 1329, 1261, 
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0.24 mL of methanesulfonic acid was added to a pre-cooled (0 °C) mixture of 4-
hydroxybenzaldehyde (250 mg, 2.05 mmol) and 4-chlororesorcinol (739.8 g, 5.12 
mmol)  in 3 ml of Et2O/DCM (1/1, v/v). The reaction vessel was sealed and the reaction 
allowed to stir for 5 h. The resulting mixture was diluted with diethyl ether, poured into 
distilled water and allowed to stir vigorously until a suspension was obtained. The 
product was collected by Büchner filtration, washed with abundant distilled water and 
DCM. The product was recrystallised from DCM/MeOH to give a light orange solid.  
Yield: 20.5% (calculated from NMR to account for solvent of crystallisation) 
MP: 226-228 °C 
1H-NMR (400 MHz, DMSO) δ 9.76 (s, 2H), 9.34 (s, 2H), 9.17 (s, 1H), 6.74 (d, J = 8.5 
Hz, 2H), 6.66 (d, J = 8.5 Hz, 2H), 6.48 (s, 2H), 6.39 (s, 2H), 5.60 (s, 1H). 
13C-NMR (101 MHz, DMSO) δ 155.76, 154.58, 151.96, 134.13, 130.07, 129.89, 
123.72, 115.34, 109.04, 104.13, 41.36. 
IR (νmax, cm-1): 3307, 1613, 1600, 1511, 1487, 1422, 1335, 1239, 1209, 1189, 1170, 
1122, 1026, 902, 882, 870, 848, 830, 801. 
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Compound 145 
 
1.2 mL of methanesulfonic acid was added to a pre-cooled (0 °C) mixture of 4-
formylbenzoic acid (500 mg, 3.33 mmol) and 4-chlororesorcinol (1.2036 g, 8.33 mmol)  
in 15 ml of Et2O/DCM (1/1, v/v). The reaction vessel was sealed and the reaction 
allowed to stir for 6 h. The resulting mixture was diluted with diethyl ether, poured into 
distilled water and allowed to stir vigorously until a suspension was obtained. The 
product was collected by Büchner filtration, washed with abundant distilled water and 
dried in a desiccator. 
Yield: 75% (calculated from NMR to account for solvent of crystallisation) 
1H-NMR (400 MHz, DMSO) δ 12.79 (s, 1H), 9.87 (s, 2H), 9.49 (s, 2H), 7.85 (d, J = 8.3 
Hz, 2H), 7.08 (d, J = 8.3 Hz, 2H), 6.52 (s, 2H), 6.41 (s, 2H), 5.76 (s, 1H). 
13C-NMR (101 MHz, DMSO) δ 167.73, 154.72, 152.40, 149.67, 130.00, 129.72, 
129.29, 128.88, 122.19, 109.31, 104.21, 42.45. 
IR (νmax, cm-1): 3497, 3249, 1691, 1606, 1503, 1427, 1384, 1316, 1268, 1234, 1218, 
1189, 1168, 1118, 1018, 899, 840. 
  




0.24 mL of methanesulfonic acid was added to a pre-cooled (0 °C) mixture of 3-
formylbenzoic acid (200 mg, 1.33 mmol) and 4-chlororesorcinol (481.4 mg, 3.33 mmol)  
in 3 ml of Et2O/DCM (1/1, v/v). The reaction vessel was sealed and the reaction allowed 
to stir for 7 h. The resulting mixture was diluted with diethyl ether, poured into distilled 
water and allowed to stir vigorously until a suspension was obtained. The product was 
collected by Büchner filtration, washed with abundant distilled water and dried in a 
desiccator to give a light pink powder. 
Yield: 18% (calculated from NMR to account for solvent of crystallisation) 
MP: 253-255 °C 
1H-NMR (400 MHz, DMSO) δ 12.91 (s, 1H), 9.88 (s, 2H), 9.49 (s, 2H), 7.77 (d, J = 7.7 
Hz, 1H), 7.51 (s, 1H), 7.40 (t, J = 7.7 Hz, 1H), 7.23 (d, J = 7.7 Hz, 1H), 6.52 (s, 2H), 
6.40 (s, 2H), 5.76 (s, 1H). 
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13C-NMR (101 MHz, DMSO) δ 167.86, 154.71, 152.38, 144.82, 133.71, 130.96, 
130.00, 129.67, 128.91, 127.41, 122.34, 109.29, 104.24, 42.25. 
IR (νmax, cm-1): 3503, 1695, 1683, 1614, 1588, 1505, 1421, 1326, 1311, 1288, 1252, 
1196, 1163, 1127, 1029, 1017, 931, 896, 884. 
Compound 147 
 
0.24 mL of methanesulfonic acid was added to a pre-cooled (0 °C) mixture of 4-
fluorobenzaldehyde (200 mg, 1.61 mmol) and 4-chlororesorcinol (582.3 mg, 4.03 
mmol)  in 3 ml of Et2O/DCM (1/1, v/v). The reaction vessel was sealed and the reaction 
allowed to stir for 7 h. The resulting mixture was diluted with diethyl ether, poured into 
distilled water and allowed to stir vigorously until a suspension was obtained. The 
product was collected by Büchner filtration, washed with abundant distilled water and 
dried in a desiccator to give a light yellow powder. 
Yield: 61% (calculated from NMR to account for solvent of crystallisation) 
MP: 138-141 °C 
1H-NMR - F decoupled (400 MHz, DMSO) δ 9.83 (s, 2H), 9.43 (s, 2H), 7.08 (d, J = 8.8 
Hz, 2H), 6.98 (d, J = 8.8 Hz, 2H), 6.51 (s, 2H), 6.40 (s, 2H), 5.70 (s, 1H). 
13C-NMR (101 MHz, DMSO) δ 160.92 (d, J = 241.6 Hz), 154.64, 152.27, 140.23, 
130.83 (d, J = 8.0 Hz), 129.88, 122.83, 115.24 (d, J = 21.1 Hz), 109.23, 104.19, 41.62. 
19F-NMR (376 MHz, DMSO) δ -117.49 (tt, J = 8.9, 5.6 Hz). 
IR (νmax, cm-1): 3422, 3295, 1600, 1506, 1431, 1338, 1285, 1263, 1232, 1199, 1171, 
1156, 1122, 1027, 894, 881. 
  




0.24 mL of methanesulfonic acid was added to a pre-cooled (0 °C) mixture of 2-
fluorobenzaldehyde (200 mg, 1.61 mmol) and 4-chlororesorcinol (582.3 mg, 4.03 
mmol)  in 3 ml of Et2O/DCM (1/1, v/v). The reaction vessel was sealed and the reaction 
allowed to stir for 7 h. The resulting mixture was diluted with diethyl ether, poured into 
distilled water and allowed to stir vigorously until a suspension was obtained. The 
product was collected by Büchner filtration, washed with abundant distilled water and 
dried in a desiccator to give a white solid. 
Yield: 85% (calculated from NMR to account for solvent of crystallisation) 
MP: 200-203 °C 
1H-NMR - F decoupled (400 MHz, DMSO) δ 9.85 (s, 2H), 9.47 (s, 2H), 7.33 – 7.21 (m, 
1H), 7.16 – 7.05 (m, 2H), 6.81 (dd, J = 7.6, 1.5 Hz, 1H), 6.52 (s, 2H), 6.38 (s, 2H), 5.93 
(s, 1H). 
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13C-NMR (101 MHz, DMSO) δ 160.48 (d, J = 244.7 Hz), 154.62, 152.4, 131.19 (d, J = 
14.8 Hz), 130.37 (d, J = 4.2 Hz), 129.59, 128.45 (d, J = 8.2 Hz), 124.45 (d, J = 3.2 Hz), 
121.50, 115.56 (d, J = 21.9 Hz), 109.22, 104.23, 35.38. 
19F NMR (376 MHz, DMSO) δ -117.06 (ddd, J = 10.4, 7.9, 5.5 Hz). 
IR (νmax, cm-1): 3613,  3393, 3278, 1619, 1600, 1524, 1489, 1425, 1374, 1338, 1305, 




0.24 mL of methanesulfonic acid was added to a pre-cooled (0 °C) mixture of 3-
formylboronic acid (200 mg, 1.33 mmol) and 4-chlororesorcinol (482 mg, 3.33 mmol)  
in 3 ml of Et2O/DCM (1/1, v/v). The reaction vessel was sealed and the reaction allowed 
to stir for 7 h. The resulting mixture was diluted with diethyl ether, poured into distilled 
water and allowed to stir vigorously until a suspension was obtained. The product was 
collected by Büchner filtration, washed with abundant distilled water and dried in a 
desiccator to give a white powder. 
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Yield: 76% (calculated from NMR to account for solvent of crystallisation) 
MP: 400-405 °C 
1H-NMR (400 MHz, DMSO) δ 9.79 (s, 2H), 9.39 (s, 2H), 7.96 (s, 2H), 7.60 (d, J = 7.3 
Hz, 1H), 7.47 (s, 1H), 7.23 (t, J = 7.5 Hz, 1H), 6.96 (d, J = 7.7 Hz, 1H), 6.50 (s, 2H), 
6.41 (s, 2H), 5.72 (s, 1H). 
13C-NMR (101 MHz, DMSO) δ 154.62, 152.06, 143.04, 135.26, 134.16, 132.12, 
130.80, 130.10, 127.56, 123.20, 109.11, 104.14, 42.29. 
IR (νmax, cm-1): 3561, 3509, 3440, 3301, 1614, 1510, 1424, 1355, 1331, 1245, 1199, 




0.32 mL of methanesulfonic acid was added to a pre-cooled (0 °C) mixture of hexanal 
(250 mg, 2.5 mmol) and 4-bromoresorcinol (1.1793 g, 6.24 mmol)  in 4 ml of 
Et2O/DCM (1/1, v/v). The reaction vessel was sealed and the reaction allowed to stir 
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for 7 h. The resulting mixture was diluted with diethyl ether, poured into distilled water 
and allowed to stir vigorously until a suspension was obtained. The product was 
collected by Büchner filtration, washed with abundant distilled water and dried in a 
desiccator to give a light yellow powder. 
Yield: 41% (calculated from NMR to account for solvent of crystallisation) 
MP: 125-126 °C (lit. 107-109 °C)72 
1H-NMR (400 MHz, DMSO) δ 9.74 (s, 2H), 9.31 (s, 2H), 7.00 (s, 2H), 6.45 (s, 2H), 
4.24 (t, J = 7.8 Hz, 1H), 1.77 (q, J = 7.8 Hz, 2H), 1.29 – 1.11 (m, 6H), 0.82 (t, J = 7.0 
Hz, 3H). 
13C-NMR (101 MHz, DMSO) δ 154.79, 151.52, 128.85, 123.86, 109.33, 104.10, 36.01, 
33.82, 31.64, 27.71, 22.46, 14.40. 
Compound 10972 
 
0.32 mL of methanesulfonic acid was added to a pre-cooled (0 °C) mixture of 4-
hydroxybenzaldehyde (250 mg, 2.05 mmol) and 4-bromoresorcinol (1.7412 g, 9.21 
mmol)  in 4 ml of Et2O/DCM (1/1, v/v). The reaction vessel was sealed and the reaction 
allowed to stir for 7 h. The resulting mixture was diluted with diethyl ether, poured into 
distilled water and allowed to stir vigorously until a suspension was obtained. The 
product was collected by Büchner filtration, washed with abundant distilled water and 
dried in a desiccator. 
Yield: 34% (calculated from NMR to account for solvent of crystallisation) 
MP: 200-202 °C (lit. 201-202 °C)72 
1H-NMR (400 MHz, DMSO) δ 9.84 (s, J = 5.2 Hz, 2H), 9.37 (s, 2H), 9.17 (s, J = 5.7 
Hz, 1H), 6.74 (d, J = 8.5 Hz, 2H), 6.66 (d, J = 8.5 Hz, 2H), 6.53 (s, 2H), 6.49 (s, 2H), 
5.60 (s, 1H). 
13C-NMR (101 MHz, DMSO) δ 155.76, 155.26, 153.03, 134.12, 132.67, 130.06, 
124.38, 115.35, 104.00, 97.82, 41.36. 
  
  90 
Compound 150 
 
0.32 mL of methanesulfonic acid was added to a pre-cooled (0 °C) mixture of 3-
bromobenzaldehyde (250 mg, 1.35 mmol) and 4-bromoresorcinol (683.5 mg, 3.62 
mmol)  in 4 ml of Et2O/DCM (1/1, v/v). The reaction vessel was sealed and the reaction 
allowed to stir for 7 h. The resulting mixture was diluted with diethyl ether, poured into 
distilled water and allowed to stir vigorously until a suspension was obtained. The 
product was collected by Büchner filtration, washed with abundant distilled water and 
dried in a desiccator to give an orange powder. 
Yield: 53% (calculated from NMR to account for solvent of crystallisation) 
MP: 101-104 °C 
1H-NMR (400 MHz, DMSO) δ 9.97 (s, 2H), 9.54 (s, 2H), 7.39 (dd, J = 8.0, 1.0 Hz, 1H), 
7.25 (t, J = 7.8 Hz, 1H), 7.07 (t, J = 1.5 Hz, 1H), 6.97 (d, J = 7.8 Hz, 1H), 6.55 (s, 2H), 
6.53 (s, 2H), 5.68 (s, 1H). 
13C-NMR (101 MHz, DMSO) δ 155.36, 153.52, 147.26, 132.75, 131.52, 130.80, 
129.27, 128.29, 122.73, 121.94, 104.10, 98.05, 42.21. 
IR (νmax, cm-1): 3386, 1610, 1498, 1425, 1333, 1240, 1201, 1168, 1115, 1009, 900, 834. 
  




0.32 mL of methanesulfonic acid was added to a pre-cooled (0 °C) mixture of 
benzaldehyde (250 mg, 2.36 mmol) and 4-bromoresorcinol (1.1132 g, 5.89 mmol)  in 4 
ml of Et2O/DCM (1/1, v/v). The reaction vessel was sealed and the reaction allowed to 
stir for 7 h. The resulting mixture was diluted with diethyl ether, poured into distilled 
water and allowed to stir vigorously until a suspension was obtained. The product was 
collected by Büchner filtration, washed with abundant distilled water and dried in a 
desiccator to give a pale yellow powder. 
Yield: 74% (calculated from NMR to account for solvent of crystallisation) 
MP: 125-129 °C 
1H-NMR (400 MHz, DMSO) δ 9.90 (s, 2H), 9.46 (s, 2H), 7.27 (t, J = 7.4 Hz, 2H), 7.17 
(t, J = 7.3 Hz, 1H), 6.95 (d, J = 7.3 Hz, 2H), 6.53 (s, J = 6.5 Hz, 2H), 6.51 (s, 2H), 5.71 
(s, 1H). 
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13C-NMR (101 MHz, DMSO) δ 155.33, 153.22, 144.16, 132.78, 129.18, 128.57, 
126.29, 123.68, 104.04, 97.91, 42.25. 
IR (νmax, cm-1): 3589, 3422, 3286, 1617, 1594, 1522, 1492, 1423, 1377, 1338, 1303, 
1250, 1201, 1130, 1074, 1035, 1012, 917, 903, 866, 838, 832, 820. 
Compound 11172 
 
0.32 mL of methanesulfonic acid was added to a pre-cooled (0 °C) mixture of 2,6-
dichlorobenzaldehyde (250 mg, 1.43 mmol) and 4-bromoresorcinol (675 mg, 3.57 
mmol)  in 4 ml of Et2O/DCM (1/1, v/v). The reaction vessel was sealed and the reaction 
allowed to stir for 7 h. The resulting mixture was diluted with diethyl ether, poured into 
distilled water and allowed to stir vigorously until a suspension was obtained. The 
product was collected by Büchner filtration, washed with abundant distilled water and 
dried in a desiccator to give a light orange powder. 
Yield: 84% (calculated from NMR to account for solvent of crystallisation) 
MP: 238-240 °C (lit. 162-164 °C) The compound goes through different states, 
definition of a melting point by direct observation is misleading. 
1H-NMR (400 MHz, DMSO) δ 9.94 (s, 2H), 9.48 (s, 2H), 7.39 (d, J = 8.0 Hz, 2H), 7.25 
(t, J = 8.0 Hz, 1H), 6.65 (s, 2H), 6.49 (s, 2H), 6.18 (s, 1H). 
13C NMR (101 MHz, DMSO) δ 155.54, 153.54, 138.93, 135.76, 133.16, 129.86, 128.94, 
119.85, 103.68, 97.99, 41.43. 
Compound 153 
 
0.32 mL of methanesulfonic acid was added to a pre-cooled (0 °C) mixture of 3-
bromobenzaldehyde (200 mg, 1.08 mmol) and 2,4-dibromoresorcinol (724 mg, 2.70 
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mmol)  in 4 ml of Et2O/DCM (1/1, v/v). The reaction vessel was sealed and the reaction 
allowed to stir for 10 days. The resulting mixture was diluted with diethyl ether, poured 
into distilled water and allowed to stir vigorously until a suspension was obtained. The 
product was collected by Büchner filtration, washed with abundant toluene, distilled 
water and dried in a desiccator. 
Toluene cannot be removed by repeatedly washing with water or hexane, re-
suspension in water and filtration is useful either. Co-evaporation with water or 
methanol does not remove the impurity. 




0.32 mL of methanesulfonic acid was added to a pre-cooled (0 °C) mixture of 
benzaldehyde (200 mg, 1.88 mmol) and 2,4-dibromoresorcinol (1.26 g, 4.71 mmol)  in 
4 ml of Et2O/DCM (1/1, v/v). The reaction vessel was sealed and the reaction allowed 
to stir for 10 days. The resulting mixture was diluted with diethyl ether, poured into 
distilled water and allowed to stir vigorously until a suspension was obtained. The 
product was collected by Büchner filtration washed with abundant toluene, distilled 
water and dried in a desiccator to give a pink powder. 
Yield: 44% (calculated from NMR to account for solvent of crystallisation) 
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MP: 390 °C dec.  
1H-NMR (400 MHz, DMSO) δ 9.65 (s, 2H), 9.21 (s, 2H), 7.32 (t, J = 7.4 Hz, 2H), 7.24 
(t, J = 7.3 Hz, 1H), 7.01 (d, J = 7.3 Hz, 2H), 6.60 (s, 2H), 5.99 (s, 1H). 
13C-NMR (101 MHz, DMSO) δ 152.32, 150.28, 142.58, 131.20, 129.35, 128.91, 
126.91, 125.89, 103.74, 101.01, 44.15. 
IR (νmax, cm-1): 3505, 3465, 1594, 1575, 1492, 1471, 1425, 1333, 1275, 1217, 1173, 





Product not isolated 
Method 2 
1.2 mL of methanesulfonic acid was added to a pre-cooled (0 °C) mixture of 
terephthalaldehyde (300 mg, 2.24 mmol) and 4-bromoresorcinol (1.90 g, 10.07 mmol) 
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in 15ml of Et2O/DCM (1/1, v/v). The reaction vessel was sealed and the reaction 
allowed to stir for 7 h. The mixture was poured into 75 mL of Et2O and cooled for 18 h 
at 4°C. The resulting solid was collected and washed with diethyl ether to give the white 
crystalline product (2.5583 g). 
Yield: 87% (calculated from NMR to account for solvent of crystallisation) 
MP: 149-151°C 
1H-NMR (400 MHz, DMSO) δ 9.86 (s, 1H), 9.42 (s, 1H), 6.84 (s, 1H), 6.52 (s, 1H), 
6.49 (s, 1H), 5.68 (s, 1H). 
13C-NMR (101 MHz, DMSO) δ 154.77, 152.64, 141.02, 132.33, 128.39, 123.40, 
103.52, 97.46, 41.27. 
IR (νmax, cm-1): 3476.5, 3416.5, 1608, 1592, 1502, 1485.5, 1424, 1332.5, 1276.5, 1236, 
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Method 2 
1.2 mL of methanesulfonic acid was added to a pre-cooled (0 °C) mixture of 
isophthalaldehyde (200 mg, 1.491 mmol) and 4-bromoresorcinol (1.26 g, 6.710 mmol) 
in 15 ml of Et2O/DCM (1/1, v/v). The reaction vessel was sealed and the reaction 
allowed to stir for 6.5 h. The mixture was poured into 75 mL of Et2O and cooled for 
18h at 4°C. The resulting solid was collected and washed with diethyl ether to give a 
pale green powder (1.1071 g).  
Yield: 61% (calculated from NMR to account for solvent of crystallisation) 
MP:151-153°C 
1H-NMR (400 MHz, DMSO) δ 9.83 (s, 4H), 9.38 (s, 4H), 7.15 (t, J = 7.6 Hz, 1H), 6.77 
– 6.65 (m, 3H), 6.50 (s, 4H), 6.48 (s, 4H), 5.63 (s, 2H). 
13C-NMR (101 MHz, DMSO) δ 154.71, 152.61, 143.25, 132.22, 129.69, 127.64, 
126.09, 123.30, 103.54, 97.49, 41.58. 
IR (νmax, cm-1): 3464.5, 3390.5, 1607, 1500.5, 1485, 1423.5, 1370, 1332, 1276.5, 
1238.5, 1195.5, 1167.5, 1115.5, 1010, 896.5, 887.5, 834. 
 
  




A mixture of terephthalaldehyde (500 mg, 3.73 mmol) and 4-chlororesorcinol (2.42 g, 
16.78mmol) was dissolved in 15 ml of ethanol/HCl 37% (1/1, v/v) and allowed to stir 
at 70 °C for 5 h. The solvent was evaporated and the resulting orange solid obtained 
was suspended in water, collected by filtration and washed with water. To remove trace 
3-chlororesorcinol, the solid was suspended in dichloromethane, allowed to stir for 15 
minutes, collected by filtration and washed with dichloromethane. The orange powder 
was dried in the desiccator for one week to give 1.6505 g of product. 
Yield: 66% (calculated from NMR to account for solvent of crystallisation) 
Method 2 
1.2 mL of methanesulfonic acid was added to a pre-cooled (0 °C) mixture of 
terephthalaldehyde (500 mg, 3.73 mmol) and 4-chlororesorcinol (2.42 g, 16.78 mmol) 
in 15 ml of Et2O/DCM (1/1, v/v). The reaction vessel was sealed and the reaction 
allowed to stir for 5 h. The mixture was poured into 75 mL of Et2O and cooled for 18 h 
at 4°C. The resulting solid was collected and washed with diethyl ether to give the 
orange crystalline product (2.8132 g).  
Yield: 86% (calculated from NMR to account for solvent of crystallisation) 
MP: 225-256°C 
1H-NMR (400 MHz, DMSO) δ 9.77 (s, 4H), 9.38 (s, 4H), 6.84 (s, 4H), 6.49 (s, 4H), 
6.38 (s, 4H), 5.68 (s, 2H). 
13C-NMR (101 MHz, DMSO) δ 154.10, 151.57, 141.03, 129.52, 128.39, 122.73, 
108.67, 103.65, 41.31. 
IR (νmax, cm-1): 3498.5, 3424.5, 3209.5, 1613, 1505, 1428.5, 1355.5, 1322, 1283.5, 
1266.5, 1245, 1224, 1209, 1194.5, 1169.5, 1121.5, 1029, 905,889.5, 840.5. 
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Crystallisation procedure 
During preparation according to Method 2: the mixture obtained after 5 hours was 
poured in 75 mL of diethyl ether: the solid initially dissolved and then recrystallised 
after one night in the fridge at 4 °C. Crystals were taken directly from the solution. 
Platform 163 (Figure 49) lies about a twofold symmetry axis, normal to the central C6 
ring and through the centre of that ring. 
Each of the hydroxyl groups in this molecule is a hydrogen-bond donor, three (and the 
symmetry-related three) linked to ether (solvent) molecules, and the fourth (and its 
equivalent) forming a bond with an adjacent 163 molecule. These molecules thus form 
chains which run parallel to the crystallographic b-axis (Figure 49) in the form of 
columns of 163 molecules padded out by ether molecules. 
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Figure 49. View of a molecule of 163, indicating the atom numbering scheme and hydrogen-bonded 
atoms of neighbouring molecules.  Thermal ellipsoids are drawn at the 50% probability level. 
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Figure 50. 163 molecules linked through hydrogen bonds in chains. The oxygen atoms of the hydrogen-
bonded ether molecules are also included.  
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Compound 164 
 
Method 1  
A mixture of isophthalaldehyde (500 mg, 3.73 mmol) and 4-chlororesorcinol (2.42 g, 
16.78 mmol) was dissolved in 15 ml of ethanol/HCl 37% (1/1, v/v) and allowed to stir 
at 70 °C for 5 h. The solvent was evaporated and the resulting orange solid obtained 
was suspended in water, collected by filtration and washed with water. To remove trace 
3-chlororesorcinol, the solid was suspended in dichloromethane, allowed to stir for 15 
minutes, collected by filtration and washed with dichloromethane. The orange powder 
was dried in the desiccator for one week to give 2.4721 g of product. 
Yield: 91% (calculated from NMR to account for solvent of crystallisation) 
MP: 172-174 °C 
1H-NMR (400 MHz, DMSO) δ 9.75 (s, 4H), 9.35 (s, 4H), 7.15 (t, J = 7.6 Hz, 1H), 6.72 
(d, J = 7.6 Hz, 2H), 6.47 (s, 4H), 6.34 (s, 4H), 5.63 (s, 2H). 
13C-NMR (101 MHz, DMSO) δ 154.03, 151.55, 143.26, 129.65, 129.42, 127.69, 
126.12, 122.64, 108.73, 103.67, 41.61. 
IR (νmax, cm-1): 3477.5, 3420.5, 3061, 1617, 1602, 1500, 1430, 1381, 1360.5, 1319.5, 
1295.5, 1281.5, 1263, 1232, 1208.5, 1194.5, 1179, 1159.5, 1128, 1119, 1089, 1029.5, 
900,889.5, 839.5. 
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Crystallisation procedure 
A sample of compound was suspended in a solution 1:1 of DCM:Et2O and heated to 
reflux. The minimum amount of methanol necessary to obtain complete dissolution was 
added; the clear solution obtained was sealed in the tube and left at room temperature 
to obtain transparent needles. 
Platform 164 molecules are linked, directly and through bridging methanol molecules, 
in an extensive hydrogen-bonded network.  Principally, the octa-phenols are linked in 
ladder-like chains through O(243)-H…O(14) and O(34)-H…O(443) hydrogen bonds; 
there are also O(32)-H…O(421) hydrogen bonds, about centres of symmetry, that link 
these chains into double-ladder chains. These chains are linked through one or more 
bridging methanol molecules. 
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Figure 51. View of a molecule of 164.  Thermal ellipsoids are drawn at the 50% probability level. 
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Figure 52. Linking, through hydrogen bonds, of the 164 molecules, showing the ladder formation and 








A mixture of phthaldialdehyde (500 mg, 3.73 mmol) and 4-chlororesorcinol (2.425 g, 
16.78 mmol) was dissolved in 15 ml of ethanol/HCl 37% (1/1, v/v).and allowed to stir 
at 70 °C for 6.5 h. The solvent was evaporated and the resulting orange solid obtained 
was suspended in water, collected by filtration and washed with water. To remove trace 
3-chlororesorcinol, the solid was suspended in dichloromethane, allowed to stir for 15 
minutes, collected by filtration and washed with dichloromethane. The orange powder 
was dried in the desiccator for one week to give 2.4915 g of product. 
Yield: 80% (calculated from NMR to account for solvent of crystallisation) 
Method 2 
1.2 mL of methanesulfonic acid was added to a pre-cooled (0 °C) mixture of 
phthaldialdehyde (500 mg, 3.73mmol) and 4-chlororesorcinol (2.425 g, 16.78 mmol) in 
15 ml of Et2O/DCM (1/1, v/v). The reaction vessel was sealed and the reaction allowed 
to stir vigorously for 6 h. The mixture was poured into 75 mL of Et2O and cooled for 
18 h at 4 °C. The resulting solid was collected and washed with diethyl ether to give a 
pale yellow powder (398.1 mg).  
Note stirring must be vigorous, the amount of precipitate formed can give uneven 
stirring and isolation of 11; use of reaction tubes is discouraged. 
Yield: 94% (calculated from NMR to account for solvent of crystallisation) 
MP: 282-283 °C 
1H-NMR (400 MHz, DMSO) δ 9.57 (s, 4H), 8.86 (s, 4H), 7.08 (dd, J = 5.7, 3.5 Hz, 2H), 
6.73 (dd, J = 5.7, 3.5 Hz, 2H), 6.41 (s, 4H), 6.28 (s, 4H), 5.63 (s, 2H). 
13C-NMR (101 MHz, DMSO) δ 154.32, 151.18, 141.82, 129.76, 128.72, 125.39, 
122.41, 108.34, 103.50, 39.1. (The peak at 39.6 is overlaid with DMSO and was 
assigned by HSQC) 
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IR (νmax, cm-1): 3492, 3397, 1614, 1598.5, 1502.5, 1424, 1367.5, 1334, 1248, 1191.5, 
1126.5, 1029, 905, 895, 876.5, 864, 836.5, 822. 
 
Crystallisation procedure 
A sample of compound was suspended in diethyl ether and heated to reflux. The 
minimum amount of methanol necessary to obtain complete dissolution was added; the 
clear solution obtained was sealed in the tube and left at room temperature to obtain 
transparent needles. 
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The phenyl rings of Platform 165 lie in three essentially orthogonal planes, Figure 53
 
Figure 53.   
All eight phenolic groups are donors in hydrogen bonds, and several are also acceptor 
atoms. The O(12) and O(32) each form pairs of links about centres of symmetry with 
neighbouring 165 molecules and thus form ladder-like chains through the crystal, 
(horizontally in Figure 54).  
The two principal methanol molecules combine in a double bridging link between 
chains, forming a “square” hydrogen bonding cycle, Figure 54, thus forming sheets of 
linked molecules.  
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Figure 53. View of a molecule of 165.  Thermal ellipsoids are drawn at the 50% probability level. 
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Figure 54. The molecules are linked through hydrogen bonds in chains (horizontally) about centres of 
symmetry, and in sheets and through methanol bridges. 
 
Compound 166 and 167 
 
1.2 mL of methanesulfonic acid was added to a pre-cooled (0 °C) mixture of 
phthaldialdehyde (500 mg, 3.73 mmol) and 4-chlororesorcinol (1.07 g, 7.46 mmol) in 
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15 ml of Et2O/DCM (1/1, v/v). The reaction vessel was sealed and the reaction allowed 
to stir vigorously for 6 h. The mixture was poured into 75 mL of Et2O and cooled for 
18 h at 4 °C. The resulting solid was collected and washed with diethyl ether. The 
product was dried in the oven at 60 °C for 18 h to give 773.2 mg of 167 as a white 
powder  
Yield: 44% (calculated from NMR to account for solvent of crystallisation) 
To isolate 166: after collecting the solid 167, the remaining liquor was washed with a 
solution of 1.55 g of NaHCO3 in 20 mL of water and then with brine. The organic layer 
was dried over MgSO4 and the product was crystallised by solvent evaporation. 
Compound 166 
Yield: 11% 
MP: 259-260 °C 
1H-NMR (400 MHz, DMSO) δ 10.19 (s, 2H), 7.55 (d, J = 7.3 Hz, 1H), 7.47 (s, 2H), 
7.45 – 7.31 (m, 3H), 6.86 (s, 1H), 6.53 (s, 2H), 5.07 (s, 1H). 
13C-NMR (101 MHz, DMSO) δ 152.80, 151.33, 141.67, 130.97, 130.15, 129.86, 
128.76, 127.55, 125.58, 119.92, 112.82, 106.99, 99.82, 50.26. 
IR (νmax, cm-1): 3476.5, 3427.5, 1612, 1486.5, 1431, 1319, 1278, 1240, 1218.5, 1210, 
1145, 1122.5, 1067.5, 1042, 978.5, 953.5, 940.5, 923, 901, 870.5, 858.5, 840.5, 822.5. 
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The compound forms a rigid triplanar molecule which crystallises with an ether 
(solvent) molecule. 
The only atoms that do not lie on one of the three planes are the phenolate hydrogen 
atoms which are directed in forming hydrogen bonds which link the diphenolate 
molecules in chains and to the ether molecules. 
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Figure 55. View of a molecule of 166 and hydrogen-bonded solvent (Et2O) molecule, indicating the 
atom numbering scheme.  Thermal ellipsoids are drawn at the 50% probability level. 
 
Figure 56. A chain of hydrogen-bond linked 166 and ether molecules. 
 
Compound 167 
MP: 214-216 °C 
1H-NMR (400 MHz, DMSO) δ 10.20 (s, 1H), 9.92 (s, 2H), 9.57 (s, 2H), 7.80 (dd, J = 
7.6, 1.4 Hz, 1H), 7.56 (dt, J = 7.7, 1.4 Hz, 1H), 7.42 (adt, J = 7.6 Hz, 1H), 6.94 (add, J 
= 7.7 Hz, 1H), 6.55 – 6.53 (m, 3H), 6.36 (s, 2H). 
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13C-NMR (101 MHz, DMSO) δ 191.70, 153.88, 152.05, 146.41, 133.80, 132.95, 
129.76, 129.39, 128.92, 126.67, 121.67, 108.95, 103.79, 37.06. 
IR (νmax, cm-1): 3420.5, 3366, 3168, 1649, 1613.5, 1594.5, 1521, 1420.5, 1366, 1274, 





A mixture of terephthalaldehyde (116.3 mg, 0.87 mmol) and 4-fluororesorcinol (500 
mg, 3.90 mmol) was dissolved in 3 ml of ethanol/HCl 37% (1/1, v/v) and allowed to 
stir at 70 °C for 5 h. The solvent was evaporated and the resulting orange solid obtained 
was suspended in water, collected by filtration and washed with water. The light orange 
powder was dried in the desiccator for one week to give 238.9 mg of product. 
Yield: 35% (calculated from NMR to account for solvent of crystallisation) 
Method 2 
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0.56 mL of methanesulfonic acid was added to a pre-cooled (0 °C) mixture of 
terephthalaldehyde (104.7 mg, 0.78 mmol) and 4-fluororesorcinol (500 mg, 3.90 mmol) 
in 7 ml of Et2O/DCM (1/1, v/v). The reaction vessel was sealed and the reaction allowed 
to stir for 7 h. The mixture was poured into 75 mL of Et2O and cooled for 18 h at 4 °C. 
The resulting solid was collected and washed with diethyl ether to give a pale yellow 
powder (398.1 mg).  
Yield: 65% (calculated from NMR to account for solvent of crystallisation) 
MP: 194-195 °C 
1H-NMR - F decoupled (400 MHz, DMSO) δ 9.45 (s, 4H), 9.04 (s, 4H), 6.84 (s, 4H), 
6.42 (s, 4H), 6.25 (s, 4H), 5.70 (s, 2H). 
13C-NMR (101 MHz, DMSO) δ 144.07 (d, J = 230.0 Hz), 142.82 (d, J = 13.4 Hz), 
120.88 (d, J = 4.6 Hz), 116.03 (d, J = 20.1 Hz), 104.41 (d, J = 1.5 Hz). 
IR (νmax, cm-1): 3360, 1631, 1526, 1510.5, 1441, 1326, 1265.5, 1240, 1227, 1209.5, 
1158.5, 1090.5, 901, 878.5, 844, 820.5. 
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Compound 180 
 
1.28 mL of methanesulfonic acid was added to a pre-cooled (0 °C) mixture of 
terephthalaldehyde (500 mg, 3.73 mmol) and 2,4-dibromoresorcinol (6 g, 22.40 mmol)  
in 16 ml of Et2O/DCM (1/1, v/v). The reaction vessel was sealed and the reaction 
allowed to stir vigorously for 8 d. The resulting solid was collected and washed with 
dichloromethane. The product was dried in the oven at 60 °C for 3 d to give 2.2748 g 
of 180 as a white powder  
Yield: 85% (calculated from NMR to account for solvent of crystallisation) 
MP: 244-245 °C 
1H-NMR (400 MHz, DMSO) δ 9.98 (s, 1H), 9.71 (s, 2H), 9.30 (s, 2H), 7.86 (d, J = 8.3 
Hz, 2H), 7.24 (d, J = 8.3 Hz, 2H), 6.62 (s, 2H), 6.06 (s, 1H). 
13C-NMR (101 MHz, DMSO) δ 192.61, 151.92, 150.09, 149.44, 134.63, 130.74, 
129.70, 129.57, 124.44, 103.34, 100.69, 43.99. 
IR (νmax, cm-1): 3492.5, 3469.5, 2759, 1575, 1311, 1276.5, 1253, 1237.5, 1112, 1033.5, 
1014.5, 982, 912.5, 871, 850.5. 
  




0.72 ml of methanesulfonic acid was added to a pre-cooled (0 °C) mixture of 180 (400 
mg, 0.61 mmol) and 4-bromoresorcinol (289.9 g, 1.534 mmol) in 9 ml of Et2O/DCM 
(1/1, v/v). The reaction vessel was sealed and the reaction allowed to stir for 3 d. The 
mixture was poured into distilled water and extracted with ethyl acetate three times. The 
organic layers were combined, washed with brine and dried over anhydrous Na2SO4. 
The solvent was evaporated and the resulting solid was suspended in 50 mL of water. 
The mixture was allowed to stir vigorously for 15 minutes before being centrifuged 
(8500 rpm for 10 min). The supernatant solution was removed and the solid was washed 
two more times with a total of 100 mL of distilled water. The pink solid was dried in 
the desiccator for one week (485.6 mg). 
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Yield: 75.64% (calculated from NMR to account for solvent of crystallisation) 
MP: 189-191 °C 
1H-NMR (400 MHz, DMSO) δ 9.87 (s, 2H), 9.61 (s, 2H), 9.43 (s, 2H), 9.19 (s, 2H), 
6.89 (s, 4H), 6.58 (s, 2H), 6.53 (s, 2H), 6.50 (s, 2H), 5.95 (s, 1H), 5.69 (s, 1H). 
13C-NMR (101 MHz, DMSO) δ 154.78, 152.70, 151.76, 149.71, 141.80, 139.48, 
132.34, 130.78, 128.72, 128.57, 125.57, 123.26, 103.52, 103.18, 100.55, 97.50, 43.21, 
41.32. 
IR (νmax, cm-1): 3477.5, 1606, 1595.5, 1503.5, 1471, 1427, 1329, 1274.5, 1189.5, 1170, 
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0.96 mL of methanesulfonic acid was added to a pre-cooled (0 °C) mixture of 180 (500 
mg, 0.77 mmol) and 2-chlororesorcinol (277.2 mg, 1.91 mmol) in 12 ml of Et2O/DCM 
(1/1, v/v). The reaction vessel was sealed and the reaction allowed to stir for 2 d. The 
mixture was poured into distilled water and extracted with ethyl acetate three times. The 
organic layers were combined, washed with brine and dried over anhydrous Na2SO4. 
The solvent was evaporated and the resulting solid was suspended in 50 mL of water. 
The mixture was allowed to stir vigorously for 15 minutes before being centrifuged 
(8500 rpm for 10 min). The supernatant solution was removed and the solid was washed 
two more times with a total of 100 mL of distilled water. The solid was dried in the 
desiccator for one week. 
MP: 184-186 °C 
1H-NMR (400 MHz, DMSO) δ 9.79 (s, 2H), 9.61 (s, 2H), 9.40 (s, 2H), 9.20 (s, 2H), 
6.89 (s, 4H), 6.58 (s, 2H), 6.49 (s, 2H), 6.38 (s, 2H), 5.95 (s, 1H), 5.69 (s, 1H). 
13C-NMR (101 MHz, DMSO) δ 154.61, 152.27, 152.12, 150.21, 142.29, 139.97, 
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Compound 183 
 
Palladium over carbon (catalytic) was added to a solution of 163 (3.18 mmol) and 
triethylamine (12.37 mL, 88.72 mmol) in 150 mL of methanol. A hydrogen atmosphere 
was applied and the mixture was allowed to stir at 40 °C for 18 h. The catalyst was 
removed by filtration and the solution was dried under reduced pressure. The product 
was suspended in HCl 1.2 M and extracted with ethyl acetate three times. The organic 
layers were combined, washed with HCl 1.2 M, brine and dried over Na2SO4. Upon 
evaporation of the solvent the product was obtained as an orange powder (1.9341 g). 
Note: the reaction can be carried out using 158 as substrate and comparable yields can 
be obtained at room temperature in the same timescale. 
Yield: 96% (calculated from NMR to account for solvent of crystallisation) 
MP: 178-180 °C 
1H NMR (400 MHz, DMSO) δ 8.94 (s, 4H), 8.92 (s, 4H), 6.78 (s, 4H), 6.41 (d, J = 8.3 
Hz, 4H), 6.22 (d, J = 2.3 Hz, 4H), 6.07 (dd, J = 8.3, 2.3 Hz, 4H), 5.73 (s, 2H). 
13C NMR (101 MHz, DMSO) δ 156.52, 155.74, 142.49, 130.49, 128.62, 122.10, 105.80, 
102.79, 41.21. 
IR (νmax, cm-1): 3291, 1601, 1512.5, 1504.5, 1452, 1374.5, 1298.5, 1248, 1197, 1158.5, 
1091, 972, 834.5. 
  




Palladium over carbon (catalytic) was added to a solution of 164 (0.34 mmol) and 
triethylamine (1.24 mL, 8.87 mmol) in 20 mL of ethanol. A hydrogen atmosphere was 
applied and the mixture was allowed to stir at 60 °C for 18 h. The catalyst was removed 
by filtration and the solution was dried under reduced pressure. The product was 
suspended in HCl 1.2 M and extracted with ethyl acetate three times. The organic layers 
were combined, washed with HCl 1.2 M, brine and dried over Na2SO4. Upon 
evaporation of the solvent the product was obtained as an orange powder (160.9 mg). 
Yield: 62% (calculated from NMR to account for solvent of crystallisation) 
MP: 165-167 °C 
1H NMR (400 MHz, DMSO) δ 8.98 (d, 4H), 8.91 (s, 4H), 7.01 (t, J = 7.8 Hz, 1H), 6.71 
(s, 1H), 6.64 (d, J = 7.8 Hz, 2H), 6.34 (d, J = 8.3 Hz, 4H), 6.21 (d, J = 2.2 Hz, 4H), 6.04 
(dd, J = 8.3, 2.2 Hz, 4H), 5.67 (s, 2H). 
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13C NMR (101 MHz, DMSO) δ 156.49, 155.72, 145.03, 130.66, 130.49, 127.24, 126.15, 
122.08, 105.70, 102.80, 41.77. 





Palladium over carbon (catalytic) was added to a solution of 165 (0.23 mmol) and 
triethylamine (0.99 mL, 7.10 mmol) were dissolved in 12 mL of ethanol. A hydrogen 
atmosphere was applied and the mixture was allowed to stir at 60 °C for 18 h. The 
catalyst was removed by filtration and the solution was dried under reduced pressure. 
The product was suspended in HCl 1.2 M and extracted with ethyl acetate three times. 
The organic layers were combined, washed with HCl 1.2 M, brine and dried over 
Na2SO4. Upon evaporation of the solvent the product was obtained as an orange powder 
(101.6 mg). 
Yield: 69% (calculated from NMR to account for solvent of crystallisation) 
MP: 216-218 °C 
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1H NMR (400 MHz, DMSO) δ 8.79 (s, 4H), 8.20 (s, 4H), 6.98 (dd, J = 5.7, 3.5 Hz, 2H), 
6.74 (dd, J = 5.7, 3.5 Hz, 2H), 6.26 (d, J = 8.3 Hz, 4H), 6.14 (d, J = 2.4 Hz, 4H), 5.99 
(dd, J = 8.3, 2.4 Hz, 4H), 5.73 (s, 2H). 
13C NMR (101 MHz, DMSO) δ 155.89, 155.33, 142.77, 130.07, 129.01, 124.67, 121.08, 
104.95, 102.20, 38.8. (The peak at 38.8 is overlaid with DMSO and was assigned by 
HSQC) 
IR (νmax, cm-1): 3501.5, 3306.5, 1599, 1516.5, 1505.5, 1454, 1373.5, 1336.5, 1291.5, 




A solution of freshly recrystallised NBS (0.5 g, 0.585 mmol) in 10 mL of acetonitrile 
was added to a stirring solution of 163 (0.5 g, 2.81 mmol) in 10 mL of acetonitrile. After 
25 minutes the solid product was collected by Büchner filtration and thoroughly washed 
with water. The solid was dried under vacuum to give the product as a red-orange 
powder. 
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Yield: 63% (calculated from NMR to account for solvent of crystallisation) 
1H-NMR (400 MHz, DMSO) δ 9.63 (s, 4H), 9.21 (s, 4H), 6.96 (s, 2H), 6.60 (s, 2H), 
5.97 (s, 1H). 
13C-NMR (101 MHz, DMSO) δ 152.26, 150.26, 140.72, 131.26, 129.38, 125.93, 




NBS (505.3 mg, 2.84 mmol) was added to a stirring solution of 163 (400 mg, 0.59 
mmol) in 16 mL of acetonitrile. After 30 minutes the reaction was diluted with water. 
The solid product was collected by Büchner filtration and thoroughly washed with 
water. The solid was dried under vacuum to give the product as a light orange powder. 
Yield: 39.3% (calculated from NMR to account for solvent of crystallisation) 
1H-NMR (400 MHz, DMSO) δ 9.78 (s, 2H), 9.17 (s, 2H), 6.94 (s, 2H), 6.44 (s, 2H), 
5.97 (s, 1H). 
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13C-NMR (101 MHz, DMSO) δ 151.75, 149.38, 140.72, 129.37, 128.37, 125.09, 




A solution of freshly recrystallised NBS (107.9 mg, 0.601 mmol) in 2 mL of acetonitrile 
was added to a stirring solution of 165 (100 mg, 0.148 mmol) in 2 mL of acetonitrile. 
After 20 minutes the reaction was quenched with 70 mg (0.555 mmol) of 
phloroglucinol, and diluted with water. The solid product was collected by Büchner 
filtration and thoroughly washed with water. The solid was dried under vacuum to give 
the product as a brown powder. 
Yield: 84.3% (calculated from NMR to account for solvent of crystallisation) 
1H-NMR (400 MHz, DMSO) δ 9.53 (s, 2H), 8.46 (s, 2H), 7.25 – 7.13 (m, 2H), 6.89 – 
6.79 (m, 2H), 6.28 (s, 2H), 6.23 (s, 1H). 
13C-NMR (101 MHz, DMSO) δ 151.49, 149.05, 140.92, 129.57, 128.46, 126.82, 
124.06, 111.52, 103.08, 40.81. 
  




To a allowed to stir solution of 3-formylphenylboronic acid (1.0 g, 6.669 mmol), 3-
bromobenzaldehyde (0.778 mL, 6.669 mmol), DMF (160 mL) and Na2CO3 (4.241 g, 
40.014 mmol) in water (16 mL), a catalytic amount of 5% Pd(dppf)Cl2 (0.033 mmol) 
was added. The flask was flushed with argon and the reaction mixture was allowed to 
stir for 18 hours at 40 °C. The solvent was removed under reduced pressure and the 




+ = 228.1016 (Calculated: 228.1019) 
MP: 93-95 °C (lit. 92-94 °C)95 
1H-NMR (400 MHz, CDCl3) δ 10.14 (s, 1H), 8.18 (s, 1H), 8.04 – 7.86 (m, 2H), 7.69 (t, 
J = 7.7 Hz, 1H). 
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0.16 mL of methanesulfonic acid was added to a pre-cooled (0 °C) mixture of 191 
(100.6 mg, 0.48 mmol) and 4-bromoresorcinol (406.4 mg, 2.15 mmol) in 2 ml of 
Et2O/DCM (1/1, v/v). The reaction vessel was sealed and the reaction allowed to stir 
for 6 h. The resulting mixture was diluted with diethyl ether, poured into distilled water 
and allowed to stir vigorously until a suspension was obtained. The product was 
collected by Büchner filtration, washed with abundant distilled water and dried in a 
desiccator to give an orange powder. 
Yield: 87.5% (calculated from NMR to account for solvent of crystallisation) 
MP: 257-258 °C 
1H-NMR (400 MHz, DMSO) δ 9.90 (s, 4H), 9.46 (s, 4H), 7.39 – 7.31 (m, 4H), 7.22 (s, 
2H), 6.94 – 6.87 (m, 2H), 6.61 (s, 4H), 6.51 (s, 4H), 5.76 (s, 2H). 
13C-NMR (101 MHz, DMSO) δ 155.35, 153.28, 144.93, 140.46, 132.75, 129.22, 
128.24, 127.61, 124.72, 123.48, 104.12, 97.99, 42.55. 
IR (νmax, cm-1): 3624, 3526, 3480, 3278, 1606, 1591, 1501, 1488, 1430, 1393, 1335, 
1277, 1211, 1190, 1161, 1116, 1010, 904, 836, 823. 
  




0.16 mL of methanesulfonic acid was added to a pre-cooled (0 °C) mixture of 191 
(101.2 mg, 0.48 mmol) and 4-chlororesorcinol (310.5 mg, 2.15 mmol) in 2 ml of 
Et2O/DCM (1/1, v/v). The reaction vessel was sealed and the reaction allowed to stir 
for 6 h. The resulting mixture was diluted with diethyl ether, poured into distilled water 
and allowed to stir vigorously until a suspension was obtained. The product was 
collected by Büchner filtration, washed with abundant distilled water and dried in a 
desiccator to give an off yellow powder. 
Yield: 99.5% (calculated from NMR to account for solvent of crystallisation) 
MP: 261-270 °C 
1H-NMR (400 MHz, DMSO) δ 9.82 (s, 4H), 9.43 (s, 4H), 7.33 (m, 4H), 7.21 (s, 2H), 
7.00 – 6.84 (m, 2H), 6.50 (s, 4H), 6.47 (s, 4H), 5.76 (s, 2H). 
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13C-NMR (101 MHz, DMSO) δ 154.67, 152.21, 144.93, 140.47, 129.96, 129.22, 
128.26, 127.59, 124.71, 122.82, 109.24, 104.24, 42.53. 
IR (νmax, cm-1): 3526, 3491, 1612, 1595, 1491, 1434, 1335, 1278, 1244, 1226, 1214, 




Palladium over carbon (catalytic) was added to a solution of 193 (0.97 mmol) and 
triethylamine (3.55 mL, 25.5 mmol) in 48 mL of ethanol. A hydrogen atmosphere was 
applied and the mixture was allowed to stir at 50 °C for 18 h. The catalyst was removed 
by filtration and the solution was dried under reduced pressure. The product was 
suspended in HCl 1.2 M and extracted with ethyl acetate three times. The organic layers 
were combined, washed with HCl 1.2 M, brine and dried over Na2SO4. The solvent was 
removed under reduced pressure and the solid obtained was suspended in water, 
collected by Büchner filtration and washed thoroughly with water. The product was 
then dried in a desiccator to give an orange powder. 
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Yield: 38.8% (calculated from NMR to account for solvent of crystallisation) 
1H-NMR (400 MHz, DMSO) δ 9.01 (s, 4H), 8.97 (s, 4H), 7.31 – 7.19 (m, 4H), 7.11 (s, 
2H), 6.91 (d, J = 7.3 Hz, 2H), 6.45 (d, J = 8.3 Hz, 4H), 6.25 (d, J = 2.3 Hz, 4H), 6.11 
(dd, J = 8.3, 2.3 Hz, 4H), 5.83 (s, 1H). 
13C-NMR (101 MHz, DMSO) δ 156.70, 155.79, 146.66, 140.46, 130.54, 128.72, 
128.35, 127.63, 124.03, 121.59, 105.95, 102.89, 41.97. 




To a allowed to stir solution of 4-formylphenylboronic acid (1.0 g, 6.669 mmol), 4-
bromobenzaldehyde (1.3 g, 6.8 mmol), DMF (160 mL) and Na2CO3 (4.3 g, 0.04 mol) 
in water (16 mL), a catalytic amount of 5% Pd(dppf)Cl2 (0.033 mmol) was added. The 
flask was flushed with argon and the reaction mixture was allowed to stir for 18 hours 
at 40 °C. The solvent was removed under reduced pressure and the product was purified 
by column chromatography (DCM/Hexane 1:1) to give 197 as white solid. 
Yield: 86% (calculated from NMR to account for solvent of crystallisation) 
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MP: 155-158 °C 
1H NMR (400 MHz, DMSO) δ 10.10 (s, 2H), 8.10 – 7.98 (m, 8H).  
13C NMR (101 MHz, DMSO) δ 193.29, 144.86, 136.28, 130.67, 128.40. 
Compound 198 
 
0.56 mL of methanesulfonic acid was added to a pre-cooled (0 °C) mixture of 197 (0.3 
g, 1.2 mmol) and 4-chlororesorcinol (0.8 mg, 5.4 mmol) in 7 ml of Et2O/DCM (1/1, 
v/v). The reaction vessel was sealed and the reaction allowed to stir for 18 h. The 
resulting mixture was diluted with diethyl ether, poured into distilled water and allowed 
to stir vigorously until a suspension was obtained. The product was collected by 
Büchner filtration, washed with abundant distilled water and dried in a desiccator to 
give an orange powder. 
Yield: 79% (calculated from NMR to account for solvent of crystallisation) 
MP: 195-200 °C 
1H-NMR (400 MHz, DMSO) δ 9.83 (s, 4H), 9.45 (s, 4H), 7.56 (d, J = 8.3 Hz, 4H), 7.03 
(d, J = 8.3 Hz, 4H), 6.52 (s, 4H), 6.45 (s, 4H), 5.74 (s, 2H). 
13C-NMR (101 MHz, DMSO) δ 154.69, 152.21, 143.28, 137.93, 129.97, 129.73, 
126.73, 122.91, 109.21, 104.22, 41.99. 
IR (νmax, cm-1): 3335, 2359, 2361, 2338, 1612, 1492, 1432, 1330, 1275, 1233, 1169, 
1122, 1025, 1007, 896, 882, 867. 
  




Palladium over carbon (catalytic) was added to a solution of 198 (300 mg, 0.348 mmol) 
and triethylamine (1.33 mL, 9.57 mmol) in 20 mL of ethanol. A hydrogen atmosphere 
was applied and the mixture was allowed to stir at 50 °C for 5 h. The catalyst was 
removed by filtration and the solution was dried under reduced pressure. The product 
was suspended in HCl 1.2 M and extracted with ethyl acetate three times. The organic 
layers were combined, washed with HCl 1.2 M, brine and dried over Na2SO4. The 
solvent was removed under reduced pressure and the solid obtained was suspended in 
water, collected by Büchner filtration and washed thoroughly with water. The product 
was then dried in a desiccator to give an orange powder. 
Yield: 68.7% (calculated from NMR to account for solvent of crystallisation) 
MP: 180-185 °C 
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1H NMR (400 MHz, DMSO) δ 9.02 (s, 4H), 8.97 (s, 4H), 7.46 (d, J = 8.3 Hz, 4H), 7.00 
(d, J = 8.3 Hz, 4H), 6.45 (d, J = 8.3 Hz, 4H), 6.26 (d, J = 2.4 Hz, 4H), 6.10 (dd, J = 8.3, 
2.4 Hz, 4H), 5.81 (s, 2H). 
13C NMR (101 MHz, DMSO) δ 156.71, 155.83, 144.95, 137.67, 130.54, 129.75, 126.31, 




A stirring mixture of 4-hydroxybenzaldehyde (5 g, 40.94 mmol) and potassium 
carbonate (14.1 g, 102 mmol) in acetone (250 mL) was boiled under reflux for 1 hour. 
1,2-Dibromoethane (1.41 mL, 16.376 mmol) was added and the mixture was allowed 
to stir overnight. The solid residue was removed by filtration and washed with DCM. 
The filtrates were combined and evaporated under reduced pressure. The product was 
purified by column chromatography (DCM). 
Yield: 12% 
MP: 120-122 °C (lit. 127-129 °C)87 
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1H-NMR (400 MHz, CDCl3) δ 9.84 (s, 1H), 7.89 – 7.74 (m, 2H), 7.09 – 6.94 (m, 2H), 
4.38 (s, 2H). 
13C-NMR (101 MHz, CDCl3) δ 190.76, 163.40, 132.04, 130.43, 114.89, 66.51. 
Compound 20596 
 
A stirring mixture of 4-hydroxybenzaldehyde (5 g, 40.94 mmol) and potassium 
carbonate (14.1 g, 102 mmol) in acetone (250 mL) was boiled under reflux for 1 hour. 
1,4-Dibromobutane (1.96 mL, 16.376 mmol) was added and the mixture was allowed 
to stir overnight. The solid residue was removed by filtration and washed with DCM. 
The filtrates were combined and evaporated under reduced pressure. The product was 
purified by column chromatography (DCM). 
Yield: 68.2% 
MP: 275-277 °C 
1H-NMR (400 MHz, CDCl3) δ 9.92 (s, 1H), 7.94 – 7.80 (m, 2H), 7.08 – 6.96 (m, 2H), 
4.26 – 4.08 (m, 2H), 2.14 – 1.94 (m, 2H). 
13C-NMR (101 MHz, DMSO) δ 190.78, 163.96, 132.02, 129.98, 114.73, 67.76, 25.81. 
Compound 20687 
 
A stirring mixture of 4-hydroxybenzaldehyde (5 g, 40.94 mmol) and potassium 
carbonate (14.1 g, 102 mmol) in acetone (250 mL) was refluxed for 1 hour. 1,6-
Dibromohexane (2.52 mL, 16.376 mmol) was added and the mixture was allowed to 
stir overnight. The solid residue was removed by filtration and washed with DCM. The 
filtrates were combined and evaporated under reduced pressure. The product was 
purified by column chromatography (DCM). 
Yield: 48.5% 
MP: 109-111 °C (lit. 113-115 °C)87 
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1H-NMR (400 MHz, CDCl3) δ 9.91 (s, 1H), 7.93 – 7.78 (m, 2H), 7.08 – 6.95 (m, 2H), 
4.09 (t, J = 6.4 Hz, 2H), 1.96 – 1.80 (m, 2H), 1.63 – 1.57 (m, 2H). 




0.16 mL of methanesulfonic acid was added to a pre-cooled (0 °C) mixture of 204 
(136.1 mg, 0.50 mmol) and 4-bromoresorcinol (443.6 mg, 2.35 mmol)  in 2 ml of 
Et2O/DCM (1/1, v/v). The reaction vessel was sealed and the reaction allowed to stir 
for 24 h. The resulting mixture was diluted with diethyl ether, poured into distilled water 
and allowed to stir vigorously until a suspension was obtained. The product was 
collected by Büchner filtration, washed with abundant distilled water and dried in a 
desiccator to give an orange powder. 
Yield: 57.9% (calculated from NMR to account for solvent of crystallisation) 
MP: 180-182 °C 
1H-NMR (400 MHz, DMSO) δ 9.87 (s, 4H), 9.41 (s, 4H), 6.88 (m, 8H), 6.54 (s, 4H), 
6.50 (s, 4H), 5.65 (s, 2H), 4.26 (s, 4H). 
13C-NMR (101 MHz, DMSO) δ 156.90, 155.30, 153.14, 136.20, 132.67, 130.16, 
124.07, 114.53, 104.04, 97.88, 66.70, 41.44. 
IR (νmax, cm-1): 3543, 3434, 1607, 1507, 1418, 1331, 1242, 1224, 1209, 1189, 1174, 
1114, 1073, 1058, 1010, 930, 898, 871, 830. 
  




0.32 mL of methanesulfonic acid was added to a pre-cooled (0 °C) mixture of 204 
(199.7 mg, 0.74 mmol) and 4-chlororesorcinol (492 mg, 3.4 mmol)  in 4 ml of 
Et2O/DCM (1/1, v/v). The reaction vessel was sealed and the reaction allowed to stir 
for 24 h. The resulting mixture was diluted with diethyl ether, poured into distilled water 
and allowed to stir vigorously until a suspension was obtained. The product was 
collected by Büchner filtration, washed with abundant distilled water and dried in a 
desiccator to give an orange powder. 
Yield: 75.1% (calculated from NMR to account for solvent of crystallisation) 
MP: 162-163 °C 
1H-NMR (400 MHz, DMSO) δ 9.79 (s, 4H), 9.37 (s, 4H), 6.88 (s, 8H), 6.49 (s, 4H), 
6.40 (s, 4H), 5.65 (s, 2H), 4.26 (s, 4H). 
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13C-NMR (101 MHz, DMSO) δ 156.90, 154.62, 152.07, 136.22, 130.17, 129.89, 
123.40, 114.52, 109.12, 104.16, 66.71, 41.45. 
IR (νmax, cm-1): 3538, 3503, 3422, 1606, 1509, 1423, 1333, 1241, 1225, 1209, 1181, 




0.16 mL of methanesulfonic acid was added to a pre-cooled (0 °C) mixture of 205 
(130.6 mg, 0.44 mmol) and 4-bromoresorcinol (285.2 mg, 1.97 mmol)  in 2 ml of 
Et2O/DCM (1/1, v/v). The reaction vessel was sealed and the reaction allowed to stir 
for 24 h. The resulting mixture was diluted with diethyl ether, poured into distilled water 
and allowed to stir vigorously until a suspension was obtained. The product was 
collected by Büchner filtration, washed with abundant distilled water and dried in a 
desiccator to give an orange powder. 
Yield: 70.7% (calculated from NMR to account for solvent of crystallisation) 
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MP: 219-220 °C 
1H-NMR (400 MHz, DMSO) δ 9.86 (s, 4H), 9.40 (s, 4H), 6.84 (s, 8H), 6.54 (s, 4H), 
6.49 (s, 4H), 5.64 (s, 2H), 3.99 (s, 4H), 1.86 (s, 4H). 
13C-NMR (101 MHz, DMSO) δ 157.19, 155.29, 153.12, 135.86, 132.66, 130.10, 
124.12, 114.48, 104.04, 97.87, 67.49, 41.43, 26.05. 
IR (νmax, cm-1): 3480, 3382, 1610, 1585, 1511, 1492, 1425, 1414, 1386, 1328, 1271, 




0.16 mL of methanesulfonic acid was added to a pre-cooled (0 °C) mixture of 205 
(100.1 mg, 0.34 mmol) and 4-chlororesorcinol (218.3 mg, 1.51 mmol)  in 2 ml of 
Et2O/DCM (1/1, v/v). The reaction vessel was sealed and the reaction allowed to stir 
for 24 h. The resulting mixture was diluted with diethyl ether, poured into distilled water 
and allowed to stir vigorously until a suspension was obtained. The product was 
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collected by Büchner filtration, washed with abundant distilled water and dried in a 
desiccator to give an orange powder. 
Yield: 69.7% (calculated from NMR to account for solvent of crystallisation) 
MP: 294-295 °C 
1H-NMR (400 MHz, DMSO) δ 9.78 (s, 4H), 9.36 (s, 4H), 6.84 (s, 8H), 6.49 (s, 4H), 
6.40 (s, 4H), 5.64 (s, 2H), 3.99 (s, 4H), 1.85 (s, 4H). 
13C-NMR (101 MHz, DMSO) δ 157.19, 154.61, 152.05, 135.87, 130.11, 129.88, 
123.45, 114.48, 109.10, 104.16, 67.48, 41.43, 26.05. 
IR (νmax, cm-1): 3584, 3491, 3382, 1610, 1588, 1504, 1424, 1387, 1330, 1244, 1234, 
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0.24 mL of methanesulfonic acid was added to a pre-cooled (0 °C) mixture of 206 
(151.5 mg, 0.46 mmol) and 4-bromoresorcinol (391 mg, 2.1 mmol)  in 3 ml of 
Et2O/DCM (1/1, v/v). The reaction vessel was sealed and the reaction allowed to stir 
for 24 h. The resulting mixture was diluted with diethyl ether, poured into distilled water 
and allowed to stir vigorously until a suspension was obtained. The product was 
collected by Büchner filtration, washed with abundant distilled water and dried in a 
desiccator to give an orange powder. 
Yield: 83.8% (calculated from NMR to account for solvent of crystallisation) 
MP: 184-185 °C 
1H-NMR (400 MHz, DMSO) δ 9.86 (s, 4H), 9.40 (s, 4H), 6.93 – 6.74 (m, 8H), 6.53 (s, 
4H), 6.49 (s, 4H), 5.64 (s, 2H), 3.92 (t, J = 6.3 Hz, 4H), 1.72 (bs, 4H), 1.47 (bs, 4H). 
13C-NMR (101 MHz, DMSO) δ 157.23, 155.28, 153.11, 135.78, 132.66, 130.09, 
124.12, 114.45, 104.03, 97.86, 67.70, 41.41, 29.25, 25.89. 
IR (νmax, cm-1): 3474, 2937, 2862, 1608, 1592, 1506, 1425, 1333, 1234, 1194, 1171, 
1116, 1007, 901, 876, 834. 
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Compound 212 
 
0.32 mL of methanesulfonic acid was added to a pre-cooled (0 °C) mixture of 206 
(199.7 mg, 0.61 mmol) and 4-chlororesorcinol (398.9 mg, 2.76 mmol)  in 4 ml of 
Et2O/DCM (1/1, v/v). The reaction vessel was sealed and the reaction allowed to stir 
for 24 h. The resulting mixture was diluted with diethyl ether, poured into distilled water 
and allowed to stir vigorously until a suspension was obtained. The product was 
collected by Büchner filtration, washed with abundant distilled water and dried in a 
desiccator to give a red powder. 
Yield: 60.7% (calculated from NMR to account for solvent of crystallisation) 
MP: 132-133 °C 
1H-NMR (400 MHz, DMSO) δ 9.78 (s, 4H), 9.37 (s, 4H), 6.92 – 6.76 (m, 8H), 6.49 (s, 
4H), 6.40 (s, 4H), 5.64 (s, 2H), 3.92 (t, J = 6.3 Hz, 4H), 1.72 (bs, 4H), 1.47 (bs, 4H). 
13C-NMR (101 MHz, DMSO) δ 157.23, 154.61, 152.05, 135.79, 130.10, 129.88, 
123.46, 114.45, 109.10, 104.16, 67.70, 41.42, 29.26, 25.89. 
IR (νmax, cm-1): 3399, 1607, 1504, 1427, 1335, 1235, 1198, 1171, 1118, 1024, 1010, 
899, 881, 870, 836. 
  




Prepared according to Dimick.97 
Concentrated sulphuric acid (2.5 mL) was added to a stirring solution of benzene-1,3,5-
tricarboxylic acid (10 g, 47.62 mmol) in methanol (175 mL) and the solution was heated 
at reflux for 24 hours. The solvent was removed under reduced pressure and the residue 
was dissolved in chloroform. The organic phase was washed twice with a saturated 
solution of sodium bicarbonate, dried over magnesium sulfate and then evaporated 
under reduced pressure to give the product. 
Product was used as crude for the synthesis of 215, 1H-NMR (CDCl3) is reported for 
reference. 
  
  142 
Compound 21588 
 
Prepared according to Kaur,88 with minor modifications. 
154R (5 g, 19.84 mmol) in dry THF (75 mL) and added drop-wise to a mixture of 
LiAlH4 (4.6 g, 121.2 mmol) in anhydrous THF (165 mL) and allowed to stir for 36 
hours. The reaction was quenched by addition of a mixture of NaHSO4 and Celite (4:1). 
After 112 hours of stirring at room temperature, the mixture was filtered and washed 
with ethanol. The filtrate was evaporated under reduced pressure to give 215. 





Prepared according to Kaur.88 
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Pyridinium chlorochromate (11.661 g, 54.1 mmol) was slowly added to a stirring 
mixture of 215 (2.0487 g, 12.18 mmol) in dichloromethane (50 mL). After 30 minutes 
the mixture was diluted with acetone (20 mL) and allowed to stir for 3 hours. The solid 
residue was removed by filtration and washed with DCM. The organic layers were 
collected, washed with three times with a saturated solution of sodium carbonate, dried 
over sodium sulfate and evaporated under reduced pressure. The residue was purified 
by flash chromatography (DCM). 
Yield: 31.4% 
1H-NMR (400 MHz, DMSO) δ 10.23 (s, 1H), 8.67 (s, 1H). 
13C-NMR (101 MHz, DMSO) δ 189.82, 137.82, 134.79. 
Compound 217 
 
0.48 mL of methanesulfonic acid was added to a pre-cooled (0 °C) mixture of 216 (100 
mg, 0.6 mmol) and 4-bromoresorcinol (816.5 mg, 4.32 mmol) in 6 ml of Et2O/DCM 
(1/1, v/v). The reaction vessel was sealed and the reaction allowed to stir for 24 h. The 
resulting mixture was diluted with diethyl ether, poured into distilled water and allowed 
to stir vigorously until a suspension was obtained. The product was collected by 
Büchner filtration, washed with abundant distilled water and dried in a desiccator to 
give a yellow powder. 
Yield: 57.6% (calculated from NMR to account for solvent of crystallisation) 
1H-NMR (400 MHz, DMSO) δ 9.74 (s, 6H), 9.29 (s, 6H), 6.51 (s, 6H), 6.50 (s, 3H), 
6.44 (s, 6H), 5.57 (s, 3H). 
13C-NMR (101 MHz, DMSO) δ 155.01, 152.93, 142.85, 132.65, 127.73, 123.98, 
104.03, 98.13, 41.83. 
IR (νmax, cm-1): 3526, 3462, 3376, 3179, 1632, 1505, 1427, 1411, 1245, 1195, 1176, 
1118, 1012, 915, 894, 880, 838, 822.  
  




0.48 mL of methanesulfonic acid was added to a pre-cooled (0 °C) mixture of 216 (100 
mg, 0.6 mmol) and 4-chlororesorcinol (624 mg, 4.32 mmol) in 6 ml of Et2O/DCM (1/1, 
v/v). The reaction vessel was sealed and the reaction allowed to stir for 24 h. The 
resulting mixture was diluted with diethyl ether, poured into distilled water and allowed 
to stir vigorously until a suspension was obtained. The product was collected by 
Büchner filtration, washed with abundant distilled water and dried in a desiccator to 
give a yellow powder. 
Yield: 68.5% (calculated from NMR to account for solvent of crystallisation) 
1H-NMR (400 MHz, DMSO) δ 9.66 (s, 6H), 9.26 (s, 6H), 6.47 (s, 3H), 6.43 (s, 6H), 
6.32 (s, 6H), 5.56 (s, 3H). 
13C-NMR (101 MHz, DMSO) δ 154.34, 151.88, 142.96, 129.83, 127.66, 123.31, 
109.34, 104.14, 41.88. 
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IR (νmax, cm-1): 3549, 3439, 3347, 3203, 1614, 1506, 1430, 1417, 1338, 1242, 1195, 
1176, 1126, 1031, 973, 912, 894, 883, 838, 823. 
 
Scrambling experiments 
Method 1: A mixture of 163 (50 mg, 0.07 mmol) and 4-bromoresorcinol (55.9 mg, 0.30 
mmol) was dissolved in 3ml of ethanol/HCl 37% (1/1, v/v). The solution obtained was 
allowed to stir at 70 °C for 5 hours; a sample was dried with compressed air and 
analysed with 1H-NMR. 
Method 2: A mixture of 163 (50 mg, 0.07 mmol) and 4-bromoresorcinol (55.9 mg, 0.30 
mmol) was dissolved in 3ml of Et2O/DCM (1/1, v/v); 0.24 mL of methanesulfonic acid 
were added, and the reaction vessel was sealed The mixture was allowed to stir for five 
hours; a sample was dried with compressed air and analysed with 1H-NMR. 
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3. Bis-phenols, Benzophenones, Xanthones 
and Xanthenes 
3.1 Introduction to the structures 
Bis-phenols have simplified structure compared to the previously reported 
natural products and synthesised compounds. Both dimers and tetramers are 
substantially based on two resorcinol units bridged by a methylene group. This unit is 
adorned with a substituent on the bridge, either aliphatic or aromatic, possibly leading 
to a tetrameric structure.  
The bis-phenol family is a simplified version, where the bis-phenol unit does 
not have a substituent on the bridge (Figure 57). Its purpose is to provide the basic 
model compound and assess whether a sidechain produces any improvement in activity.  
 
Figure 57. Structures described in Chapter 2. 
A specific approach was chosen to access the bis-phenol family, such that 
intermediates would constitute interesting compounds to extend the investigable SAR. 
Benzophenones are the starting point for the synthesis and offer an additional oxygen 
on the bridge (Figure 58), which introduces extended conjugation and potential 
intramolecular hydrogen bonding, producing conformational effects and altering the 
pKa of the hydroxyl groups. 
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Figure 58. General structures of the compounds presented in Chapter 3. 
 With benzophenones at hand, cyclisation to xanthones and subsequent reduction 
to xanthenes leads to fundamentally flat structures, with only two hydroxyl groups, and 
allows easy access to a different halogenated motif for our investigations. 
3.1.1 Synthetic approach 
The idea which drove the design of the synthetic approach for this family of 
compounds came from a report by Hu. He described a facile synthesis of 
hydroxybenzophenones as α-Glucosidase Inhibitors. One step preparation of the 
product benzophenones was obtained by Friedel-Crafts acylation in POCl3 with ZnCl2 
as catalyst (Scheme 29) and purification was carried out by simple crystallisation.98 
 
Scheme 29. Synthesis of benzophenones according to Hu.98 
 A solid base to work with is fundamental and hydroxybenzophenones appeared 
to be a flexible starting point for a number of structural modifications. Moreover, Hu’s 
method allows access to varied starting compounds, extending the scope of the method 
(Scheme 30, A).  
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Scheme 30. Synthetic approach towards benzophenones, bis-phenols, xanthones, xanthenes and their 
brominated analogues. 
The significant difference in reactivity due to the activating effect of hydroxyl 
groups, reported in the literature75 and experienced directly for the synthesis of 4-
bromoresorcinol, could be exploited to achieve selective bromination of benzophenones 
(Scheme 30, C). The carbonyl of the benzophenone is expected to act similarly to the 
carboxylic group in the previously described synthesis of 4-bromoresorcinol (Chapter 
2), where it acts as “protecting group” and reduces the reactivity of the resorcinol, 
allowing convenient access to a monohalogenated derivative (Scheme 31). 
 
Scheme 31. Bromination of 2,4-dihydroxybenzoic acid and similarity with benzophenones. 
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As previously reported, benzophenones and their brominated derivatives with 
matching hydroxyl groups (positions 2 and 2´) can be cyclised (Scheme 30, D) in very 
high yields.99,100 The reaction is performed in a sealed tube with water at high 
temperatures (220 °C) and without any additional reactant. The reaction can also be 
catalysed by addition of a base, as reported by Azuma.101 Whilst alternative methods 
for cyclisation are available, high temperatures are always required and additional 
reactants are employed. The reaction can be catalysed with acids, such as Py·HCl,100 
Eaton’s reagent102,103 and polyphosphoric acid.104 Other methods, using bases such as 
tetramethylammonium hydroxide have also been reported.105 Considering that 
polyphosphoric acid and Eaton’s reagent can catalyse the cyclisation, it is reasonable to 
propose the possibility of acylating and cyclising in one step, shortening the path to 
xanthones (Scheme 30, B). 
Bromination of xanthones (Scheme 30, E) offers an alternative route to the 
synthesis of their halogenated analogues. 
Xanthones and their halogenated derivatives can be reduced (Scheme 30, F) in 
high yields with borane, as previously reported by Shi.100,106 Borane is not a strong base 
and the reduction is favoured. In these examples, reductions are performed with a slight 
excess of reagent.100,106  
 
 Direct reduction of benzophenones (Scheme 30, H) has not been described 
often, especially concerning highly hydroxylated or halogenated compounds. The 
challenge, in the case of halogenated derivatives, is complicated by potential 
debromination. Olah reported a series of ionic reductions using triethylsilane.107,108 
However, all these reducing systems involve the use of acids (HF•Pyridine, 
trifluoroacetic acid or trifluoromethanesulfonic acid) and the model compounds used 
are much less activated than the poly-hydroxybenzophenones of interest. The resulting 
bis-phenols, similarly to the tetramers, would undergo acid-catalysed fragmentation. On 
the other hand, borane appears to be a feasible option; it is not reported in the literature 
for the reduction of benzophenones but, despite the different electronic density of the 
aromatic rings and their spatial arrangement compared to xanthones, it remains a 
suitable route for exploration. 
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 Bromination and debromination of bis-phenols (Scheme 30, J) could also be 
alternative strategies to allow access to particular products if more elegant synthetic 
routes were not successful. 
3.2 Synthesis 
3.2.1 Synthesis of hydroxy benzophenones 
Synthesis of a first family of benzophenones was attempted according to the 
procedure by Hu.98 All three different structural isomers of 2,4-dihydroxybenzoic acid 
reacted with both resorcinol and phloroglucinol in the presence of anhydrous zinc 
chloride (II) and phosphorus oxychloride, at 70 °C. 
 
Scheme 32. Synthesis of 220. 
Synthesis of compound 220, which is known and also commercially available, 
was used as a test for the reaction (Scheme 32). Due to possible cyclisation of adjacent 
hydroxyl groups, it enabled verification of the selectivity of the reaction. Identification 
was also possible by comparing the product with an authentic sample. The acylation 
was achieved using phosphorus oxychloride as solvent and reactant, in the presence of 
excess zinc chloride at 70 °C over the course of 3 hours. Upon quenching of the POCl3, 
the product was isolated by filtration in 40% yield. Since the reaction successfully led 
to the expected product, it was tested with phloroglucinol and with different 
regioisomers of dihydroxybenzoic acid, to obtain a portfolio of starting products with a 
different hydroxyl group distribution. 
 
Scheme 33. Synthesis of 222. 
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 To begin with, the same 2,4-dihydroxybenzoic acid was treated with 
phloroglucinol. However, in contradiction to the report by Hu,98 the benzophenone 
product was not isolated as it is directly cyclised to the corresponding xanthone, 222, in 
91 % yield (Scheme 33). 
 
Figure 59. 1H-NMR and 13C-NMR of 222. 
 Cyclization is evident in both 1H-NMR and 13C-NMR. The carbon NMR 
presents 13 signals, suggesting that there is no element of symmetry within the molecule 
and that carbons a and b are different (Figure 59). The hydrogens on the same positions 
are also different, displaying about 0.2 ppm difference in shift and a long range coupling 
between each other.  
 
Scheme 34. Synthesis of 225 and 227. 
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As expected from the cyclization of 222, reaction of 2,6-dihydroxybenzoic acid 
with both resorcinol and phloroglucinol leads to the xanthones 225 and 227, in 27 % 
and 9.4 % yield respectively (Scheme 34). The presence of two hydroxyl groups facing 
the acylated partner is likely to facilitate the ring closure. 
 
Figure 60. Comparison of the 13C-NMR spectra of 224 (top) and 225 (bottom). 
 As discussed for 222, cyclization of a potentially symmetric unit, increases the 
number of signals in the carbon NMR. In Figure 60, 224 and 225 (see Chapter 3.2.6 
for synthesis) are compared. Cyclization increases the number of signals from 11 to 13 
due to the 2,6-dihydroxyphenyl unit losing its symmetry. 
 
Scheme 35. Synthesis of 229 and attempted synthesis of 230. 
 Interestingly, 3,5-dihydroxybenzoic acid did not appear to be particularly 
reactive under these conditions, and led to 229 in low yield (5%) by reaction with 
resorcinol. Intact starting material was also recovered from the reaction. Reaction of the 
same acid with phloroglucinol did not provide any product, thus isolation of 230 was 
not possible, and starting materials were recovered from the reaction mixture, even after 
22 hours (compared to the usual 2-8 hours) (Scheme 35). 
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 Although the results did not lead to all expected benzophenones, they are 
nonetheless interesting, and allowed direct access to two benzophenones and three 
xanthones. 
3.2.2 Synthesis of methoxy benzophenones 
The previous approach did not lead, in some cases, to the expected 
benzophenones. Moreover, it has a number of drawbacks. Phosphorus oxychloride is a 
dangerous compound, being both corrosive and toxic, and the reaction is quenched with 
ice-water, with which it reacts violently, producing toxic gases. Also, the reaction 
mixture is very viscous, with consequent setup limitations. 
Alternative approaches to the synthesis of benzophenones normally require 
protected hydroxyl groups, both to reduce potential side reactions and avoid 
interference/quenching of catalysts. Methoxy groups were chosen due to their resorcinol 
and phloroglucinol precursors being readily available and cheap (Scheme 36). 
 
Scheme 36. Retrosynthesis of 224. 
A traditional approach could be a Friedel-Crafts acylation. The acid is firstly 
converted to acyl chloride and then, with the aid of a Lewis acid, undergo electrophilic 
substitution on the aromatic partner. This approach requires two steps and anhydrous 
conditions to prevent decomposition of the chloride. Eaton’s reagent (7.7% phosphorus 
pentoxide in methanesulfonic acid) is a valid alternative, it is a relatively stable reagent 
and it is commercially available. Due to its better performance and handling ease, it 
replaced the previously used polyphosphoric acid. However, it requires anhydrous 
conditions.99 
Among various reports, two methods drew our attention. They both involve a 
heterogeneous catalyst and offer, at least on the presented model compounds, high 
yields and selectivity, simple handling and purification. Also, they do not require 
transition metals and employ compounds with low toxicity. 
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3.2.3 Synthesis of methoxy benzophenones with SiO2-P2O5 
The acylation of aromatic compounds with carboxylic acids in the presence of 
P2O5/SiO2 was reported by Zarei in 2008 (Scheme 37).
109 The same type of catalyst has 
other applications and was reported to catalyse the Ritter reaction,110 deprotection of 
diacetates,111 condensation of indoles with carbonyl compounds112 and to prepare 
benzimidazoles.113 The catalyst was used in solvent-free conditions for some of the 
mentioned applications. 
 
Scheme 37. Acylation of aromatic compounds with P2O5/SiO2, examples from Zarei.109 
The catalyst was readily prepared from silica (for column chromatography) and 
P2O5 and it is stable for long periods of time.
109 
Since the model compounds reported by Zarei are very different from our 
methoxy derivatives, a model reaction to refine the conditions was necessary. Synthesis 
of 225, whose unprotected analogue was not obtained with phosphorus oxychloride, 
was first investigated (Scheme 38). 
 
Scheme 38. Synthesis of 225. 
The reaction was tested with different combinations of temperature (RT, 40, 70 
and 90 °C) with different amounts of catalyst (0.4 to 1.5 g of catalyst per mmol of acid) 
and different reaction times (Table 5). 
Temperature (°C) Catalyst (g/mmol of acid) Time (hours) Yield (%) 
90 0.4 2 26 
70 0.4 2 19 
40 0.73 24 50 
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40 0.73 72 52 
40 1.5 72 43 
RT 0.4 24 0 
Table 5. Reaction conditions for the synthesis of 225. 
The best result was obtained at 40 °C with 0.73 gcatalyst/mmolacid and 72 hours 
reaction time, with a yield of 52%. However, with only one day of reaction, the yield is 
just 2% lower. The reaction time was preferred over the small increase in yield and the 
method was adjusted accordingly. On a larger scale, the reaction produces a total yield 
of 66%. Of this 66%, a part was immediately recovered by extraction and trituration 
(45%) and the remaining by decomposition of the catalyst, which traps a good amount 
of product, and column filtration of the crude with DCM (21%). The additional amount 
of product which can be recovered from the catalyst was not considered during the small 
scale tests under different conditions. 
 
Scheme 39. Attempted synthesis of 231. 
 Unfortunately, the method did not provide any product when 3,5-
dimethoxybenzoic acid was used (Scheme 39). The reaction was attempted at higher 
temperature as well (70 °C) without any success. 
3.2.4 Synthesis of methoxy benzophenones with graphite-MeSO3H 
 The acylation of aromatic ethers with methanesulfonic acid in presence of 
graphite, was initially reported by Sarvari114 in 2004. The author optimised the 
conditions of the reaction for anisole and acetic acid and then evaluated the scope of the 
reaction with a short series of different coupling partners. 
 
Scheme 40. Acylation of anisole with acetic acid in the presence of methanesulfonic acid and graphite 
reported by Sarvari.114 
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 The reaction was performed in neat methanesulfonic acid at 80 °C in the 
presence of graphite (Scheme 40). The scope of the reaction covers differently 
substituted benzoic acids, including 2-hydroxybenzoic acid, suggesting compatibility 
with unprotected hydroxyl groups, and produces in all tested cases excellent (80-90%) 
yields.114 
Since the reaction was optimised for relatively different compounds, the 
synthesis of 225 was used again to test the reaction conditions. Initially, the reaction 
was performed at 80 °C, as in the original procedure, and instead of the expected 
compounds we were surprised to find that a rearrangement had occurred (Scheme 41). 
The same result was also obtained at 40 °C. Isolation of the product is straightforward 
and quick, without any chromatographic process involved. Upon dilution with DCM, 
graphite can be removed from the reaction by filtration and any excess of acid can be 
neutralised with sodium hydrogen carbonate, which also neutralises the 
methanesulfonic acid. After evaporation of the organic solvent, a simple trituration with 
hexane, which can dissolve dimethylresorcinol but not the product, leads to the pure 
compound. 
 
Scheme 41. Acylation of 1,3-dimethoxybenzene with 2,6-dimethoxybenzoic acid. 
 The compound isolated proved to be 233. For reference, this compound was also 
synthesised by alkylation of 220 with methyl iodide (Scheme 42). 
 
Scheme 42. Methylation of 220. 
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Both 1H-NMRs (Figure 61), which are superimposable, shows only two singlets 
for the methoxy groups, confirming that the structure is consistent with 233. 
 
Figure 61. 1H-NMR of 233. 
Since 233 was also obtained with the reaction at 40 °C, the behaviour of the 
reaction was studied at this temperature. In particular, the destiny of 2,6-
dimethoxybenzoic acid in the presence of methanesulfonic acid and graphite was 
investigated (Scheme 43). Interestingly, after two days, the reaction led to the isolation 
of 233 despite the absence of the partner resorcinol. 
 
Scheme 43. Synthesis of 233 from 2,6-dimethoxybenzoic acid. 
 Decarboxylation of 2,6-dimethoxybenzoic acid leads to dimethyl resorcinol 
(Scheme 44). It has to be noted that the reaction is immediately evident due to 
effervescence of the mixture and the product has a characteristic sweet smell. 
 
Scheme 44. Decarboxylation of 2,6-dimethoxybenzoic acid. 
As previously seen, reaction of dimethyl resorcinol with the initial acid leads to 
233 (Scheme 42). However, if the reaction is halted after 1 hour, 225 can be 
conveniently isolated (Scheme 45), suggesting that 225 is a kinetic product of the 
reaction.  
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Scheme 45. Acylation of 1,3-dimethoxybenzene with 2,6-dimethoxybenzoic acid, halted before 
rearrangement. 
 If the reaction is allowed to proceed for longer, in order to lead to 233 (Scheme 
46, a), as previously observed, formation of 2,4-dimethoxybenzoic acid is necessary. 
This leads to the supposition that 225, upon breakage of the bond on the 2,6-dimethoxy 
side, releases 2,4-dimethoxybenzoic acid. This also implies that, as experimentally 
verified, decomposition of 225 alone leads to 233 (Scheme 46, b). 
 
Scheme 46. Synthesis of 233 from 1,3-dimethoxybenzene and 2,6-dimethoxybenzoic acid and 
subsequent rearrangement (a). Rearrangement of 225 to give 233 (b). 
The formation of 2,4-dimethoxybenzoic acid (234) from decomposition of 225 
(Scheme 47) can be verified by NMR. A sample of the reaction can be directly diluted 
with DMSO-d6 and tested. Due to the presence of methanesulfonic acid, the shift of the 
peaks can be variable. To confirm the presence of the acid, the NMR is recorded before 
and after the addition of a sample of the pure analyte (Figure 62). 
 
Scheme 47. Fragmentation of 225. 
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Figure 62. 1H-NMR of the fragmentation of 225 (red) and spiking with 2,4-dimethoxybenzoic acid 
(blue). 
Breakdown of 233 (Scheme 48, a) and decarboxylation of 2,4-
dimethoxybenzoic acid (Scheme 48, b) have also been observed. Prolonged exposure 
of these to the reaction conditions lead to dimethylresorcinol. 
 
Scheme 48. Breakdown of 233 (a) and decarboxylation of 2,4-dimethoxybenzoic acid (b). 
 All these results can be summarised in a single scheme, highlighting the 
concurrent transformations observed. Decarboxylation of 2,6-dimethoxybenzoic acid 
leads to dimethylresorcinol (Scheme 49, a). Friedel-Crafts acylation leads to 225 
(Scheme 49, b). Fragmentation of the newly formed benzophenone leads to 2,4-
dimethoxybenzoic acid (Scheme 49, c), allowing access to 233 (Scheme 49, d). 
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Scheme 49. Summary of the reactions involved in the synthesis of 225 and 233. 
 An extensive search of the literature, indicated that this rearrangement has 
previously been seen in the work of Kasbekar115 and Hosangadi116 when using 
polyphosphoric acid at 80 °C. However, here, using this catalyst, the temperature can 
be lowered to 40 °C and the method allows isolation of the kinetic and the 
thermodynamic product.  
 Reaction of dimethylresorcinol and 3,5-dimethoxybenzoic acid in presence of 
methanesulfonic acid and graphite did not lead to the expected compound, 231 (Scheme 
50). The reaction was attempted both at 40 and 80 °C but the starting material proved 
to be unreactive and was recovered from the reaction mixture. 
 
Scheme 50. Attempted synthesis of 231 with methane sulfonic acid and graphite. 
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3.2.5 Compound 231 
 Since compound 231 was not obtained with either of the acylation procedures 
attempted (Scheme 51), it is relevant to note that its synthesis has only been reported 
once in 1913 by Mauthner.117  
 
Scheme 51. Attempted approaches for the synthesis of 231. 
In this paper it was synthesised from the acid, which was firstly converted to 
acyl chloride and subsequently converted to the benzophenone by Friedel-Crafts 
acylation in the presence of AlCl3 (Scheme 52).
117 
 
Scheme 52. Potential alternative approach to the synthesis of 231. 
Since the analytical data is limited to the procedures available at the time, it may 
be interesting to attempt the synthesis and prove whether the reaction actually leads to 
the expected compound. 
Other strategies to prepare these compounds are available, such as the one 
employed by Pettit and co-workers.118 They prepared one of the compounds reported in 
Mauthner’s work using a completely different synthetic approach. They used 
butyllithium to prepare 4-methoxyphenyllithium from its parent bromide and 
subsequently obtain a benzhydrol (Scheme 53, 238) by nucleophilic attack to an 
aldehyde. The benzophenone (Scheme 53, 239) was then obtained by oxidation of 238 
with pyridinium dichromate (PDC). 
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Scheme 53. Pettit’s benzophenones synthesis.118 
 This strategy would be considered if any further development of these products 
is required. 
3.2.6  Deprotection of methoxybenzophenones 
 Dealkylation of aryl methyl ethers with boron tribromide is a well known and 
established method.119,120 Compound 225 was used as a model to test the reaction. The 
deprotection required low temperatures (-70 °C) during the addition of BBr3, thus 
preventing fragmentation. It also required long reaction times to remove all methyl 
groups. The product was isolated in 67% yield (Scheme 54). 
 
Scheme 54. Synthesis of 224. 
 Since the reaction did not lead to significant scrambling or cyclisation, it is a 
reasonable way to complete the synthesis of the hydroxybenzophenones. 
3.2.7 Bromination of benzophenones 
 We initially focused on the bromination of 220, the most simple of resorcinol 
based benzophenones. It is commercially available and allows access to the first family 
of derivatives. 
 
Scheme 55. Synthesis of 240 and 241. 
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Bromination was achieved by reaction with bromine at room temperature, using 
acetic acid as solvent (Scheme 55), as described for the synthesis of 5-bromo-2,4-
dihydroxybenzoic acid (117, Chapter 2). Initially, partial bromination of 220 with 1.5 
equivalents of bromine and subsequent isolation of both 240 and 241 with silica gel 
chromatography was attempted. However, it was evident that such an approach was not 
providing good results as the products tend to tail and co-elute upon chromatography. 
Therefore, addition of stoichiometric amounts of bromine was investigated 
(Scheme 56). Using two or four equivalents of bromine led specifically to 241 and 242, 
respectively. It has to be noted that control of the reaction leading to 241 is not trivial: 
NBS could be an interesting alternative, since it is easier to handle and less reactive than 
bromine. Nonetheless, the reactions produced the expected compounds in adequately 
pure form for further use; the result suggests that, as expected, the selectivity of 
bromination in position 5,5´ of the benzophenone is significantly higher than in 3,3´. 
 
Scheme 56. Synthesis of 241 and 242. 
 By substitution of equivalent hydrogens on 220 (Figure 63, top), the 1H-NMR 
of 241 loses a signal and the splitting of a, which is not coupled to c anymore (Figure 
63, middle). In 242 only one aromatic signal is left (Figure 63, bottom). Progressive 
addition of bromine also produces a shift downfield of hydrogen a. 
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Figure 63. 1H-NMRs of 220 (top), 241 (middle) and 242 (bottom). 
3.2.8 Cyclisation of benzophenones 
 Cyclisation was conducted as previously reported by Kurduker99 and Shi.100 
Parent benzophenones were suspended in water, sealed in a pressure tube and thermally 
induced cyclisation was achieved at 220 °C. Cyclisation of 220 proceeded as expected 
from literature, giving the pure product, 243, in crystalline form and almost quantitative 
yield (Scheme 57). 
 
Scheme 57. Synthesis of 243. 
Cyclisation induces a significant downfield shift of the aromatic protons, as a 
consequence of the bridging oxygen being conjugated to two rings instead of one 
(Figure 64). 
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Figure 64. 1H-NMRs of 220 (top), 243 (bottom). 
Using the same approach, 244 and 245 were also obtained in high yields, 83 and 
90%, respectively (Scheme 58). However, the method proved impractical, the sealed 
tube was heated in the oven and the rubber seal, due to the temperature, quickly broke 
down or deformed, leading to evaporation of the water and decomposition of the 
product. 
 
Scheme 58. Synthesis of 244 and 245. 
To avoid the problem, a sand bath was used to obtain the required temperatures, 
leaving the seal and stopper outside the heating block, thus preventing damage to the 
rubber. Unfortunately, uneven heating required the temperature to be raised to 230 °C, 
which is the highest limit attainable with water, and an increase in the reaction time 
(about 18 hours). Under these conditions, synthesis of 245 was not possible, as the 
reaction does not reach completion and some decomposition is observed. On the other 
hand, preparation of 243, whose precursor is commercially available, became more 
convenient, as it could be easily monitored (the colour changes from yellow to 
colourless) and was not subject to technical failures. 
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3.2.9 Bromination of xanthones 
 As 245 could not be readily prepared by this route, while 243 can be, we then 
considered obtaining 245 through the bromination of 243. Full bromination to give 245 
was easily achieved in 90% yield by reaction of 243 with a large excess of bromine in 
acetic acid over about one week (Scheme 59). Purification of any remaining, 
incomplete, product could be achieved by hot filtration of a boiling mixture of the 
product in water. The reaction’s progress was monitored by NMR. 
 
Scheme 59. Synthesis of 245. 
Interestingly, two sets of doublets were often identified before the reaction 
reached completion. The presence of doublets (Figure 65, B) suggests that either 
positions 1 and 2 or 7 and 8 are untouched. 244, which is also a reasonable intermediate 
pre-245, displays only 2 singlets (Figure 65, D).   
 
Figure 65. 1H-NMRs of 245 (A), reaction mixture for 245 before completion (B), 246 (C) and 244 (D). 
To investigate this potential selectivity, which would lead to an unreported 
product, partial bromination of 243 with 2 equivalents of bromine was attempted and 
led to 246, in close-to-absolute selectivity. Out of curiosity, the reaction was repeated 
in DCM to verify whether an aprotic solvent led to a different result; however, it appears 
that selectivity is maintained. By swapping the order of the steps, cyclisation-
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bromination (Scheme 60, a) and bromination-cyclisation (Scheme 60, b) of a 
benzophenone, we were able to isolate the two different, partially brominated, isomers. 
 
Scheme 60. Synthesis of 246 (a) and 244 (b). 
3.2.10 Reduction of benzophenones 
Reductive deoxygenation of xanthones using borane-THF complex was 
described by Shi (Scheme 61).100 
 
Scheme 61. Synthesis of 247 described by Shi.100 
The reduction was directly obtained on unprotected xanthones, suggesting that 
it might be applicable to our benzophenones in the same way, although a larger excess 
of reducing agent might be necessary to compensate for the number of interfering 
hydroxyl groups.100 Reduction of benzophenones with this method was employed for 
the synthesis of 248 and 135. 
 
Scheme 62. Synthesis of 248. 
Benzophenone 220 was reduced at room temperature with borane-THF complex 
in anhydrous THF, under inert atmosphere (Scheme 62). Compound 248 was obtained 
in poor yield (16%). As Figure 66 shows, the crude of the product is reasonably pure; 
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however, a great part of the material is lost during column chromatography, which is a 
necessary step to obtain a product suitably pure for biological applications. 
 
Figure 66. 1H-NMR of 248. 
Compound 135 was previously synthesised by condensation of 4-
bromoresorcinol with formaldehyde (Scheme 63), as described in Chapter 2. However, 
due to the low yield of the previous method, its synthesis by reduction was attempted. 
Following the procedure for the reduction of 220, preparation of 135 provided a 
considerably better yield (39%) than the acid-catalysed dimerization (3%) 
 
Scheme 63. Different synthetic approaches to 135. 
Synthesis of 136 was previously achieved by condensation in 20% yield, as 
described in Chapter 2. Its reduction by borane-THF complex was possible, although 
it required heating at 40 °C (Scheme 64). Purification proved more tedious than in the 
case of the condensation and the method was thus abandoned. 
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Scheme 64. Different synthetic approaches to 136. 
3.2.11 Bromination of bis-resorcinols 
Since all brominated bis-phenols have previously been obtained by 
condensation or reduction, bromination of bis-resorcinols has not been attempted. 
However, this method has been employed by Oh for the synthesis of 136. The method 
employed is the same as we used for the bromination of benzophenones and xanthones, 
involving bromination with Br2 in acetic acid. The published method claims a yield of 
90% after reverse phase HPLC purification.23 Thus, it appears that bromination of bis-
resorcinol is indeed feasible and high yielding, offering an applicable alternative, were 
it necessary. 
 
Scheme 65. Synthesis of 136 by bromination. 
3.2.12 Reduction of xanthones 
 As previously illustrated in the introduction to this chapter, reduction of 
xanthones has been achieved by reaction with borane in dry THF and described by 
Shi.100  
Reduction of 243 with borane-THF complex in dry THF proceeded at room 
temperature to yield 247, as expected from literature (Scheme 66) in excellent yield 
(96%). After reaction the solvent was evaporated under reduced pressure and the solid 
residue was treated with diluted HCl, leading to a dark yellow product which can be 
conveniently isolated by filtration.  
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Scheme 66. Synthesis of 247. 
On the other hand, synthesis of 249 (Scheme 67) was not as smooth. It required 
heating at 45 °C and 7 equivalents of reducing agent. In contrast to 247, the quality of 
the product after precipitation is not acceptable, and further purification is required. 
However, column chromatography led to isolation of traces of product. The product 
also appears to be decomposing during elution, leading to mixed fractions with lower 
purity than the starting material. Moreover, the product appeared to degrade pretty when 
exposed to natural light or as a consequence of heating. 
 
Scheme 67. Synthesis of 249. 
 As expected from the previous result, due to a poorly activated starting material, 
deoxygenation of 245 to 250 required a large excess of borane (9 eq) and 12 hours of 
reaction at 40 °C (Scheme 68). Once again, the compound is not very stable and its 
formation was identified by 1H-NMR but its purification by flash chromatography led 
to a product with worse quality than the starting crude. 
 
Scheme 68. Synthesis of 250. 
 The 1H-NMR profile is consistent in all cases: reduction of the xanthone leads 
to a high field shift in the position of all aromatic and hydroxyl protons. The appearance 
of a peak around 3.4-4 ppm is diagnostic of a successful deoxygenation (Figure 67). 
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Figure 67. 1H-NMR of 247 (a), 243 (b), 244 (c), 249 (d), 245 (e) and 250 (f). 
 The reduction of the carbonyl is blatant in the 13C-NMR, with the reduced 
carbon shifting from 175 ppm to 25 ppm (Figure 68). 
 
Figure 68. 13C-NMR of 247 (bottom) and 243 (top). 
Since the purification and the stability of 249 and 250 were not ideal, the 
xanthene group was not considered for further development and testing. The results 
presented come from explorative reactions, therefore, yields and full characterisation of 
249 and 250 are not reported and further investigation and optimisation are necessary if 
the compounds were to become of interest. 
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3.3 Conclusions 
In Chapters 2 and 3, the synthesis of a number of novel structures have been 
described. Most notable among these are the tetramers and hexamers, interesting both 
for their potential biological application and for the construction of dendrimers, as 
described in the following chapter. The simpler structures, bis-resorcinols, 
benzophenones and xanthones presented in this chapter are interesting as comparison 
against the dimers and tetramers. A flexible approach for their synthesis has been 
presented and discussed. The presented compounds which will be investigated in 
Chapters 5 and 6 are summarised in Figure 69. 
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Figure 69. Structures presented in the previous chapters and considered for the in vitro/in vivo testing 
in the following chapters. 
  




All reagents and solvents for synthesis were commercial and used without further 
purification. NMR spectra were recorded at 293 K, unless otherwise stated, using a 400 
MHz Spectrometer. Shifts are referenced relative to deuterated solvent residual peaks. 
Infrared spectra were recorded using an FT-IR spectrometer with ATR attachment. MS 
were run on an LTQ orbitrap XL and were recorded by the EPSRC Mass Spectrometry 
National facility. Thin-layer chromatography (TLC) was carried out on aluminium 
sheets coated with silica gel 60 F254 (Merck). TLC plates were inspected by UV light 





A mixture of 2,4-dihydroxybenzoic acid (3.1 g, 20.11 mmol), resorcinol (2 g, 18.16 
mmol) and zinc chloride (12 g, 88.05 mmol) in 15 mL of POCl3 was allowed to stir at 
70 °C for 3 hours. The reaction was poured on ice and allowed to stir for an hour. The 
solid was collected, washed with cold water and dried in the oven (60 °C) to give a 
yellow powder. 
Yield: 40.1% 
1H-NMR (400 MHz, DMSO) δ 11.27 (s, 2H, ArOH), 10.25 (s, 2H, ArOH), 7.19 (d, 
J=9.2, 2H, ArH), 6.37 – 6.28 (m, 4H, ArH). 
13C-NMR (101 MHz, DMSO) δ 199.24, 162.77, 160.62, 133.48, 115.20, 107.29, 
102.38. 
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MP = 199-202 °C (lit. 200-201 °C)121 
Compound 222122 
 
A mixture of 2,4-dihydroxybenzoic acid (2 g, 20.11 eq), phloroglucinol (1.5 g, 11.89 
mmol) and zinc chloride (6.5 g, 47.7 mol) in 7.5 mL of POCl3 was allowed to stir at 70 
°C for 3 hours. The reaction was poured on ice and allowed to stir for an hour. The solid 
was collected, washed with cold water and dried in the oven (60 °C) to give a yellow 
powder. 
Yield: 90.5% 
1H-NMR (400 MHz, DMSO) δ 13.11 (s, 1H, ArOH), 11.04 (b, 2H, ArOH), 8.03 (d, 
J=8.7, 1H, ArH), 6.95 (dd, J=8.7, 2.2, 1H, ArH), 6.88 (d, J=2.2, 1H, ArH), 6.41 (d, 
J=2.1, 1H, ArH), 6.23 (d, J=2.1, 1H, ArH). 
13C-NMR (101 MHz, DMSO) δ 179.55, 165.63, 164.72, 163.30, 157.91, 157.82, 
127.65, 114.48, 112.78, 102.51, 102.09, 98.43, 94.41. 
MP = 295 °C decomp. (lit. 323-324 °C)122 
Compound 225123 
 
A mixture of 2,6-dihydroxybenzoic acid (3.1 g, 20.11 mmol), resorcinol (2 g, 18.16 
mmol) and zinc chloride (12 g, 88.05 mmol) in 15 mL of POCl3 was allowed to stir at 
70 °C for 3 hours. The reaction was poured on ice and allowed to stir for an hour. The 
solid was collected, washed with cold water and extracted with ethyl acetate. The 
organic layer was washed with brine, dried on magnesium sulfate and the solvent was 
removed under reduced pressure. The solid was purified by flash chromatography on 
silica gel using 40/1 DCM/MeOH as eluent to give a yellow powder. 
Yield: 26.5% 
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1H-NMR (400 MHz, DMSO) δ 12.85 (s, 1H, ArOH), 11.20 (s, 1H, ArOH), 8.05 (d, 
J=8.8, 1H, ArH), 7.68 (t, J=8.3, 1H, ArH), 7.03 (d, J=8.3, 1H, ArH), 6.95 (dd, J=8.8, 
2.1, 1H, ArH), 6.88 (d, J=2.1, 1H, ArH), 6.79 (d, J=8.3, 1H, ArH). 
13C-NMR (101 MHz, DMSO) δ 180.61, 164.95, 161.03, 157.80, 155.75, 136.71, 
127.50, 114.51, 112.45, 110.13, 107.83, 106.96, 102.04. 
MP: 258-261 °C (lit. 258-259 °C)123 
Compound 227 
 
A mixture of 2,6-dihydroxybenzoic acid (4 g, 25.95 mmol), phloroglucinol (3 g, 23.79 
mmol) and zinc chloride (13 g, 95.39 mmol) in 15 mL of POCl3 was allowed to stir at 
70 °C for 3 hours. The reaction was poured on ice and allowed to stir for an hour. The 
solid was collected, washed with cold water and extracted with ethyl acetate. The 
organic layer was washed with brine, dried on magnesium sulfate and the solvent was 
removed under reduced pressure. The solid was purified by flash chromatography on 
silica gel using 40/1 DCM/MeOH as eluent to give a yellow powder. 
Yield: 9.4% 
1H-NMR (400 MHz, DMSO) δ 11.86 (s, 1H, ArOH), 11.82 (s, 1H, ArOH), 11.26 (s, 
1H, ArOH), 7.70 (t, J=8.3, 1H, ArH), 7.01 (d, J=8.3, 1H, ArH, 6.81 (d, J=8.3, 1H, ArH), 
6.41 (d, J=2.1, 1H, ArH), 6.24 (d, J=2.1, 1H, ArH). 
13C-NMR (101 MHz, DMSO) δ 183.43, 166.52, 162.16, 160.26, 157.46, 155.48, 
137.21, 110.59, 107.08, 106.86, 101.16, 98.54, 94.33. 
Compound 229 
 
A mixture of 3,5-dihydroxybenzoic acid (3.1 g, 20.11 mmol), resorcinol (2 g, 18.16 
mmol) and zinc chloride (12 g, 88.05 mmol) in 15 mL of POCl3 was allowed to stir at 
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70 °C for 2 hours. The reaction was poured on ice and allowed to stir for 24 hours. The 
precipitate was collected by Büchner filtration, washed with a 3% solution of NaHCO3 
and dried in the oven (60 °C). The solid was dispersed in water, the solution was 
saturated with NaHCO3 and the product was extracted with ethyl acetate. The organic 
layer was dried over sodium sulfate, and the solvent was removed to give 229. 
Yield: 4.9% 
[M+H]+ = 247.0601 (Calculated: 247.0601) 
1H-NMR (400 MHz, DMSO) δ 12.23 (s, 1H, ArOH), 10.70 (s, 1H, ArOH), 9.64 (s, 2H, 
ArOH), 7.43 (d, J=8.8, 1H, ArH), 6.42 (s, 3H, ArH), 6.38 (dd, J=8.8, 2.3, 1H, ArH), 
6.34 (d, J=2.3, 1H, ArH). 
13C-NMR (101 MHz, DMSO) δ 198.84, 164.79, 164.52, 158.24, 139.69, 135.24, 
112.26, 107.98, 106.59, 105.42, 102.66. 
SiO2/P2O5 catalyst 
Prepared according to the method by Zarei, with minor modifications.109 Silica gel was 
washed with 10% HCl and dried in the oven at 120 °C over three days. Three grams of 
silica were then mixed with 3 grams of P2O5 using a glass rod for 10 minutes to give a 
very thin powder, which was then dried in the oven for 1 hour. The catalyst was stored 
in a sealed plastic box. 
Compound 225 
 
Method with SiO2/P2O5 
A mixture of 2,6-dimethoxybenzoic acid (2.5 g, 13.7 mmol), 1,3-dimethoxybenzene 
(3.792 g, 27.4 mmol) and SiO2/P2O5 (10 g) in DCE (50 mL) was allowed to stir for 24 
hours at 40 °C. The resulting mixture was shaken vigorously with DCM (50 mL) and 
the liquid was decanted. The procedure was repeated three times. The solid was then 
suspended with 50 mL of DCM and removed by filtration. The solid was washed a last 
time with 50 mL of DCM and the organic layers were combined. The organic extract 
was washed with a saturated solution of NaHCO3, brine and dried over sodium sulfate. 
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The solvent was removed under reduced pressure and the resulting oil was triturated 
with hexane to give the product (1.82 g) as white solid. 
To recover a larger amount of product, the solid residue previously discarded was 
treated with a saturated solution of NaHCO3 in water, and the resulting mixture was 
extracted with ethyl acetate. The organic layer was washed with brine, dried over 
sodium sulfate and the solvent was removed under reduced pressure. Upon purification 
by flash chromatography (DCM) an additional 0.86 g of product were collected. 
 Total yield: 65.7% 
Method with MeSO3H and graphite 
A mixture of 2,6-dimethoxybenzoic acid (364.3 mg, 2 mmol), 1,3-dimethoxybenzene 
(0.26 mL, 2 mmol), graphite (0.2 g) in MeSO3H (0.6 mL, 8 mmol) was heated at 40 °C 
for 1 hour. The mixture was diluted with DCM and graphite was removed by filtration. 
The solution was treated with saturated NaHCO3 and the organic layer was separated, 
washed with saturated NaHCO3 twice, with brine and dried over sodium sulfate. The 
solvent was removed under reduced pressure and the residue was triturated with hexane 
to give 225. 
1H NMR (400 MHz, DMSO) δ 7.50 (d, J = 8.5 Hz, 1H), 7.31 (t, J = 8.4 Hz, 1H), 6.70 
(d, J = 8.4 Hz, 2H), 6.61 – 6.53 (m, 2H), 3.83 (s, 3H), 3.64 (s, 9H). 
13C NMR (101 MHz, DMSO) δ 190.95, 164.97, 162.00, 156.82, 134.36, 130.24, 121.51, 
120.63, 106.07, 104.67, 99.32, 56.19, 56.14, 56.05. 
MP: 130-132 °C 
Compound 233124 
 
Method with MeI 
A mixture of 2,2´,4,4´-tetrahydroxybenzophenone (4g, 16.2 mmol), K2CO3 (23.4g, 
169.3 mmol), and MeI (6 mL, 96.4 mmol) in 200 mL of DMF was allowed to stir at 
room temperature for 41 hours. 600 mL of distilled water were added and allowed to 
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stir for 15 minutes. The white precipitate was collected by Büchner filtration and 
washed with 800 mL of distilled water. The solid was dissolved in 400 mL of ethyl 
acetate and washed with 400 mL of water, 400 mL of brine and dried over sodium 
sulfate. The solvent was evaporated under reduced pressure to give 4.3 g of white 
product. 
Yield: 87.5% 
Method with 2,4-dimethoxybenzoic acid and 1,3-dimethoxybenzene 
A mixture of 2,4-dimethoxybenzoic acid (364.3 mg, 2 mmol), 1,3-dimethoxybenzene 
(0.26 mL, 2 mmol), graphite (0.2 g) in MeSO3H (0.6 mL, 8 mmol) was heated at 40 °C 
for 62 hours. The mixture was diluted with DCM and graphite was removed by 
filtration. The solution was treated with saturated NaHCO3 and the organic layer was 
separated, washed with saturated NaHCO3 twice, with brine and dried over sodium 
sulfate. The solvent was removed under reduced pressure and the residue was triturated 
with hexane to give 233. 
Method with 2,6-dimethoxybenzoic acid and 1,3-dimethoxybenzene 
A mixture of 2,6-dimethoxybenzoic acid (364.3 mg, 2 mmol), 1,3-dimethoxybenzene 
(0.26 mL, 2 mmol), graphite (0.2 g) in MeSO3H (0.6 mL, 8 mmol) was heated at 40 °C 
for 36 hours. The mixture was diluted with DCM and graphite was removed by 
filtration. The solution was treated with saturated NaHCO3 and the organic layer was 
separated, washed with saturated NaHCO3 twice, with brine and dried over sodium 
sulfate. The solvent was removed under reduced pressure and the residue was triturated 
with hexane to give 233. 
Method with 2,6-dimethoxybenzoic acid alone 
Same as previous method, without 1,3-dimethoxybenzene. 
Method from 225 
A mixture of 225 (180 mg, 0.6 mmol), graphite (0.1 g) in MeSO3H (0.3 mL, 4 mmol) 
was heated at 40 °C for 27 hours. The mixture was diluted with DCM and graphite was 
removed by filtration. The solution was treated with saturated NaHCO3 and the organic 
layer was separated, washed with saturated NaHCO3 twice, with brine and dried over 
sodium sulfate. The solvent was removed under reduced pressure and the residue was 
triturated with hexane to give 233. 
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1H NMR (400 MHz, DMSO) δ 7.35 (m, 2H), 6.62 – 6.53 (m, 4H), 3.83 (s, 6H), 3.61 (s, 
6H). 
13C NMR (101 MHz, DMSO) δ 192.05, 163.58, 160.19, 132.09, 123.66, 105.50, 98.76, 
56.05, 55.91. 
MP: 124-125 °C (lit. 138-140 °C)124 
Compound 224 
 
Within a sealed system, saturated with Argon, a solution of BBr3 (2.55 mL, mmol) in 
17 mL of DCM was added (over 30 minutes) to a stirring solution of 225 (850 mg, 
mmol) in 17 mL DCM, and the temperature was maintained at -78 °C. After 30 minutes 
the cold bath was removed and the reaction was allowed to reach room temperature. 
The reaction was allowed to stir for three days and then cooled to 0 °C. Ice-cold water 
(40 mL) was slowly added to the mixture and DCM was subsequently evaporated under 
reduced pressure. The solid product was collected by Büchner filtration. 
Yield: 66.9% 
Note: the product decomposed after being exposed for prolonged times to air and light, 
and was purified by flash chromatography with DCM/MeOH 12/1.  
1H-NMR (400 MHz, DMSO) δ 12.63 (s, 1H), 10.65 (s, 1H), 9.57 (s, 2H), 7.13 (d, J = 
8.5 Hz, 1H), 7.05 (t, J = 8.2 Hz, 1H), 6.38 (d, J = 8.2 Hz, 2H), 6.34 – 6.27 (m, 2H). 
13C-NMR (101 MHz, DMSO) δ 200.06, 165.46, 164.93, 155.53, 135.86, 130.85, 
114.70, 114.55, 108.64, 106.82, 102.54. 
MP = 254 -260 °C 
[M+H]+ = 247.0602 (Calculated: 247.0601) 
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Compound 24199 
 
A solution of bromine (0.83 mL, 16.24 mmol) in acetic acid (12 mL) was added drop 
wise to a allowed to stir solution of 220 (2 g, 8.12 mmol) in acetic acid (20 mL). Two 
hours after completing the addition of bromine, the reaction was poured in ice water. 
The solid was collected by Büchner filtration and washed with distilled water. The 
product was purified by filtration from boiling water and then, if necessary, by column 
chromatography (30/1 DCM/MeOH) to give a yellow powder. 
Note: dissolution of 220 in acetic acid requires heating to 40-50 °C. After complete 
dissolution, the mixture is allowed to cool down below 30 °C. 
Yield: 94% 
1H NMR (400 MHz, DMSO) δ 11.24 (s, 4H), 7.43 (s, 2H), 6.55 (s, 2H). 
13C NMR (101 MHz, DMSO) δ 196.93, 159.73, 159.66, 135.85, 117.12, 103.82, 99.96. 
MP: 224-228 °C (lit. 211 °C)99 
Compound 24299 
 
A solution of bromine (0.83 mL, 16.24 mmol) in acetic acid (4 mL) was added drop 
wise to a stirring solution of 220 (1 g, 4.6 mmol) in acetic acid (8 mL) at 50 °C. The 
mixture was allowed to stir for 4 hours and then it was poured in ice water. The solid 
was collected by Büchner filtration and washed with distilled water. The product was 
purified by filtration from boiling water to give a yellow solid. 
Yield: 61.6% 
1H NMR (400 MHz, DMSO) δ 11.54 (s, 2H), 7.49 (s, 2H). 
13C NMR (101 MHz, DMSO) δ 195.93, 156.06, 155.95, 133.48, 117.26, 101.30, 101.00. 
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MP: 275-277 °C (254 °C)99 
Compound 243 
 
A mixture of 220 (200 mg, 0.876 mmol) in distilled water (6 mL) was heated to 220-
230 °C in an Ace pressure tube fitted with a silicone back seal using a preheated sand 
bath at 230 °C. When a completely colourless solution was obtained, the tube was 
removed and allowed to cool down slowly to room temperature. The tube was than 
cooled down to 4 °C in the fridge to complete the crystallization of the product. The 
solid was then collected by Büchner filtration and washed with cold water to give white 
needles. 
Note 1: silicone is the material of choice as it provides the highest working 
temperatures. However, the reaction temperature is close to its limits. Worn out seals 
and higher temperatures have to be avoided. If the seal fails, a jet of steam is produced: 
adequate shielding and attention is required. 
Note 2: reaction duration is not provided as very different times were experienced, 
colour proved to be an effective way to check the reaction progress. 
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Yield: 94.8% 
MP: > 350 °C 
1H NMR (400 MHz, DMSO) δ 10.83 (s, 2H), 7.99 (d, J = 8.7 Hz, 2H), 6.87 (dd, J = 
8.7, 2.2 Hz, 2H), 6.83 (d, J = 2.2 Hz, 2H). 
13C NMR (101 MHz, DMSO) δ 173.88, 163.33, 157.44, 127.74, 113.95, 113.63, 102.05. 
Compound 24499 
 
A mixture of 241 (100 mg, 0.259 mmol) in distilled water (6 mL) was heated to 220-
230 °C in an Ace pressure tube fitted with a silicone back seal using a preheated sand 
bath at 230 °C. The tube was removed after 18 hours and allowed to cool down slowly 
to room temperature. The solid was then collected by Büchner filtration and washed 
with cold water to give a white solid. 
Note 1: silicone is the material of choice as it provides highest working temperatures. 
However, the reaction temperature is close to its limits. Worn out seals and higher 
temperatures have to be avoided. If the seal fails, a jet of steam is produced: adequate 
shielding and attention is required. 
Note 2: 18 hours is indicative, very different times were experienced. The reaction 
progress can be easily checked by NMR and the reaction can be allowed longer times. 
Yield: 83.3% 
1H NMR (400 MHz, DMSO) δ 11.86 (s, 2H), 8.16 (s, 2H), 7.01 (s, 2H). 
13C NMR (101 MHz, DMSO) δ 172.65, 160.23, 156.63, 130.33, 115.18, 107.80, 103.73. 




  184 
Method with sealed tube 
A mixture of 242 (200 mg, 0.356 mmol) in distilled water (6 mL) was heated to 220 °C 
in an Ace pressure tube fitted with a silicone back seal using an oven. The tube was 
removed after 14 hours and allowed to cool down slowly to room temperature. The solid 
was then collected by Büchner filtration and washed with cold water. 
Yield: 89.7% 
Method by bromination 
A solution of bromine (0.38 mL, 7.362 mmol) in acetic acid (2 mL) was slowly added 
to a mixture of 243 (400 mg, 1.753 mmol) in acetic acid (4 mL) and allowed to stir at 
room temperature. The reaction was checked daily by 1H-NMR to verify its completion. 
An excess of bromine was always maintained in the reaction by addition of further 0.38 
mL of bromine when the solution lost its light orange colour. Upon completion, air was 
bubbled through the mixture to remove any excess of bromine the solid was collected 
by Büchner filtration and washed with distilled water. The product was purified by 
filtration from boiling water to give a white solid. 
Yield: 90.6% 
1H NMR (400 MHz, DMSO) δ 8.22 (s, 2H). 
13C NMR (101 MHz, DMSO) δ 172.3, 157.7 (uncertain), 153.5, 109.2, 100.2. 
MP: 330-332 °C (lit. 281 °C)99 
  




A solution of bromine (0.45 mL, 8.76 mmol) in acetic acid (100 mL) was added drop 
wise to a stirring solution of 243 (1 g, 4.38 mmol) in acetic acid (120 mL). The mixture 
was allowed to stir for 18 hours at room temperature and then it was poured in ice water. 
The solid was collected by Büchner filtration and washed with distilled water. The 
product was purified by filtration from boiling water to give a white solid. 
Yield: 83.7% 
1H NMR (400 MHz, DMSO) δ 11.74 (s, 2H), 8.01 (d, J = 8.8 Hz, 2H), 7.09 (d, J = 8.8 
Hz, 2H). 
13C NMR (101 MHz, DMSO) δ 173.91, 161.06, 154.48, 126.73, 114.97, 113.95, 97.43. 
IR (νmax, cm-1): 3463, 3081, 1599, 1570, 1425, 1353, 1335, 1305, 1206, 1176, 1124, 
1047, 843, 775. 
MP = 329-332 °C 
  




A solution of BH3·THF 1M (14 mL, 14 mmol) was added to a allowed to stir solution 
of 220 (1.55 g, 6.3 mmol) in 100 mL of dry THF under argon. The mixture was allowed 
to stir overnight, then THF was removed under reduced pressure. The solid was 
dissolved in a solution of aq. NaOH and precipitated by acidification with HCl. The 
solid was collected by Büchner filtration and purified by flash chromatography using 
15/1 DCM/MeOH as eluent to give an off white powder. 
Yield: 16% 
1H-NMR (400 MHz, DMSO) δ 9.04 (s, 2H), 8.89 (s, 2H), 6.65 (d, J=8.2, 2H), 6.26 (d, 
J=2.4, 2H), 6.09 (dd, J=8.2, 2.4, 2H), 3.52 (s, 2H). 
13C-NMR (101 MHz, DMSO) δ 156.08, 155.47, 130.27, 118.03, 105.82, 102.18, 27.80 
(Ar2CH2). 
IR (νmax, cm-1): 3203, 1612, 1601, 1511, 1462, 1433, 1405, 1326, 1314, 1305, 1268, 
1220,  1167, 1106, 970, 850, 839, 825. 
MP: 207-210 °C (250 °C)125 
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Compound 135 
 
A solution of BH3·THF 1M (3.1 mL, 3.1 mmol) was added to a allowed to stir solution 
of 241 (500 mg, 1.24 mmol) in 30 mL of dry THF under argon. The mixture was allowed 
to stir overnight, then THF was removed under reduced pressure. The solid was 
dissolved in a solution of aq. NaOH and precipitated by acidification with HCl. The 
solid was collected by Büchner filtration and purified by flash chromatography using 
20/1 DCM/MeOH as eluent to give an off white solid. 
Yield: 39% 
See Chapter 2 for an alternative method and analytical data. 
Compound 247100 
 
Prepared according to the procedure by Shi.100 
Yield: 96.3% 
1H NMR (400 MHz, DMSO) δ 9.44 (s, 2H), 7.00 (d, J = 8.2 Hz, 2H), 6.48 (dd, J = 8.2, 
2.4 Hz, 2H), 6.42 (d, J = 2.4 Hz, 2H), 3.79 (s, 2H). 
13C NMR (101 MHz, DMSO) δ 157.25, 152.15, 130.04, 111.26, 111.16, 103.06, 26.01. 
MP: 215-218 °C 
Compound 249 
 
BH3-THF complex 1 M in THF (7 mL, 7 mmol) was slowly added to a allowed to stir 
solution of 244 (400 mg, 1.04 mmol) in 30 mL of dry THF. The reaction was performed 
under argon and after addition of the reducing agent was allowed to stir for 2.5 hours at 
45 °C. The solvent was carefully removed by evaporation and the residue was treated 
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with 20 mL of HCl 1M. The mixture was allowed to stir for two hours and solid product 
was collected by Büchner filtration. 
1H NMR (400 MHz, DMSO) δ 10.34 (s, 2H), 7.35 (s, 2H), 6.62 (s, 2H), 3.84 (s, 2H). 
Compound 250 
 
BH3-THF complex 1 M in THF (1.65 mL, 1.65 mmol) was slowly added to a allowed 
to stir solution of 245 (100 mg, 0.184 mmol) in 10 mL of dry THF. The reaction was 
performed under argon and after addition of the reducing agent was allowed to stir for 
12 hours at 40 °C. The solvent was carefully removed by evaporation and the residue 
was treated with 20 mL of HCl 1M. The mixture was allowed to stir for two hours and 
then extracted with ethyl acetate (3 x 20 mL). The organic layers were dried with 
magnesium sulfate and evaporated under reduced pressure. The solid obtained was 
resuspended in HCl 1M and collected by Büchner filtration. 
1H NMR (400 MHz, DMSO) δ 10.01 (s, 2H), 7.49 (s, 2H), 3.99 (s, 2H). 
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4. Synthesis of dendrimers 
4.1 Dendrimers 
 As the etymology of the word suggests, dendrimers are branched structures, 
somewhat resembling a tree. They are characterised by a central core and present one 
or more layers (generations) of branches. Differently from polymers, they are well 
defined structures. They are often synthesised with repetitive reaction sequences 
(Figure 70), proceeding either from the core and adding fragments outwards (divergent 
synthesis) or, viceversa, external fragments can be built and eventually bound to the 
core (convergent synthesis).126,127 
 
Figure 70. Convergent and divergent synthesis of dendrimers. 
 Dendrimers and multivalent structures have applications in a wide range of 
fields. Being able to carry different structures, they can be adapted to interact with a 
range of biological and non-biological targets and with well-defined structures they can 
also be used to build supramolecular structures and in crystal engineering.128-130 
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4.2 Calixarenes 
 Within our research group, dendrimers have been developed in a number of 
ways using calixarenes as key building blocks.131,132 Calixarenes are macrocyclic 
structures obtained by reaction of phenols with aldehydes.133 As the name suggests, 
calix[n]arenes are constituted by n phenolic units to form a chalice-like structure. The 
two main types of structures employed within the group are calix[4]arenes based on 
phenol (and henceforth, simply addressed as calixarene) and calix[4]resorcinarenes 
(resorcinarene), based on resorcinol (Figure 71). The tetramers previously described 
can be considered as an “open” form of a calix[4]resorcinarene, and the hexamer an 
“open” calix[6]resorcinarene. 
 
Figure 71. Basic structure of calix[4]arenes and calix[4]resorcinarenes. 
Calixarenes are easily accessible on large scales and are extremely flexible 
building blocks. They can be conveniently and selectively functionalised at the upper 
rim, lower rim and methylene bridges. Also, upon introduction of sterically hindering 
groups, they can be locked into specific conformations, providing access to differently 
presented and well organised structures (Figure 72). 
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Figure 72. Conformations of calix[4]arenes. 
4.3 Previous work 
 Previous work in our research group investigated the synthesis and potential 
biological applications of calixarene and resorcinarene dendrimers. The first type of 
dendrimers investigated were based on cone and 1,3-alternate calixarenes. In contrast 
to the work presented in this thesis, growth of the dendrimer was obtained by reaction 
of activated carboxylic acids and amines (Error! Reference source not found.). The 
approach also allowed access to the convergent synthesis of a large dendrimer, with 21 
calixarenes on the third generation.131,132,134 
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Scheme 69. Dendrimers obtained by reaction of activated carboxylic acids and amines. 
 More importantly, a set of dendrimers based on amino-functionalised 
calixarenes were also synthesised and were shown to bind effectively to DNA. These 
studies highlighted how the binding is related to both charge and structure.131,134 The 
ability to bind DNA was subsequently exploited to investigate the ability of cationic 
calix dendrimers to transfect cells. For this purpose, a library of calix dendrimers was 
synthesised using a click chemistry approach. The results showed that all the 
compounds are able to internalise a plasmid, and they are especially efficient when 
bearing aliphatic amines.135 
 Subsequent investigations evaluated synthetic routes to multicalixarene 
glycoconjugates. The rationale behind the synthesis of these molecules lies in the 
potential ability of targeting specific cells through the glycosides (e.g. bacterial lectins) 
and thus, deliver a specific DNA sequence or drug with high selectivity.135 
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Figure 73. 21 units multicalixarene built using click chemistry.135 
 With the intent of building larger and even more complex dendrimers, the 
potential of click chemistry was also exploited to build different 21 unit 
multicalixarenes such as 254, represented in Figure 73, proving that construction of 
larger and more varied structures is possible by the click chemistry approach.135 
 Mixed resorcinarene-calixarene based multicalixarenes such as those reported 
in Figure 74 (A) have also been investigated. They are based on click chemistry and 
bear a resorcinol-based core, with the dendrimer developing on the lower rim of the 
resorcinarene.136 
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Figure 74. Previously investigated resorcinarene-calixarene based multicalixarenes (A)136 and current 
work (B). 
 Our novel resorcinol-based platforms Figure 74 (B) present an alternative 
distribution of anchors for the growth of the dendrimers. The resorcinol units, instead 
of being cyclised, are arranged in couples around a phenyl core (which can also be 
substituted with variable length spacers, as described for compounds 208, 210 and 212, 
Chapter 2). The attachment to the central ring is variable, allowing three different 
regioisomers (ortho, meta, para) to present the dendrimer branches in different 
orientations. Despite lacking (at the moment) a viable option for convenient 
functionalization of the bridges, as in resorcinarenes, they are very simple to obtain and 
functionalise in high yields. The functionalization of the cores and synthesis of octa-
calixarene dendrimers (Figure 74 (B)) will be discussed in this chapter. 
4.4 CuAAC, a quick overview 
Working with large structures provides a number of challenges, ranging from 
low yields to purification, characterization and solubility issues. To minimise yield and 
purification problems, robust reaction methodologies, with high yields and selectivity 
are required. Click chemistry encompasses a range of reactions endowed with these 
  
  195 
features.137-139 The most representative of these reactions is probably the Copper-
Catalysed Azide-Alkyne Cycloaddition (CuAAC). It is reliable, simple and high 
yielding, with varied applications, high tolerance to different solvents and 
accommodates both homogeneous and heterogeneous phases.137,139  
 Cycloaddition of an azide with an alkyne to give 1,2,3-triazoles can be achieved 
by thermal activation: the reaction is known as the Huisgen 1,3-dipolar cycloaddition. 
The reaction did not initially attract much attention due to its poor regioselectivity, 
leading to mixtures of products. The reaction also required high temperatures, and long 
reaction times, all of these limiting the potential scope of the reaction. More interest 
was placed on the reaction when subsequent studies by Sharpless and Meldal140,141 
revealed that copper (I) could catalyse the reaction, not only allowing a reduction of the 
operating temperature, but also leading to high regioselectivity (Scheme 70). The 
reaction can also be catalysed by silver142 and ruthenium. The latter, most importantly, 
selectively leads to the 1,5-regioisomer.143 
 
Scheme 70. Azide-alkyne cycloaddition. 
 A further improvement to the reaction, is the production in situ of the copper 
catalyst, often generated from copper (II) sulphate, which can be achieved by addition 
of sodium ascorbate. The presence of an excess of sodium ascorbate allows an easier 
setup, as the oxygen in the air can oxidise Cu(I) to Cu(II), quickly reducing the amount 
of catalyst. The presence of a reducing agent, which reconverts the catalyst, prevents 
the necessity of working under inert atmosphere. 
 The mechanism of the reaction (Scheme 71) had been elusive and was recently 
clarified by Worrell. Initially, formation of a π-bound Cu-alkyne complex occurs (a), 
which allows deprotonation and formation of a σ-bound complex (b). Recruitment of a 
second copper atom is required to for the catalytic complex (c). This step is critical, the 
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authors proved the necessity of the recruitment of a second copper atom using a stable 
alkyne-Cu σ-bound complex as reagent and noted that reaction does not proceed unless 
additional catalyst is added. In the following step, the copper atoms become equivalent 
(d) and upon elimination of a copper atom (e) and subsequent protonation of the triazole 
(f) the cycle is closed. The equivalence of the two copper in step d was demonstrated 
using an enriched copper catalyst with the stable alkyne-Cu σ-bound complex, which 
produces an enriched triazole-Cu σ-bound complex.144 
 
Scheme 71. Mechanism of CuAAC.144 
4.5 Functionalization of the Cores 
 Initially, to evaluate whether the scaffolds were suitable for dendrimer 
construction through click chemistry, we decided to functionalise a core and test the 
click reaction with a simple and readily available materials. Since functionalization of 
the calixarene units with either an azide or alkyne is simple, the choice for the core is 
open to both functional groups. Hence, the initial functionalization of the core must be 
chosen based on the ease of purification and scalability. Two options were thus 
considered (Scheme 72). A first option is the alkylation with a bifunctional alkane, such 
as 1-bromo-3-chlorobutane, and subsequent substitution of the terminal chlorine with 
azide. The second option requires propagyl bromide as an alkylating agent. Despite its 
toxicity, it allows direct access to the functionalised core in one step and the purification 
is simple.  
The first option provided a complicated mixture, probably as a consequence of 
crosslinking. Since the 1H-NMR did not reveal any clear evidence of the product and 
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the TLC did not identify a specific product, the route was discounted in favour of the 
second option. 
 
Scheme 72. Functionalization of the cores. 
 Alkylation of 183 with propargyl bromide was achieved in the presence of 
potassium carbonate, at 80 °C in DMF (Scheme 73). The purification of 255 by flash 
chromatography is very simple. However, for the sake of obtaining an optimal starting 
material for the subsequent reactions, which may increase the complexity and thus the 
difficulty of purification, only the main fractions were collected. The isolated yield 
(59%) is good but not excellent, and is probably lower than the true reaction yield.  
 
Scheme 73. Synthesis of 255. 
 Examining the 1H-NMR (Figure 75) it is possible to highlight how the features 
of the core remain intact and its peaks are only slightly shifted as a consequence of the 
alkylation. As expected, the signals of the hydroxyl groups are lost in exchange for the 
newly introduced propargyl groups. Probably as a consequence of steric hindrance 
around the bridge, their signals are not equivalent, resulting in two sets of signals, one 
for the ortho and one for the para position chains. 
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Figure 75. 1H-NMR of 183 (top), and 255 (bottom). 
4.5.1 Hexameric Core 
Compound 219 is arguably the most interesting core structure available from 
this work, presenting twelve extremities to be functionalised. In the previous chapter, 
219 was prepared by dehalogenation of its chloro-substituted analogue 218, but the 
purity of the product was not acceptable, at least for biological evaluation. Purification 
of the hexamer is not practical, however, the reaction of the crude with propargyl 
bromide leads to an easy to purify product, allowing access to 256 in 32% yield over 
two steps (Scheme 74). 
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Scheme 74. Synthesis of 256 and its 3D representation (the image is only meant to provide a better 
visualization of the structure, it is not a representative conformation. MarvinSketch and UCSF 
Chimera) 
The 1H-NMR profile (Figure 76) is similar to that of 255. Propargyl substituents 
present two sets of signals, each with a triplet for the terminal hydrogen (2.32 ppm, 2.46 
ppm) and a doublet for the -CH2- (2.30 ppm, 2.57 ppm). The bridge hydrogens are all 
equivalent and show a singlet (5.72 ppm). Similarly, the central ring produces a singlet 
(6.44 ppm). The remaining signals, partly overlapped, represent the resorcinol aromatic 
hydrogens. 
 
Figure 76. 1H-NMR of 256. 
  
  200 
 The approach thus provides access to a method to recover insufficiently clean 
phenolic precursors, paving the way to additional dendrimer cores. 
4.5.2 Test of click reaction 
The click reaction of a simple azide (benzyl azide) was used to test the optimal 
conditions for the reaction. In the presence of copper sulphate and sodium ascorbate in 
DMF at 80 oC, the reaction proceeded in a few hours, leading to the expected product 
in 92% (Scheme 75). The yield is surprising considering that eight individual 
cyclisation reactions are necessary for each product molecule. 
 
Scheme 75. Synthesis of test dendrimer 257. 
The 1H-NMR of 257 retains the characteristic features of the previously 
described 183. Observing Figure 77, it is possible to see that the symmetry is not lost, 
the bridge (a), the three peaks of the resorcinol unit (b) and the core (c) are immediately 
identifiable. Correlation between the hydrogens of the resorcinol can also be confirmed 
by COSY. Integration according to these peaks reveals that the signal at 8.1 ppm (i), 
which can be assigned to a triazole due to its deshielded position, represents only four 
of the moieties. This is an expected result since chains e-f-g and h-i-j (Figure 77) reside 
in different environments, as previously observed with 255. 
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Figure 77. 1H-NMR of 257. 
Using a combination of HSQC (Figure 78) and HMBC (Figure 79), all signals 
were assigned. Chain e-f-g was identified by HMBC correlation: the hydrogen of the 
bridge has a 3J relationship with only one carbon bearing an oxygen (these have 
typically shifts around 160 ppm in our resorcinol based platforms). The same carbon is 
three bonds away from hydrogens e. Moving along the chain, f and g were also 
identified. In a similar fashion, h-i-j were identified starting from the interaction of the 
second (and last) 13C signal around 160 ppm and hydrogen h. 
Chain e-f-g (Figure 77) is interesting, as the hydrogen of the triazole (f) is 
particularly shielded, 0.8 ppm more than i. Also, the benzylic hydrogens g are 
diastereotopic, which is surprising as e, supposedly more hindered, is not. This could 
be a consequence of π-stacking between two equivalent e-f-g chains.  
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Figure 78. HSQC of of 257. 
 
Figure 79. HMBC of of 257. 
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4.5.3 Synthesis of a hindered model compound 
 To evaluate potential limitations due to the steric hindrance of the molecules 
clicked onto the core, a model calixarene was synthesised. Compound 258 was prepared 
according to the procedure reported by Regayeg145 from material available within the 
group. Substitution of the bromine with an azide was achieved by stirring the precursor 
with sodium azide in DMF at 60 °C, thus obtaining the clickable product 259 (Scheme 
76). The reaction was clean and produced a product of ideal quality by simple filtration. 
Since the substitution only produces a shift in the hydrogen signals, NMR analysis was 
supported by IR spectroscopy to confirm the introduction of the azide, which produces 
a clear signal around 2100 cm-1 (Figure 80). 
 
Scheme 76. Synthesis of 259. 
 
Figure 80. IR spectra of 259. 
 Click reaction of the calixarene onto the core was undertaken with the same 
procedure described for the first model compound and produced the expected dendrimer 
in excellent yield: 86% (Error! Reference source not found.). 
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Scheme 77. Synthesis of 260. 
The 1H-NMR of this dendrimer bears similarities with that of the previously 
described dendrimer 257, with the additional complexity of the calixarenes (Figure 81).  
The triazoles have two distinct peaks (a), exactly as in the previous model dendrimer. 
The structure of the core is still identifiable, although the signal is poor. Central ring b, 
resorcinol units (d) and bridge e do not overlap with the hydrogens of the calixarene (c) 
and their relationship can be identified using COSY and HMBC. The bridging 
methylenes of the former propargyl group (f) stand out at around 5 ppm and can be 
confirmed by long range coupling with the carbons of the core. As it is usual for cone 
calixarene conformations, the hydrogens of the bridges are diastereotopic and split (g). 
Hydrogens h, i and j are the last signals around 4 ppm and were confirmed by HMBC. 
The remaining peaks were assigned to the alkyl chains. 
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Figure 81. 1H-NMR of 260. 
The result shows that clicking bulky extremities to the core is feasible and it was 
therefore possible to move to a practical application. 
4.5.4 Synthesis of a clickable tetra-amino calixarene 
 As described in the introduction to this chapter, cationic multicalixarenes are 
interesting DNA-binding platforms.131 The approach used for the synthesis of 260 was 
thus employed to prepare a novel octa-tetraminocalixarene. 
Compound 258 was also used as a starting material to prepare a calixarene which 
bears four protected amines on the upper rim and an azide on the lower rim (Scheme 
78). The ipso nitration to substitute the tert-butyl group with a nitro group, originally 
described by Verboom,146 was also employed by Regayeg.145 The reaction with nitric 
acid and acetic acid in dichloromethane is rapid and leads to the product in 1-6 hours 
(the colour turns from black to light brown and is a good indication of the reaction 
progress). In contrast to Regayeg, the crude material was not crystallised but triturated 
in methanol producing a very clean product which was directly used for the following 
reaction. 
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Scheme 78. Synthesis of 264. 
For the reduction of the nitro group, a consolidated method widely used within 
the group, and previously reported by Budka,147 was employed. A mixture of 261 and  
tin(II) chloride in ethanol was heated  at reflux for 48 hours to yield the expected 
compound. The extraction of the product from the reaction mixture is tedious as a 
consequence of the presence of large amounts of salts and foaming. 
A subsequent protection of the amino groups is necessary for two reasons: 
firstly, if left unprotected they would interfere with the click reaction by coordinating 
the copper catalyst. Secondly, the product cannot be conveniently purified by flash 
chromatography on silica gel. For these reasons, the amines were protected with di-tert-
butyl dicarbonate, according to a method reported by Saadioui,148 and the product was 
then purified by chromatography to give 263 in 29% yield over three steps. The choice 
of the protecting group might appear odd, since Boc is removed with acids. However, 
it can be removed under mild conditions, and it provides an interesting evaluation of 
whether the deprotection of acid-labile groups is feasible despite the relative instability 
of the cores to acid-catalysed retro-Friedel-Crafts reaction. Boc protection is a well 
known method, it has been used within the group, and has the additional advantage of 
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allowing access to selective, partial protection of calixarenes,148 thus increasing the 
potential scope of the attainable derivatives. 
Finally, the bromine was substituted with sodium azide, as previously described 
for 259, to give the clickable product 264 in quantitative yield. 
4.5.5 Synthesis of a functionalised dendrimer 
 Azide 264 was clicked onto the core using the same method used for the 
previous tetramers to obtain 265 in 77% yield (Scheme 79). Because a two-fold excess 
of azide was used, it is relevant to note that such excess can be recovered in 93% yield 
during the purification of the product, thus minimising the loss of the building block. 
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Scheme 79. Synthesis of 266. 
Formation of the triazole is confirmed by appearance of typical deshielded peaks 
(a, Figure 82), and disappearance of the alkyne terminal hydrogens (b, Figure 82). 
Other characteristic peaks from the core, are slightly shifted in their positions (c, d 
Figure 82), especially the linker to the triazole (e, Figure 82). The remaining peaks, 
although quite broad, originate from the newly attached calixarene. 
 
Figure 82.  1H-NMR of 255 (top), 265 (centre) and 264 (bottom). 
The product was then deprotected. HCl deprotection is a critical step (Scheme 
79), as previously discussed, because of potential retro-Friedel-Crafts reactions. With 
the hydroxyl groups “protected” as ethers, the nucleophilicity of the resorcinol 
fragments is partially reduced. The starting material is dissolved in DCM and 
deprotected by HCl, which is bubbled into the solution. Salification of the newly formed 
amines, produces precipitation, blocking the reaction. To complete it, addition of 
methanol, which re-dissolves the partially reacted product, is required. This step is 
critical: dissolution of hydrochloric acid in methanol is an exothermic process. To 
minimise potential fragmentation, the temperature is controlled with an ice bath and the 
amount of methanol is maintained at the minimum necessary, which also helps maintain 
the polarity as low as possible, contributing to the reduction of the rate of retro-Friedel-
Crafts. The product was purified by preparative RP-HPLC to give the product in 79% 
yield. The identity of the compound was confirmed by high resolution mass 
spectrometry and by NMR, which shows a similar profile to that of 265, although some 
peaks are covered by the solvent (Figure 83). The result confirms the possibility of 
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using this approach to remove acid-labile protecting groups without significant loss of 
material. 
 
Figure 83. 1H-NMR of 266. 
4.6 Conclusions 
In this Chapter, a suitable method for the functionalization of our multivalent 
core structures with alkyne sidechains have been presented. The method also allowed 
derivatization and subsequent purification of the hexameric core (219), for further use 
in dendrimer synthesis. 
A sample core have been functionalised with model compounds and 
subsequently with tetra-aminocalix[4]arenes, producing a first-generation octacalix 
with 32 exposed amines. This work is a proof of concept and first step toward new, 
potential DNA binding structures. 
In conclusion, an efficient procedure for the functionalization of our novel octa- 
and dodeca-valent dendrimer cores has been developed, allowing easy access to a new 
range of resorcinol based dendrimers. 
  
  




All reagents and solvents for synthesis were commercial and used without further 
purification. NMR spectra were recorded at 293 K, unless otherwise stated, using a 400 
MHz Spectrometer. Shifts are referenced relative to deuterated solvent residual peaks. 
Infrared spectra were recorded using an FT-IR spectrometer with ATR attachment. MS 
were run on an LTQ orbitrap XL and were recorded by the EPSRC Mass Spectrometry 
National facility. Thin-layer chromatography (TLC) was carried out on aluminum 
sheets coated with silica gel 60 F254 (Merck). TLC plates were inspected by UV light 
(λ = 254 nm). Silica gel column chromatography was performed with silica gel Si 60 
(40–63 µm). 
 
Purification by preparative RP-HPLC was performed on an Agilent 1260 Infinity using 
an Agilent Eclipse XDB-C18 column, 21.2 x 150mm, 5µM.  
Solvent A: 5% methanol in water + 0.05% TFA. 
Solvent B: 5% water in methanol + 0.05% TFA. 
Gradient: Solvent A to Solvent B in 20 minutes. Flow rate = 20 mL/min. Detection 
wavelength = 254 nm. 
 
  




A mixture of 183 (3.26 mmol), anhydrous potassium carbonate (10.4236 g, 75,42 
mmol), and propargyl bromide (5.5446 g, 57.46 mmol) in 100 ml of DMF was allowed 
to stir at 70 °C for 5 h and then for 18 h at 80 °C. The solvent was evaporated under 
reduced pressure and the resulting solid suspended in water and extracted three times 
with diethyl ether. The organic layers were combined, washed with NaHCO3, brine and 
then dried over MgSO4. The crude product obtained upon evaporation of the solvent 
was purified via flash chromatography on silica gel (DCM as eluent) and dried in the 
oven at 120 °C. A pale yellow solid was obtained (1.6239 g). 
Yield: 59% 
[M+NH4]
+ = 860.3217 (Calculated: 860.3218) 
MP: 135-137 °C 
1H-NMR (400 MHz, DMSO) δ 6.84 (s, 4H), 6.69 (d, J = 2.3 Hz, 4H), 6.64 (d, J = 8.5 
Hz, 4H), 6.52 (dd, J = 8.5, 2.3 Hz, 4H), 5.89 (s, 2H), 4.74 (d, J = 2.3 Hz, 8H), 4.67 (d, 
J = 2.3 Hz, 8H), 3.55 (t, J = 2.3 Hz, 4H), 3.47 (t, J = 2.3 Hz, 4H). 
13C-NMR (101 MHz, DMSO) δ 156.61, 155.46, 140.93, 129.91, 128.42, 125.55, 
105.94, 101.22, 79.24, 79.16, 78.18, 78.00, 56.07, 55.50, 41.01. 
IR (νmax, cm-1): 3286, 1607.5, 1586, 1498, 1451, 1428, 1370.5, 1285, 1247, 1162.5, 
1109, 1025, 941.5, 920.5, 832, 800. 
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Compound 219 and 256 
 
Palladium over carbon (catalytic) was added to a solution of 218 (0.33 mmol) and 
triethylamine (1 mL, 7.17 mmol) were dissolved in 24 mL of ethanol. A hydrogen 
atmosphere was applied and the mixture was allowed to stir at 50 °C for 5 h. The catalyst 
was removed by filtration and the solution was dried under reduced pressure. The 
product was suspended in HClaq 10% v/v and extracted with ethyl acetate three times. 
The organic layers were combined, washed with HClaq 10% v/v, brine and dried over 
Na2SO4. Upon evaporation, 260 mg of crude were obtained as an orange powder. 
The crude was used without any further purification for the synthesis of 256. A 1H-
NMR is reported for reference. 
 
 
A mixture of crude 219 (160 mg), anhydrous potassium carbonate (948.7 mg, 6.86 
mmol), and propargyl bromide 80 % in toluene (680.9 mg, 4.58 mmol) in 10 ml of DMF 
was allowed to stir at 70 °C for 5 h and then for 18 h at 80 °C. The solvent was 
evaporated under reduced pressure and the resulting solid suspended in water and 
extracted three times with diethyl ether. The organic layers were combined, washed 
with NaHCO3, brine and then dried over MgSO4. The crude product obtained upon 
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evaporation of the solvent was purified via flash chromatography on silica gel (DCM 
as eluent). 
Yield: 31.8% over two steps 
 
1H-NMR (400 MHz, CDCl3) δ 6.56 – 6.47 (m, 12H), 6.44 (s, 3H), 6.34 (dd, J = 8.5, 2.4 
Hz, 6H), 5.72 (s, 3H), 4.57 (d, J = 2.4 Hz, 12H), 4.30 (d, J = 2.4 Hz, 12H), 2.46 (t, J = 
2.4 Hz, 6H), 2.32 (t, J = 2.4 Hz, 6H). 
13C-NMR (101 MHz, CDCl3) δ 156.85, 156.20, 142.69, 130.52, 128.02, 127.11, 106.09, 
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Benzylazide (0.51 mL, 3.80 mmol) was added to a mixture of 255 (200 mg, 0.24 mmol), 
CuSO4·5H2O (5.9 mg, 0.02 mmol) and sodium ascorbate (18.8mg, 0.09 mmol) in 4 ml 
of DMF under argon. The mixture was slowly heated to 80 °C. After 3 h at 80 °C, the 
DMF was evaporated under reduced pressure. The dark yellow product was suspended 
in chloroform absorbed onto silica and purified by flash chromatography (ethyl 
acetate/acetone 9:1 and acetone) to give 0.4158 g of a pale yellow product  
Yield: 92% 
[M+2H]2+ = 954.9080 (Calculated: 954.9087)  
MP: 89-90 °C 
1H-NMR (400 MHz, Acetone) δ 8.08 (s, 4H), 7.44 – 7.11 (m, 44H), 6.80 (s, 4H), 6.79 
(s, 4H), 6.62 (s, 4H), 6.59 (d, J = 8.5 Hz, 4H), 6.51 (dd, J = 8.5, 2.4 Hz, 4H), 5.87 (s, 
2H), 5.63 (s, 8H), 5.47 (d, J = 15.0 Hz, 4H), 5.40 (d, J = 15.0 Hz, 4H), 5.16 (s, 8H), 
4.95 (s, 8H). 
13C-NMR (101 MHz, Acetone) δ 159.12, 157.59, 145.06, 144.75, 142.42, 137.00, 
136.86, 130.96, 129.71, 129.69, 129.14, 129.07, 128.91, 128.71, 126.67, 124.68, 
124.02, 106.83, 101.69, 63.40, 62.49, 54.22, 54.15, 43.34. 
IR (νmax, cm-1): 1606, 1585, 1497, 1455, 1432, 1284, 1253.5, 1221.5, 1167.5, 1108.5, 
1049, 1031.5, 1015.5, 823.5, 799. 
Compound 258145 
 
Prepared according to Regayeg.145 
MP: 184-186 °C (180 °C)145 
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1H-NMR (400 MHz CDCl3, ppm): δ 6.80 (s, 4H), 6.74 (m, 4H), 4.39 (t, J = 12.4 Hz, 
4H), 3.89 (t, J = 7.6 Hz, 2H), 3.81 (m, 6H), 3.50 (t, J = 6.8, 2H), 3.12 (m, 4H), 2.16 (m, 
2H), 2.01 (m, 8H), 1.06 (m, 45H). 
13C NMR (101 MHz, CDCl3) δ 153.74, 153.60, 153.54, 144.49, 144.24, 144.19, 134.00, 
133.93, 133.68, 133.50, 125.02, 124.93, 124.80, 76.90, 74.08, 33.85, 33.84, 33.79, 
33.56, 31.50, 31.49, 31.44, 31.08, 31.07, 29.83, 29.06, 23.40, 23.28, 10.39, 10.33. 
Compound 259 
 
Sodium azide (0.43 g, 6.62 mmol) was added to a solution of 258 (4.00 g, 4.40 mmol) 
in DMF (80 mL) and allowed to stir at 60 °C for 18 hours. The mixture was then diluted 
with water and extracted with DCM. The organic layers were combined and washed 
three times with 3.6% HCL (100 mL), once with brine (100 mL) and then dried with 
MgSO4. The solvent was removed under reduced pressure, to give the expected 
compound. 
Yield: 88.4% 
1H-NMR (400 MHz, CDCl3) δ 6.83 (s, 4H), 6.72 (m, 4H), 4.39 (t, J = 12.4 Hz, 4H), 
3.90 (t, J = 7.6 Hz, 2H), 3.81 (m, 6H), 3.37 (t, J = 7.2, 2H), 3.12 (m, 4H), 2.13 (m, 2H), 
2.00 (m, 8H), 1.74 (m, 2H), 1.07 (m, 45H). 
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Compound 260 
 
259 (741.8 mg, 0.850 mmol) was added to a mixture of 255 (44.8 mg, 53.1 μmol), 
CuSO4·5H2O (1.3 mg, 5.31 µmol) and sodium ascorbate (2.1 mg, 10.62 µmol) in 7 ml 
of DMF under argon. The mixture was slowly heated to 80 °C. After 4 h at 80 °C, the 
DMF was evaporated under reduced pressure. The dark yellow product was suspended 
in DCM, absorbed onto silica and purified by flash chromatography (DCM until the 
remaining 259 has been recovered, then DCM/MeOH 70/1). 
Yield: 85.7% 
1H NMR (400 MHz, CDCl3) δ 7.49 (s, 4H), 7.04 (s, 4H), 6.86 (s, 4H), 6.69 (m, 64H), 
6.60 (m, 8H), 6.37 (m, 4H), 5.92 (s, 2H), 5.02 (s, 8H), 4.88 (s, 8H), 4.38 – 4.11 (m, 
48H), 3.90-3.63 (m, 64H), 3.03 (t, J = 12.8 Hz, 32H), 2.07 – 1.78 (m, 80H), 1.16 – 0.78 
(m, 360H). 
13C NMR (101 MHz, CDCl3) δ 158.07, 156.74, 153.68, 153.54, 153.48, 153.40, 153.30, 
144.61, 144.42, 144.25, 143.95, 143.91, 133.96, 133.86, 133.74, 133.66, 133.42, 
130.37, 129.12, 126.40, 125.09, 124.99, 124.81, 122.45, 105.40, 100.83, 77.23, 76.90, 
74.11, 73.94, 62.80, 62.09, 50.44, 50.27, 33.86, 33.84, 33.82, 33.79, 31.49, 31.45, 
31.09, 27.35, 27.28, 27.22, 23.42, 23.34, 23.32, 10.46, 10.41, 10.39, 10.37. 
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Compound 261145 
 
To a stirring solution of 258 (2 g, 2.2 mmol) in DCM (138 mL) were added, in sequence, 
glacial acetic acid (13.8 mL) and concentrated nitric acid (13.8 mL). After 6 hours, the 
reaction was diluted with 350 mL of distilled water, the organic layer was collected, 
washed with distilled water (twice), with brine (once) and dried with MgSO4. The 
solvent was removed under reduced pressure and the residue was triturated with 
methanol to give 261 (1.72 g). The white solid obtained was used for the synthesis of 
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A mixture of crude 261 (1.70 g) and tin chloride dihydrate (11.31 g, 50.1 mmol) in 
ethanol (110 mL) was allowed to stir at reflux for 48 hours. The solvent was removed 
under reduced pressure and the result was treated with 350 mL of a solution of 10% 
NaOH in water. The mixture was then extracted with DCM three times. The organic 
layers were collected, washed with distilled water (twice), brine (once) and dried with 
MgSO4. The solvent was removed under reduced pressure to give 1.18 g of brown solid. 
The crude was used directly for the synthesis of 263. A 1H-NMR (400 MHz, CDCl3) is 




Boc-anhydride (10.83 g, 49.6 mmol) was added to a stirring solution of crude 262 (1.17 
g) and DIPEA (6.41 g, 49.6 mmol) in 40 mL of DCM and allowed to stir for 60 hours 
at room temperature. The resulting mixture was diluted with DCM and the organic layer 
was washed with water (twice), brine (once) and dried with MgSO4. The solvent was 
removed under reduced pressure and the residue was purified by column 
chromatography (ethyl acetate/DCM 1/20) to give 263. 
Yield: 29% over three steps, from 258 
[M+NH4]
+ = 1164.5651 (Calculated: 1164.5670)  
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1H NMR (400 MHz, CDCl3) δ 6.69 – 6.56 (m, 8H), 6.22 – 6.11 (m, 4H), 4.44 – 4.30 
(m, 4H), 3.91 – 3.83 (m, 2H), 3.83 – 3.73 (m, 6H), 3.60 (t, J = 6.6 Hz, 1H), 3.47 (t, J = 
6.3 Hz, 1H), 3.18 – 3.06 (m, 4H), 2.08 – 1.96 (m, 4H), 1.96 – 1.81 (m, 6H) 1.60 – 1.41 
(m, 36H), 1.03 – 0.93 (m, 9H). 
13C NMR (101 MHz, CDCl3) δ 153.38, 153.37, 153.35, 152.86, 152.84, 152.78, 152.65, 
152.61, 135.30, 135.21, 135.03, 132.20, 132.00, 119.96, 119.91, 119.83, 80.06, 80.01, 
77.23, 76.79, 73.90, 44.86, 33.36, 31.11, 29.69, 29.50, 28.84, 28.45, 27.57, 23.16, 
23.09, 10.35.  
Compound 264 
 
Sodium azide (0.12 g, 1.85 mmol) was added to a solution of 263 (0.6 g, 0.52 mmol) in 
DMF (10 mL) and allowed to stir at 60 °C for 18 hours. The mixture was then diluted 
with water and the solid was collected by Büchner filtration. The product was washed 
with abundant distilled water and dried in air. 
Yield: quantitative 
[M+NH4]
+ = 1125.6575 (Calculated: 1125.6594)  
1H NMR (400 MHz, CDCl3) δ 6.68 (s, 4H), 6.58 (s, 4H), 6.17 (s, 2H), 6.11 (s, 2H), 4.42 
– 4.30 (m, 4H), 3.91 – 3.84 (m, 2H), 3.84 – 3.71 (m, 6H), 3.35 (t, J = 6.9 Hz, 2H), 3.17 
– 3.05 (m, 4H), 2.03 – 1.79 (m, 8H), 1.77 – 1.63 (m, 2H), 1.50 (dd, J = 10.5, 5.0 Hz, 
36H), 1.07 – 0.91 (m, 9H).  
13C NMR (101 MHz, CDCl3) δ 153.41, 153.36, 153.35, 152.89, 152.71, 152.64, 135.41, 
135.36, 135.08, 134.92, 132.22, 132.04, 132.00, 119.99, 119.89, 119.81, 80.07, 80.03, 
80.00, 77.23, 76.80, 74.19, 51.51, 31.13, 31.10, 28.45, 27.26, 25.70, 23.17, 23.07, 
10.36, 10.30.  
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IR (νmax, cm-1): 2977, 2931, 2873, 2096, 1700, 1601, 1522, 1472, 1416, 1367, 1291, 
1241, 1215, 1149, 1066, 1037, 1004, 964, 872, 770. 
Compound 265 
 
Compound 264 (600 mg, 0.541 mmol) was added to a mixture of 255 (28.5 mg, 33.8 
μmol), CuSO4·5H2O (25 mg, 0.1 mmol) and sodium ascorbate (250 mg, 1.26 mmol) in 
7 ml of DMF under argon. The mixture was slowly heated to 80 °C. After 4 h at 80 °C, 
the DMF was evaporated under reduced pressure. The dark yellow product was 
suspended in DCM, absorbed onto silica and purified by flash chromatography 
(DCM/ethyl acetate 10/1 until the remaining 264 has been recovered, then DCM/MeOH 
20/1 to elute the product). 
Yield: 76.8%. Excess of 264 was recovered in 92.5% yield. 
[M+(NH4)5]
5+ = 1959.8908 (Calculated: 1959.8962)  
1H NMR (400 MHz, CDCl3) δ 7.59 (s, 4H), 7.14 (s, 4H), 6.88 (s, 4H), 6.71 – 6.48 (m, 
68H), 6.44 (d, J = 8.4 Hz, 4H), 6.40 (s, 4H), 6.32 (s, 16H), 6.18 (s, 16H), 5.96 (s, 2H), 
5.08 (s, 8H), 4.93 (s, 8H), 4.44 – 4.15 (m, 48H), 3.91 – 3.63 (m, 64H), 3.17 – 2.90 (m, 
32H), 2.07 – 1.70 (m, 80H), 1.57 – 1.33 (m, 288H), 1.07 – 0.79 (m, 72H). 
13C NMR (101 MHz, CDCl3) δ 158.04, 153.49, 153.44, 153.41, 153.39, 152.83, 152.79, 
152.75, 152.68, 152.40, 152.30, 143.86, 135.34, 135.31, 135.28, 135.19, 135.11, 
135.09, 135.00, 134.86, 132.41, 132.35, 132.08, 131.98, 122.61, 122.60, 120.12, 
120.04, 120.02, 119.94, 119.88, 100.88, 80.00, 79.96, 79.89, 77.23, 73.93, 73.79, 62.03, 
62.01, 50.30, 50.15, 31.10, 28.47, 28.46, 27.24, 27.16, 27.08, 23.16, 23.12, 23.09, 
10.48, 10.42, 10.41, 10.32.  
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Compound 266 
 
HCl(g) was bubbled in a solution of 265 (82 mg, mmol) in DCM (2 mL) until a white 
precipitate formed. The mixture was cooled at 0 °C with an ice bath and MeOH was 
added dropwise to dissolve the precipitate. After one hour the source of HCl(g) was 
removed and argon was bubbled in the mixture for sixty minutes. The solvent was then 
removed under reduced pressure. The residue was dissolved in 16 mL of HPLC Solvent 
A, filtered and purified by preparative RP-HPLC. 
Yield: 78.8% (Calculated as TFA salt) 
[M+(NH4)5]
5+ = 1302.1327 (Calculated: 1302.1328)  
1H NMR (400 MHz, MeOD) δ 8.13 (d, J = 20.2 Hz, 4H), 7.43 (s, 4H), 7.04 (s, 4H), 
6.96 – 6.80 (m, J = 14.2 Hz, 34H), 6.79 – 6.57 (m, 38H), 6.49 (d, J = 8.5 Hz, 4H), 5.91 
(s, 2H), 4.62 – 4.28 (m, 48H), 4.10 – 3.74 (m, 64H), 2.20 – 2.07 (m, 8H), 2.07 – 1.79 
(m, 72H), 1.14 – 0.81 (m, 72H). 
13C NMR (101 MHz, MeOD) δ 161.24, 160.88, 160.52, 160.16, 156.65, 156.26, 156.10, 
156.01, 136.70, 136.61, 136.53, 136.05, 135.99, 135.88, 135.80, 125.07, 125.04, 
122.86, 122.84, 122.80, 122.51, 122.44, 122.35, 77.22, 77.13, 77.07, 74.66, 74.61, 
74.59, 61.14, 49.85, 30.36, 30.31, 26.85, 23.00, 22.94, 9.58, 9.47, 9.26.  
IR (νmax, cm-1): 2966, 2931, 2873, 2625, 1667, 1467, 1184, 1064, 1036, 999, 959, 839, 
798, 721, 703.
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5. Biological evaluation 
The great majority of the compounds synthesised in the previous chapters are 
novel and thus there are no available data regarding their effect on cell viability. 
Evaluation of the effects on proliferation is a relevant step required to understand the 
potential of these new molecules. Potential antioxidant or antimicrobial compounds are 
expected to have low impact on the viability of human cells. On the other hand, potent 
inhibitors could be interesting leads toward the development of anticancer drugs. For 
this reason, the effect of these compounds on the proliferation of two human cancer cell 
lines was undertaken. 
5.1 MTS assay 
Formazan dyes are the basis of a number of biological assays. These dyes are 
characterised by a central tetrazole ring with a quaternary nitrogen, adorned with three 
aromatic substituents. Upon reduction, the colourless tetrazolium substrate is converted 
to a chromogenic formazan (Scheme 80), thus allowing spectrophotometric 
detection.149,150 
 
Scheme 80. Reduction of MTS to its chromogenic formazan derivative. 
 The nature of the substituents on the tetrazolium ring affects the biophysical 
properties of the dye. MTT (4,5-dimethyl-2-thiazolyl)-3,5-diphenyl-2H-tetrazolium 
bromide), one of the most widely used reagents, produces an insoluble formazan dye. 
On the other hand, MTS ([3-(carboxymethoxy)phenyl]-3-(4,5-dimethyl-2-thiazolyl)-2-
(4-sulfo-phenyl)-2H-tetrazolium inner salt), gives a soluble dye. Ability to cross the 
membrane is also affected by the substituents and reagents that do not enter the 
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cytoplasm have additionally been developed. All these properties influence the methods 
and the applicability of the different reagents to different type of assays. 
 MTT and MTS are reduced intracellularly by NAD(P)H-dependent 
oxidoreductases and dehydrogenases (other enzymes are also involved to a minor 
extent) of viable cells. It has been demonstrated that, under controlled conditions, there 
is a correlation between the number of viable cells and the reduction of the tetrazolium 
reagent. The application of these dyes to microplate screening application made these 
methods rather popular, thanks to their simplicity and rapidity. MTT assay has been 
widely used to determine the effect of drugs and other substances on cell proliferation. 
Being a measure of the metabolic activity, the assay can be adjusted to probe the method 
of action of the drug itself by application of stimuli or modification of the assay 
conditions. 
 The principal difference between MTT and MTS assay is the solubility of the 
dye itself. In the case of MTT, a washing and solubilisation step is required, while MTS 
produces a soluble formazan, which can directly be measured (which also allows 
measurement at different time points rather than being a purely end-point assay). The 
disadvantage of MTS is the higher risk of interference caused by coloured compounds, 
which may interfere with the colorimetric detection. The MTS assay has been widely 
applied within the group and was chosen as an initial method for the screening of the 
effects on cell viability. 
5.1.1 Cell Lines 
 For the screening two cancer cell lines were employed. MCF-7 cell are adherent 
cells of breast cancer origin, while HL60 grow in suspension and are human 
promyelocytic leukaemia cells. The choice of the two lines lies in the fact that MCF-7 
express p53, a key tumour suppressor protein, whilst the gene for its expression in HL60 
presents major deletion and it is thus non-functional. The difference allows potential 
discrimination of compounds interfering with the activity of p53.151,152 
5.2 Screening 
 Inhibition of cell proliferation was evaluated at two different concentrations for 
a three day treatment, in both MCF-7 and HL60 cell lines. Proliferation is reported 
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compared to the control, reported as percentage. A summary of the results is reported 
in Table 6. 
 
HL60 MCF-7  HL60 MCF-7 
 100 μM 10 μM 100 μM 10 μM  100 μM 10 μM 100 μM 10 μM 
107 5 11 8 66 182 24 125 15 95 
109 5 82 5 101 183 0 89 7 99 
111 4 68 NA NA 184 25 106 28 124 
116 109 103 96 106 185 31 110 28 102 
135 18 78 13 99 186 24 103 23 86 
136 16 107 106 100 187 16 129 16 106 
138 100 100 93 91 188 12 105 24 107 
140 3 53 NA NA 192 3 61 NA NA 
141 5 44 NA NA 193 3 78 0 54 
142 4 61 2 92 194 6 99 0 96 
143 4 68 3 100 207 7 3 9 4 
144 4 78 NA NA 208 4 4 6 4 
145 73 88 56 90 209 6 3 8 5 
150 8 34 NA NA 210 6 5 6 3 
151 5 95 3 106 211 8 9 9 8 
158 4 106 10 100 212 4 3 7 3 
160 9 90 13 89 217 18 103 14 101 
163 5 102 7 107 218 26 105 9 94 
164 6 63 5 78 220 62 93 23 109 
165 8 72 10 58 241 7 47 NA NA 
166 0 83 3 108 242 82 94 92 105 
167 0 89 3 100 243 30 77 43 99 
168 67 112 102 117 244 36 87 78 104 
180 28 110 30 102 246 6 84 48 93 
181 19 115 17 96 248 88 97 95 83 
 
Table 6. Results of the proliferation screening against MCF-7 and HL60, at 10 and 100 μM 
concentrations for a three day treatment. Data expressed as percentage of proliferation compared to the 
control. Colour gradient from 0% proliferation (red) to white (50%) and blue (100%). 
5.2.1 Comparison of MCF-7 and HL60  
 The first discussion is related to the behaviour of the two different cell lines 
against the library of compounds. As visualised in Figure 84, both at 10 and 100 µM 
concentrations, the compounds display a lack of selectivity, producing similar effects 
on both breast cancer and leukaemia type cells.  
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Only 136, 168, 244 and 246 (Figure 85) produce a degree of selectivity across 
the two lines, at least at the concentrations considered. Of these, 136 is the most 
relevant, with HL60 almost completely inhibited (16% proliferation) and no effect on 
MCF-7 proliferation at 100 µM concentration. In the case of xanthones, 246 and 244, 
the selectivity is limited to about 40% effect on the proliferation. This makes these 
compounds potentially interesting subject for further studies. 
 
Figure 85. Compounds showing selectivity over the two cell lines. 
5.2.2 Structures with low toxicity  
 In general, for both cell lines, as one can notice from Figure 84, a good number 
of the compounds display an IC50 between 10 and 100 µM, which is relatively low 
compared to a typical anticancer drug like doxorubicin (125 nM, positive control). A 
few compounds, on the other hand, display an even lower inhibitory effect. The 
reference resorcinol monomers, 4-chlororesorcinol and 4-bromoresorcinol, both have 
substantially no effect on either cell lines at 100 µM. Structures 168 and 136, although 
only with MCF-7, display no inhibitory effect at the highest concentration used. 
Compounds 242, 248, 220, 145 and 194 are also interesting for their low effect on cell 
viability. 
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Figure 86. Structures displaying low proliferation inhibition. 
 Observing these structures (Figure 86), it is evident that lowest proliferation 
inhibition is mainly related to simple structures, monomers, benzophenones and bis-
phenols in particular, while tetramers and higher analogues lead to higher toxicity. 
5.2.3 Evaluation of tetramers 
  The tetramers synthesised (Figure 87), can be classified into three 
groups: tetramers with a central phenyl ring (a), diphenol based tetramers (b) and with 
aryloxy-alkyl linked structures (c). 
 
Figure 87. Effect of the central core of tetramers on cell viability. 
 The first group of tetramers (a), for the most part, do not display inhibitory 
effects at 10 µM concentrations, except for a few compounds. At 100 µM, on the other 
hand, they produce almost complete inhibition, suggesting an IC50 between 10 µM and 
100 µM. For the second group (b), the trend is the same, implying that changing a 
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central phenyl ring to a diphenyl does not affect the activity. The situation changes 
dramatically with group c, which displays the highest toxicity in the library, with 
complete inhibition at 10 µM. This group will be discussed further in the next chapter. 
 Effect of halogen substitution (Figure 88) on proliferation is less clear. Indeed, 
whilst it appears that fluoro-substitution (a) reduces the toxicity, it is however a single 
example in the library and a similar substitution on a geometric equivalent would be 
necessary to confirm the hypothesis.  
 
Figure 88. Effect of the halogen substitution on cell viability. 
 In general, compounds with more than four halogens (b), or without halogens 
(c), appear to be just slightly less toxic compared to their tetra-bromo (d) and tetra-
chloro (d) analogues. 
 In the case of tetramers with a central phenyl ring, it appears that the geometry 
is not particularly relevant (Figure 89). 
 
Figure 89. Effect of geometry on cell viability. 
 It is also interesting to note that increasing the number of monomers from four 
to six (Figure 90) results in less proliferation inhibition, while a reduction decreases 
cell viability. 
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Figure 90. Effect of the number of monomers on cell viability. 
5.2.4 Antiproliferative compounds as potential anticancer 
agents? 
 A small number of compounds caused complete inhibition of proliferation at 10 
µM concentration (Figure 91). The structures are closely related and characterised by 
an alkyl linker between the dimeric units. To evaluate their potential as antiproliferative 
agents, the IC50 of 207, 209, 210 and 212, was evaluated in HL60 cells. 
 
Figure 91. Tetramers with high anti proliferative activity. 
 The IC50 of the compounds tested, ranges between 3.1 and 3.7 µM, about one 
order of magnitude higher than doxorubicin (0.125 µM). More interesting is the fact 
that the structures present a substantially identical effect despite the length of the alkyl 
linker and the type of halogen. 
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5.3 Imaging 
 Since the great majority of the compounds studied are novel and display a 
certain degree of inhibition of proliferation, it was interesting to evaluate whether these 
can enter the cells effectively. A number of compounds are fluorescent, and are 
therefore easy to visualise by fluorescence microscopy. Their cell penetration was 
evaluated in MCF-7 cells, which are convenient for their size (compared to HL60) and 
the fact that they are adherent. 
 
Figure 92. Fluorescent compounds for imaging. 
 The compounds shown are 165, 187 and 143 (Figure 92). These are archetypal 
structures in the library, allowing us to assess penetration of basic tetramers (165), 
highly halogenated structures (187) and bis-phenols (143). 
The cells were treated at 500 µM concentration for 15 minutes, washed with 
media and then mounted on slides. Preliminary images appeared to show the compound 
concentrating in the nucleus, and thus a nuclear stain (Hoechst 33342) was employed 
to confirm the localisation. The counter-stain chosen is a DNA intercalator which emits 
blue fluorescence, which is different from the green or red fluorescence displayed by 
the test compounds. 
Compound 187, as every other highly halogenated compound in the library, 
exhibits strong fluorescence in DMSO and the colour changes by varying the pH. The 
effect is probably due to the acidic moieties and the effect is shared by other compounds 
in the library. It is also interesting to note that, differently from 165, its fluorescence is 
not specific to a single channel, and displays fluorescence in both green and red 
channels. 
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 The images in Figure 93, show penetration of compound 187 within MCF-7 
cells and a control. All cells are effectively stained by the compound. In contrast to what 
was expected from the preliminary evaluation, the compound appears to be localising 
mainly in the cytosol, without particular penetration through the nuclear membrane. The 
inside of the nucleus is fainter compared to its immediate surroundings.  
 
Figure 93. Fluorescence microscopy of MCF-7 cell treated with 187 and Hoescht 33342. 
 187 displays the same behaviour under the red filter (Figure 94). Similarly, MC 
126, also in red, localises mainly in the cytosol. Exactly as described for 187, the inside 
of the nucleus appears to be fainter. Compound 165, which is particularly bright, 
appears to be localising in the cytosol but also on the surface of the nucleus. Its 
fluorescence is also more specific and does not appear in the red channel. It could be an 
interesting compound for further investigation, to evaluate whether the staining is 
specific to particular structures (e.g. endoplasmic reticulum) and useful as a fluorescent 
probe, since it is cheap and easy to produce. 
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Figure 94. Fluorescence microscopy of MCF-7 cell treated with either 165, 187 or 143 and Hoescht 
33342.  
 Since it is confirmed that the compounds are able to penetrate the cells 
effectively and rapidly, both in the case of larger tetramers (more or less halogenated) 
and in the case of smaller dimers, it is reasonable to conclude that the antiproliferative 
effects observed may not be simply limited by their permeability and intracellular 
activity is very likely to be involved. 
5.4 Conclusions 
 The library was screened to evaluate the antiproliferative effects of the 
compounds available. A varied profile has been identified, with compounds displaying 
high proliferation inhibition (IC50 ~ 3 µM) and compounds without effects on viability 
at the tested concentrations (IC50 > 100 µM). 
 Compounds with lower toxicity are relevant for the development of antibacterial 
and antioxidant drugs. The small set of compounds with high antiproliferative activity 
may be an interesting lead to investigate a new class of potent xenobiotics. 
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 The ability of these compounds to permeate the cell has also been proven by 
fluorescence microscopy. Co-staining with a DNA targeting dye allowed verification 
that the compounds do not penetrate the nucleus. The prevalently perinuclear 
localisation of the compounds is worth further study to identify a potentially specific 
distribution to a defined cellular compartment. 
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5.5 Experimental 
5.5.1 Cell culture 
Both HL60 and MCF-7 cell lines were obtained from the European Collection 
of Cell Cultures. 
HL60 cells were cultured in RPMI-1640 medium (HyClone Laboratories), 
supplemented with 10% Fetal Bovine Serum (PAA Laboratories), 2 mM L-glutamine 
(HyClone Laboratories), 100 U/mL Penicillin and 100 μg/mL Streptomycin (HyClone 
Laboratories). 
MCF-7 cells were cultured in DMEM High Glucose medium (HyClone 
Laboratories) supplemented with 10% Fetal Bovine Serum (PAA Laboratories), 2 mM 
L-glutamine (HyClone Laboratories), 100 U/mL Penicillin and 100 μg/mL 
Streptomycin (HyClone Laboratories). 
Cells were maintained at 37 ºC in a humidified atmosphere with 5% CO2 and 
passaged at 1/20 dilution (HL60) or 1/10 dilution (MCF-7) twice a week.153 
Cell counting was carried out using a 1/2 dilution of cells with 0.4% trypan blue 
solution (Sigma-Aldrich) and a Malassez haemocytometer. 
5.5.2 Proliferation assay 
MCF-7 (8000 per well, 100 µL) or HL60 (30000 per well, 100 µL) in 96 well 
plates (Thermo-Scientific) were treated with 1 µL of serial dilutions of sample 
compounds or vehicle control (DMSO). The plates were subsequently incubated for 72 
hours in a humidified atmosphere at 37 ºC and 5% CO2. Cells treated with vehicle 
control were used as reference for 100% proliferation. 
The cells were then treated with 10 µL of CellTiter 96® AQueous One Solution 
Cell Proliferation Assay (MTS) (Promega) and incubated for either 1.5 hours (MCF-7) 
or 4 hours (HL-60). Absorbance was measured using the POLARstar OPTIMA plate 
reader (BMG Labtech) at 492 nm. Data analysis was performed with Microsoft Excel 
(percentage proliferation) and GraphPad Prism V6.0 (IC50 values). 
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5.5.3 Fluorescence Imaging 
 2 mL of MCF-7 cells (15000 cells/mL) were added to 6 well plates (Thermo-
Scientific) with one coverslip in each well. After 24 hours of incubation, each well was 
treated with either, or a combination of, 10 µL of sample (100 mM in DMSO), 4 µL of 
Hoechst 33342 (2.5 mg/mL in water) or vehicle. After 15 minutes of incubation, the 
cells were washed with fresh media and the coverslips were mounted on slides using 
DPX Mounting Medium (Fisher Scientific). Images were immediately recorded using 
a Leica DMII HC microscope. Image processing and postproduction was performed 
with Leica’s software and Adobe Photoshop CS6. 
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6. Antioxidant activity 
 Evaluation of the antioxidant effect of a substance is not a trivial problem, 
especially in a biological context. This is due to the complexity of the system under 
observation: the different origins of radicals, the varied type of radicals and pro/anti-
oxidant enzymes influence the results. Even compounds without significant reactivity 
versus radicals can act as cofactors of antioxidant enzymes (e.g. selenium in glutathione 
peroxidase), induce the expression or inhibit anti- or pro-oxidant enzymes or chelate 
metals with a resulting in-vivo activity. Additionally, the toxicity of the compound itself 
has to be taken into consideration. 
 Due to the multifaceted nature of the problem, a range of different assays have 
been published over the years. Many in vitro assays aim at measuring the activity of 
samples against model radicals, however, correlation with their activity in vivo may not 
be possible. 
 In this chapter, the results of a preliminary evaluation of the products previously 
synthesised against model radicals will be presented. Subsequently, a selection of 
compounds was tested for their in vivo protection against oxidative stress and the results 
are reported. 
6.1 Choice of the assay 
 As previously discussed (Chapter 1), for phenol-based structures reported in 
the literature, the activity in vitro is correlated with the number of hydroxyl groups. For 
this reason, the first assay was chosen to evaluate whether the trend is maintained with 
the compounds prepared and what influence the halogens have on these activities. For 
this reason, a simple and commonly used assay was required. 
Different assays to evaluate the antioxidant capacity of compounds, natural 
extracts or food samples have been published. In the following paragraphs, the assays 
will be described very briefly and discussed for their suitability as a starting point to 
evaluate the behaviour of the compounds presented in this thesis. 
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6.1.1 Inhibition of induced lipid auto-oxidation 
This assay evaluates the relative antioxidant efficiency of a sample, compared 
to that of α-tocopherol. Autoxidation of linoleic acid (or LDL) is induced by Cu(II) or 
2,2´-azobis(2-amidinopropane) dihydrochloride (AAPH) and progress of the reaction is 
monitored by UV absorbance at 234 nm (peak of maximum absorbance of diene 
peroxides). Before addition of the initiator, the absorbance remains constant (Figure 
95, A-B). After initiation, the autoxidation proceeds and the absorbance increases 
(Figure 95, B-C). The rate of the reaction is reduced by introduction of an antioxidant 
(Figure 95, C-D), and after its consumption the rate goes back to its original value 
(Figure 95, D-E). The authors defined the antioxidant efficiency as the slope of segment 
C-D (Figure 95) and can be reported as relative to a reference (α-tocopherol).154 
 
Figure 95. Autoxidation of linoleic acid monitored by UV absorbance. Initiator addition at point B, 
antioxidant addition at point C. 
The assay, despite the (apparently) interesting direct protection of a lipid type 
of substrate, has a number of major drawbacks. The first and main one is the wavelength 
used for monitoring the reaction. It is a limiting condition as many organic compounds 
(or their products) can display absorption around 234 nm.155 Secondly, measuring the 
change in rate might be difficult and require optimization.155 Given the chromophore of 
our compounds, this assay was discounted. 
6.1.2 ORAC, TRAP and PABA assays 
This group of assays involves the use of fluorescent probes to monitor the 
progress of the different radical reactions of interest. The oxygen radical absorbance 
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capacity (ORAC) assay underwent varied modifications to improve its performance and 
applicability. Naguib156 used a fluorescent reagent (6-carboxyfluorescein) which allows 
monitoring of reaction progress by spectrometry. AAPH initiates production of peroxyl 
radicals that consume the fluorescent probe over time, progressively reducing the 
emission to zero. The area under the kinetic curve obtained is linearly correlated to the 
concentration of a standard sample (usually α-tocopherol) used for calibration.  
The Total Peroxyl Radical-Trapping Antioxidant Parameter (TRAP) assay is a 
related assay which involves a fluorescent probe, R-phycoerythrin (R-PE, λem = 575), 
and AAPH. As with the lipid autoxidation assay, the reaction is slowed upon addition 
of a radical scavenger. In this case, the lag time is measured and reported as a function 
of the reference lag phase (Trolox, Figure 96). 
 
Figure 96. Structure of Trolox. 
The use of fluorescent probes, quenched by a radical and protected by a 
scavenger, is still being developed. 4-Aminobenzoic acid (PABA) assay has been 
published in 2014 and uses the same concept, although fluorescence is measured at a 
fixed time point, with a resulting different type of analysis.157  
Compared to the inhibition assay (Chapter 6.1.1), these methods are more 
practical, as they allow preparation of the sample and measurement, without 
intermediate steps. On the other hand, despite the availability of different fluorescent 
probes, the methods may result in potential interference by different compounds in the 
library (and their oxidation products). It is important to note that many of the products 
prepared in our study display fluorescence, of different nature and indeed variable with 
pH. In addition, considering the potential fluorescence of the oxidation products (among 
which could be fluorone like substances), fluorescence monitoring is not ideal.  
6.1.3 Ferric Reducing Ability of Plasma (FRAP) assay 
In this assay, a ferric-tripyridyltriazine complex develops colour upon reduction 
and the reaction is monitored at 593 nm (Scheme 81). The assay is run under acidic 
  
  239 
conditions, differently from other assays such as the Total Phenols Assay, which is 
conducted at basic pH. 
 
Scheme 81. Ferric-tripyridyltriazine complex, oxidised and reduced form. 
This assay was not suitable for our compounds for two reasons. Firstly, the 
presence of an excess of Fe(III) might interfere with the compounds in the library 
through co-ordination with the hydroxyl groups. Secondly, under acidic conditions the 
compounds display very poor solubility.158 
6.1.4 Cupric Reducing Antioxidant Capacity (CUPRAC) 
assay 
 In a similar fashion to the FRAP assay, the CUPRAC method is based on a 
chelated metal complex, in this case bis(neocuproine)copper(II) cation. The 
chromogenic probe turns orange yellow upon reduction of Cu(II) to Cu(I). Differently 
from FRAP, the working pH in this case is neutral.159 
The method has been developed extensively and presents varied modifications, 
including on-line HPLC applications.159 However, the colour of the chromophore is 
similar to that of many compounds in the library and, similarly to FRAP, interference 
because of the excess of metal raises doubts about the use of this method. 
6.1.5 Total Phenols Assay  
Despite its name, the total phenols assay by Folin−Ciocalteu reagent effectively 
measures the reducing capacity of a sample. The reagent, commercially available, is 
composed of yellow mixed heteropolyphosphotungstates-molybdates and turns blue 
(760-765nm) by addition of a reducing agent.160,161 
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The reaction is relatively slow, the colour develops slowly, reaches a maximum 
and then tends to fade. Nonetheless, with proper precautions readings between 1 and 6 
hours give similar analytical results. Despite the time required by the reaction, the 
method is flexible and can be scaled to the plate reader, making it very convenient. The 
assay has also been widely used on a variety of samples and is widely accepted, making 
it an interesting candidate for an initial screening, especially considering that none of 
the compounds in the library has absorbance in the same range.160,161 
6.1.6 2,2-Diphenyl-1-picrylhydrazyl (DPPH) radical 
Scavenging Capacity assay 
2,2-Diphenyl-1-picrylhydrazyl radical (DPPH) is a relatively stable, nitrogen 
centred, radical and is commercially available as a solid crystalline material. DPPH 
solutions exhibit a strong purple colour with an absorption maximum at 512 nm. 
Reaction with a scavenger reduces the absorption at the maximum, with the solution 
turning progressively yellow. The progress of the reaction, activity of the sample and 
other parameters have been reported in different ways. A typically reported parameter 
is IC50 (or EC50), representing the concentration of sample required to decrease the 
initial absorbance of DPPH by 50% at a specific time.162 The time is usually chosen 
between 1 and 10 minutes, making the assay very quick and accessible. 
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Figure 97. UV profile of the progressive conversion of DPPH into DPPHH. 
 This assay has been widely used to test natural products, some of these have 
been discussed in the introduction (Chapter 1). An interesting feature of DPPH is that, 
due to its nature, it can be also identified and quantified by electron paramagnetic 
resonance (EPR), which offers an alternative and potentially discriminating quantitation 
approach against colourful samples or reaction products.163 Alternatively, an 
amperometric determination method is available.164,165 
However, it is necessary to note that this approach is not useful for prediction of 
the in vivo protective effects of a sample, especially when emphasis is given to reaction 
stoichiometry rather than reaction kinetics and antioxidant chemistry.166 Nonetheless, 
our initial attention was focused precisely on stoichiometry, to evaluate the ability of 
different, but closely related, structures to scavenge a model radical. As subsequently 
presented, in vivo protective studies evaluate the real protective effect in cells. The assay 
was chosen as a starting point and will be further discussed in context with the results. 
6.1.7 Trolox Equivalent Antioxidant Capacity (TEAC) assay 
 The TEAC assay is based on another stable radical, prepared by oxidation of 
2,2′-Azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) diammonium salt with 
potassium persulfate in water (Scheme 82). The reaction produces a strong green-blue 
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and working solutions can be prepared when necessary. The absorption spectrum 
presents two main peaks, at 415 and 734 nm, with the latter being particularly relevant 
as most interference happens at shorter wavelengths.167 
 
Scheme 82. Synthesis of ABTS+•. 
 The parameter usually reported for reference is the TEAC, which is the 
concentration of sample giving the same percentage inhibition of 1 mM Trolox. This is 
normally evaluated at fixed time points, usually less than 30 minutes.166,167 
 Due to the nature of the radical, as in the case of DPPH, there are limitations to 
be considered and thus, this assay was used as alternative to DPPH. Further information 
about these issues will be provided with the results. 
6.1.8 In Vivo Cell Protection Assay 
 Because of the difficulties in estimating potential protective effects from in vitro 
assays, some of the compounds were directly evaluated for their potential protective 
effects in cell lines using an adapted MTS assay. 
6.2 Results and Discussion 
6.2.1 DPPH assay 
DPPH assays have been run in different protic solvents including methanol, 
methanol and water (also buffered or pH adjusted) and ethanol, although other studies 
have been conducted in aprotic solvents, e.g. acetone and benzene.162-166,168 In these 
studies, ethanol was chosen as it can dissolve all, but one, of the compounds in the 
library, thus maintaining constant conditions for all samples. 
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6.2.1.1 Initial evaluation 
 The first step was to compare the total scavenging capacity of all compounds. 
However, the reaction of DPPH with reducing agents is not always as fast as would be 
expected of strong reducing agents. For this reason, initial time course studies were run 
to evaluate whether the reaction reaches completion within a reasonable amount of time. 
 
Figure 98. Sample compounds for the initial evaluation of DPPH radical scavenging assay. 
 The compounds chosen were 163 and 142, being model structures of almost the 
entire library (Figure 98). The test compounds at 10 µM concentration were allowed to 
react with DPPH (150 µM) and the reaction was followed at 512 nm for 10 hours. In 
Figure 99, the percent of DPPH consumed (calculated as in Equation 1) is plotted 
against time. 
 
Figure 99. Time course profiles of the reaction between DPPH (150 µM) and sample compounds 
monitored at 512 nm. 
163 (10 µM)
142 (10 µM)
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% of DPPH consumed = 100 – (At × 100 / At=0) (1) 
 
At = absorbance measured at time t 
At=0 = initial absorbance 
Equation 1. Calculation of the percent of DPPH consumed. 
 
From Figure 99, it is clear that the reaction does not reach a plateau, which 
means it is not complete within the time frame of the analysis. The rate of the overall 
consumption of DPPH is not constant over time and progressively decreases. Since the 
radical is relatively stable, the decrease in absorbance might be due, in part or 
completely, to its decomposition. This is evident for Trolox, for which the reaction is 
complete almost immediately. Figure 100 shows decomposition of DPPH over time, in 
the same conditions, 142 and Trolox are reported again for scale comparison. 
  
 
Figure 100. Comparison between the scavenging effect of two sample compounds and the 
decomposition of DPPH. 
 At 600 minutes, the decomposition of DPPH reached 5%, which is considerable 
compared to the 22% consumption seen with sample 142.  The rate of decomposition 
of DPPH slows down over time, as highlighted by a linear correlation in Figure 100. 
Consistently with what has been previously reported, the decomposition of DPPH in 
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reported that the decomposition is slowed down by reaction products (undefined) 
between DPPH and solvent.169 Decomposition of DPPH is faster in the presence of light 
and oxygen,170 hence using degassed solvent, inert atmosphere and reduction of 
sampling might help to partially reduce the decomposition of DPPH, although a 
different solvent would probably be a better solution to the problem, especially 
considering that the use of ethanol has the result of reducing the effective amount of 
DPPH available for the reaction, as previously reported.164  
 Since the decomposition of the probe is significant, subtraction of its 
contribution from the sample could be attempted to evaluate whether the steady state of 
the reaction is not reached as a consequence of DPPH behaviour. However, since the 
decomposition is concentration-dependent, the effect on the sample would be 
approximate and not consistent from sample to sample. The sample would react with 
DPPH consuming a part of it, thus altering the decomposition rate of DPPH itself.  
6.2.1.2 Effect of Halogen and Geometry 
 Despite the considerable limits of the assay, a small set of compounds (Figure 
101) was tested to evaluate the effect of different geometry and halogen substitution on 
the reactivity towards DPPH. Since a steady state cannot be reached, the compounds 
were all tested at the same concentration and the progress of the reaction was followed 
for a fixed three hours. 
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Figure 101. Compounds for the evaluation of halogen and geometry effects on DPPH scavenging 
activity. 
 From the results shown in Figure 102, the activity of the compounds is split into 
two clusters. Non-halogenated 183 and fluoro derivative 168 have about twice as much 
activity as the other compounds. Lack of substitution might increase the reactivity 
towards DPPH due to reduced steric hindrance, a limiting factor, as previously 
described. Additionally, an activated position is also available for further reaction, as 
described for eugenol and proposed for these compounds in Chapter 6.2.1.3. Fluorine-
substituted compounds might display such high activity due to their higher acidity. 
Since dissociation influences the reaction, higher phenolate concentration produces 
higher rates. In fact, it appears that during the initial phase of the reaction the rate of 
DPPH depletion is higher in the case of 168, whilst 183 reacts slower but eventually 
reaches a higher value. 
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Figure 102. Progress of the reaction between DPPH (150 µM) and sample compounds (20 µM) 
monitored at 512 nm.  
 Geometrical isomerism does not appear to be significant, with 163, 164 and 165 
behaving almost identically, with only 164 displaying a slightly higher activity. This 
might be due to its inability to oxidise to a quinoid type structure. For these compounds, 
at 500 minutes (Figure 103), the activity profile is the same. 
 
Figure 103. DPPH consumed (initial concentration 150 µM) by sample compounds (10 µM) after 500 
minutes. Measures in triplicate and error expressed as standard deviation.  
 From these results, however, it is interesting to note how increased activity is 
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compounds, all activated positions on the bis-resorcinols are substituted with halogens. 
A possible explanation of this might be, as in the case of 168, linked to the acidity of 
the hydroxyl groups. Electron withdrawing groups increase the acidity of the hydroxyl 
groups, thus increasing their reactivity. The activity, however, may be limited by the 
increased steric hindrance of the halogens or the fact that additional reactive positions 
are occupied, explaining the relatively poorer performance of 181, 186 and 187. 
Additionally, the nature of the halogen is not relevant, substitution of chlorine atoms 
with bromine produced no effect (181, 186 and 187). 
 Compound 180 is interesting as it suggests that, at least within the timeframe 
considered, a large bis-resorcinol unit may be replaced with a smaller, different 
substituent whilst retaining its total scavenging activity. 
6.2.1.3 Solvent effects and Reactions with DPPH 
To explain the slow reactivity of the sample compounds, the chemistry of the 
reaction of DPPH with phenols will be described. A first element to consider is the 
structure of DPPH. The access to the N-centred radical is limited by the considerable 
steric hindrance of the substituents it bears. This is also a contributing factor to the 
stability of the radical itself, together with delocalisation. The molecules in this study 
are complex and present hardly accessible sites, thus reducing the interaction 
possibilities. 
 
Scheme 83. HAT and ET reactions shown on eugenol. 
Analysis of samples in different solvents revealed that reaction rates of phenolic 
compounds changed in different solvents, in particular it increases in hydrogen bonding 
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solvents.171 In methanol and ethanol, reaction of DPPH with phenols appears to be 
predominantly of electron transfer (ET) nature, with the rate-determining step being the 
transfer of an electron from the phenoxide anion to DPPH, rather than a hydrogen atom 
transfer (HAT) (Scheme 83). This is relevant as pH and its changes during the reaction 
might lead to different results and also highlights the potential effect of acidic or basic 
impurities.171-173 On the other hand, if necessary, the reaction might be investigated at 
different pH (or in a non-hydrogen-bonding solvent) to evaluate the contribution of the 
different mechanisms, in particular of HAT, which is considered the terminating process 
for biologically relevant peroxyl radicals.166,172 
 Simple chain-terminating reactions, proposed by the original author of the assay, 
should end the reaction by dimerization. Since termination by dimerization of DPPH 
(Scheme 84, a) is forbidden by steric hindrance, the remaining options are reaction of 
aroxyl radical with itself (Scheme 84, b) or with DPPH (Scheme 84, c).162 
 
Scheme 84. Termination reactions for DPPH. 
 However, in the case of non-minimal structures or weak reducing agents, some 
of these transformations can be slow and/or reversible, becoming limiting in the kinetics 
of the process, and other reactions can be involved. An example is a relatively simple 
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Scheme 85. Reactions of BHT with DPPH. 
 The reaction, represented in Scheme 85, involves a number of routes, mostly 
reversible. Initial and reversible reaction of BHT with DPPH leads to an aroxyl radical 
(a), which can delocalise a hydrogen atom in a slow reaction, which is rate-determining 
(b). Reaction with a second equivalent of DPPH leads to either a quinoid compound (c) 
or a DPPH bound structure (d). Alternatively, a dimerization step can occur (e), 
eventually leading to an oxidised bi-quinoid structure (f). The path is consistent with an 
experimental stoichiometric ratio DPPH/BHT of 2.8 (calculated is 3).174 
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Scheme 86. Reactions of eugenol with DPPH. 
 A mechanism has also been proposed for eugenol (Scheme 86). In this case, 
excluding equilibrium reactions similar to those of BHT, in which DPPH binds the 
reagent, a radical aromatic coupling is proposed (a).174 This is an additional interesting 
possibility to account for in regards to the compounds to be discussed. 
An interesting cyclisation of garcinol by reaction with DPPH was reported by 
Sang (Scheme 87).175 This is a further point of inspiration, as potential cyclisation steps 
may be involved. In particular, considering that DDQ mediated oxidative cyclisation is 
known to convert bis-resorcinols to their fluorone derivatives, as reported by Bacci.76 
 
Scheme 87. DPPH mediated cyclization of garcinol. Only the relevant fragment is reported.175 
Other authors have proposed additional reactions, including oxidation of 
catechol and gallate derivatives to their quinones,176 and substitution of nitro groups of 
DPPH by syringaldehyde/methyl syringate.177 
Based on the described studies, an oxidation mechanism for an example 
compound is proposed in Scheme 88. Similarly to BHT, abstraction of an electron from 
a hydroxyl group (a) and subsequent delocalization of a hydrogen (b) could lead to a 
triarylmethyl radical, the most classic type of organic radical (triphenylmethyl radical 
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was the first organic radical discovered).178 Upon abstraction of a second electron (c), a 
quinoid structure can be obtained. Repetition of the first two steps (d,e) could produce 
an equivalent quinoid structure on the other half of the tetramer. Up to this point, 4 
equivalents of DPPH are theoretically consumed. After 500 minutes, from the data 
previously presented, it is possible to calculate that almost 3 equivalents of DPPH have 
been consumed by 163. To push the reaction to completion and better evaluate the 
stoichiometry, it could be necessary to reduce the amount of sample in the reaction, 
prolong the reaction time and change the solvent to methanol. Use of basic conditions 
could also speed up the reaction, although different reactions might be observed. 
Identification or isolation of intermediates would also be ideal to prove the proposed 
mechanism. 
 
Scheme 88. Proposed reactions for tetramer 163. 
 However, the reaction probably produces an additional range of products. 
Undoubtedly, intermolecular cyclisation to xanthone by nucleophilic attack of a 
hydroxyl group (Scheme 89) to an adjacent carbonyl is possible, although the rate is 
probably limited by the absence of an acid catalyst, which would increase the rate of 
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proton delocalization and water elimination. Additional reactions may involve 
dimerizations and less favoured intermediates. 
 
Scheme 89. Cyclization to fluorone. 
 Compound 168, at 500 minutes, has consumed about 4 equivalents of DPPH, 
suggesting that this stoichiometry can indeed be matched. Due its higher reactivity, this 
compound may be a better model than 163. 
Differently from 163, the amount of DPPH consumed by 183 after 500 minutes 
is about 5 equivalents. The higher reactivity is probably due to the lower steric 
hindrance in the absence of the chlorine substituent and the additional, highly activated 
positions available in its stead (Figure 104). This position suggests possible 
intermolecular reactions similar to those illustrated for eugenol, pushing the 
stoichiometry of the reaction beyond that accessible by its halogenated analogues. 
 
Figure 104. Compound 183. 
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6.2.2 TEAC assay 
 TEAC assay, based on the reaction with ABTS+•, was chosen as the second 
option for the screening of the library. It is a convenient assay but the mechanistic 
aspects of its reactivity are not as well-known as in the case of DPPH and different 
behaviours towards the same antioxidants have been identified. Thus, it makes an 
interesting element of comparison. However, as with DPPH, it must not be considered 
predictive of in vivo activities, and only as a method to compare reactivity. 
In the case of ABTS+•, instead of preparing a solution of known concentration 
as in the DPPH assay, the standard approach consists of preparing a stock solution, 
which is then diluted to obtain an absorbance of 0.7±0.02 (734 nm) for the working 
solution (water as solvent).167 The assay for the screening involves incubation of 1 mL 
of ABTS+• with 10 µL of sample/reference in ethanol (or ethanol only for the blank) at 
30 °C and reading of absorbance (734 nm) after a predetermined amount of time. 
6.2.2.1 Initial evaluation 
Initially, since DPPH displayed a significant and non-linear decomposition 
within the considered timeframe, the behaviour of ABTS+• was evaluated. ABTS+• 
solutions were prepared at two different concentrations, one being half of the other and 
incubated with a blank of ethanol for 10 hours (Figure 105). 
 
Figure 105. Decomposition of ABTS, starting from two different concentrations. 
y = -3×10-05X + 0.7253
R² = 0.9966
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 Decomposition of the probe is reasonably linear, with a total variation of 2.6-
3.4% over 10 hours. The rate of decomposition is also very similar at different 
concentrations, suggesting that subtraction of ABTS+• contribution to a sample’s 
activity may be a reasonable approximation. 
6.2.2.2 Screening 
 The course of the reaction for a set of compounds was followed over ten hours 
to verify whether the reaction reaches completion. As with DPPH, the progress of the 
reaction is slow and plateau is not reached. Since the process is time consuming and not 
in line with a simple screening, a different approach was considered. Each sample in 
the library was tested, using the same method, at the same concentration (1 µM), at 10 
minutes and 10 hours providing a general trend for comparison. Since the 
decomposition of ABTS+• is substantially linear, its contribution to the sample activity 
is considered equal for all samples and thus ignored. The results of the screening is 
reported in Table 7 and then discussed in detail. 
Name 10 min  10 h Name 10 min 10 h Name 10 min 10 h 
107 14 30 158 21 57 198 21 26 
109 19 31 160 21 40 207 21 46 
111 15 22 163 22 62 208 24 47 
116 14 18 164 23 46 209 22 47 
135 20 25 165 20 46 210 17 45 
136 10 41 166 6 12 211 19 50 
138 13 13 167 16 23 212 20 52 
140 12 33 168 26 41 217 36 76 
141 15 29 180 10 24 218 35 63 
142 16 30 181 24 47 220 14 33 
143 13 31 182 23 51 222 5 25 
144 16 34 183 40 82 225 1 7 
145 12 28 184 37 50 241 9 25 
146 18 26 185 34 60 242 7 8 
147 17 22 186 22 37 243 0 4 
148 15 23 187 19 31 246 0 1 
149 20 22 188 20 41 248 26 31 
150 15 29 192 17 50 NaAsc 3 3 
151 16 28 193 15 45 Trolox 5 4 
154 10 22 194 35 57   
 Table 7. Summary of the scavenging activity of the tested compounds (1 µM), expressed as % of 
ABTS consumed, after 10 minutes and after 10 hours. Colour scale ranges from low activity (red) to 
high activity (blue). NaAsc = Sodium Ascorbate. 
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6.2.2.3 Family comparison 
A first comparison can be made for the different families, to evaluate whether 
the increase in complexity leads to an increased scavenging activity. From every family 
a compound with the same halogenation pattern was chosen for the comparison (Figure 
106). 
 
Figure 106. Different families of compounds, each with a representative structure. 
 Overall, as illustrated in Figure 107, activity increases progressively from the 
monomer (116), through the bis-phenol (135), tetramer (158), and hexamer (217). It is 
interesting to note, however, that at 10 minutes the difference between bis-phenol and 
tetramer is minimal, suggesting that although the tetramer can eventually consume a 
larger amount of radical, it does it at an apparently slower rate. A phenyl sidechain on 
the bis-phenol, as in dimer 151, produces a lower initial rate, while increasing the total 
amount scavenged at 10 hours. The benzophenone 241 has a considerably slower rate 
at the beginning, losing about 10% activity against its parent bis-phenol. Compound 
244 could not be compared as it is the only sample not soluble in ethanol. Arguably, as 
a consequence of the number of hydroxyl groups, the hexamer is the top-performing 
scaffold, with about 20% more activity over the tetramer. It appears that by increasing 
the number of bis-phenol units, the ABTS radical scavenging activity is indeed 
improved.  
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Figure 107. ABTS scavenging activity of compound families’ representative structures. 
6.2.2.4 Xanthones comparison 
 
Figure 108. Xanthones. 
Xanthone 244, due to its unexpectedly poor solubility, could not be tested with 
the previous compounds. On the other hand, its structural isomer 246 is soluble in 
ethanol. Compounds 246 and 243 have negligible activity, with only 1% and 4% 
inhibition, respectively, at ten hours. By inference, 244 is also probably inactive, 
making the xanthone group the least interesting for the activity against ABTS+•. Only 
222, bearing three hydroxyl groups instead of two, has an average activity of 25% after 
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Figure 109. ABTS scavenging activity of xanthones. 
6.2.2.5 Benzophenones comparison 
The open analogues of xanthones, benzophenone (Figure 110), provide a 
slightly better profile. The best compound of the group, 220, consumes 14 % DPPH and 
reaches 33 % inhibition after 10 hours (Figure 111).  
 
Figure 110. Benzophenones. 
 Interestingly, the activity decreases with an increasing number of halogens. The 
behaviour is diametrically opposed to that observed with DPPH, which is scavenged 
better by highly halogenated derivatives. In the present case, however, the increased 
steric hindrance caused by introduction of halogens might be hindering the progress of 
the reaction. An additional/alternative possibility is related to the acidity. Presence of 
more electron-withdrawing groups increases the acidity of the compound. If the 
reactions with ABTS were mainly driven by HAT processes, the reactivity would be 
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Figure 111. ABTS scavenging activity of benzophenones. 
6.2.2.6 Bis-phenols comparison  
Reduction of the benzophenones to bis-phenols in Figure 112, produces a better 
ABTS+• scavenging activity with a minimum of 10% for 136 at ten minutes, which 
appears to be reacting slower than its analogues but reaches a higher total amount of 
scavenged radical after 10 hours. The compound without bromine substituents, 248, 
appears to be the best performing at 10 minutes, with 26% inhibition (Figure 113). 
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Figure 113. ABTS scavenging activity of bis-phenols. 
6.2.2.7 Dimers comparison 
 
Figure 114. Dimers with different sidechains. 
A substitution on the bridge of bis-phenols with a sidechain, as in the case of 
dimers (Figure 114), does not provide any real advantage over bis-phenols, at least for 
the activity at 10 minutes. However, they have a better profile at 10 hours, with 
inhibitions between 22% (149) and 34% (144), suggesting that the sidechain might 
increase the total amount of radical that can be scavenged. Compound 149 (highlighted 
in Figure 115) is interesting as it is the only example of a complete reaction at 10 
minutes. It tops all other samples at 10 minutes but has a smaller total scavenging 
capacity, when its activity at ten hours is compared with that of its analogues.  It might 
be an interesting compound to further evaluate the chemistry of the reaction, thanks to 
























136 135 248 Trolox
  
  261 
 
Figure 115. ABTS scavenging activity of dimers with different sidechains. 
 The position of the substituent on the aromatic ring, at least for the compounds 
evaluated, does not seem to play a relevant role on the activity, with 145 and 146 
producing very similar results despite bearing the carboxylic acid in para and meta, 
respectively. The same can be said for 148 and 147, with a fluorine substituent in ortho 
and para, respectively. 
 Compound 140 is interesting as it does not bear an aromatic sidechain. Although 
it provides the poorest activity within the group, along with 145, at 10 minutes (12%), 
it is also the second best scavenger of the group, with 33% ABTS+• consumption after 
ten hours. Thus, it appears that the type of aromatic groups used is not particularly 
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Figure 116. Dimers with different halogens. 
Regarding the difference between bromine and chlorine substituents (Figure 
116), it has to be noted that there is only a few percentage points difference between the 
compounds with either halogen (Figure 117). More relevant is the fact that bromine 
appears to produce in most cases an initially slightly higher rate (109 > 144, 107 > 140, 
111 > 143) but smaller final activity. The suggestion would have to be confirmed with 
more data to verify if the difference is statistically significant. 
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6.2.2.8 Tetramers comparison 
 
Figure 118. Tetramers with different halogens. 
As previously said in the comparison between families, increasing the number 
of resorcinol units from two to four yields a good improvement in activity. In the case 
of tetramers (Figure 118), at 10 minutes the activity ranges between 20% and 40% of 
ABTS+• inhibition and after 10 hours is between 30% and 80% (Figure 119). 
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In this class we found the best performing compound, 183, with 40% inhibition 
at 10 minutes and 82% at 10 hours. It is the compound with the highest apparent radical 
consumption rate at the beginning and presents the best sample-ABTS+• stoichiometric 
ratio. This might not be simply related to the scarce steric hindrance compared to chloro 
and bromo derivatives. The fluoro substituted 168 does not perform anywhere near it, 
with 26% and 41% inhibition, respectively at 10 and 600 minutes. It is interesting to 
note that also 186, very hindered and with two electron withdrawing groups, performs 
similarly to 168. 
In the DPPH assay, the fluorinated 168 and the octa-halogenated 186 perform 
better than their tetra-chloro and -bromo analogues, 163 and 158 respectively. As 
discussed for benzophenones, the increased acidity conferred by strong electron-
withdrawing groups (fluorine, for 168) or increased number of halogens (for 186), could 
reduce the reactivity towards ABTS, suggesting that hydrogen atom transfers are more 
relevant to this reaction than electron transfer mechanisms. 
 
Figure 120. Tetramers with different geometries.  
Geometry (Figure 120) does not affect the activity as much as halogen 
substitution. At 10 minutes, compounds 163, 164 and 165 display a very similar 
behaviour, with about 22% inhibition. Only at 10 hours, 163, the para isomer, displays 
a slightly higher activity (62%) than 165 and 165 (46%) (Figure 121). 
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Figure 121. Activity of tetramers with different geometries. 
6.2.2.9 Biaryls comparison 
 
Figure 122. Biaryl tetramers and shorter analogues. 
 Replacement of the phenyl core of the previous tetramers with a biaryl (Figure 
122) does not provide any beneficial effect (Figure 123). If we compare 163 with 198, 
the activity after 10 minutes is similar, but the final consumption of ABTS+• for 163 is 
superior by 36%. In the case of 164 and 193, the substitution of the phenyl ring with a 
biaryl produces a lower activity (-8%) at 10 minutes. Surprisingly, considering that a 
meta substituted core is unlikely to oxidise as a para substituted one, 193 provided a 
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Figure 123. ABTS scavenging activity of biaryl tetramers and shorter analogues 
 As for the phenyl-core tetramers, 4-chloro- and 4-bromoresorcinol based biaryl 
tetramers (193 and 192, respectively) show similar profiles (Figure 124, Figure 125). 
Their dehalogenated analogue (194), on the other hand, produces a much better profile 
especially at 10 minutes. The result is in line with all the other non-halogenated 
tetramers. 
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Figure 125. ABTS scavenging activity of biaryl tetramers with different halogens. 
6.2.2.10 Alkyl-linked Tetramers Comparison 
 
Figure 126. Alkyl linked tetramers. 
 The last group of tetramers is constructed around alkyl-linked aryls (Figure 
126). All the compounds in the series produce a very similar profile, with about 20% 
activity at 10 minutes and 45% at 10 hours (Figure 127). As expected, the length of the 
alkyl linker does not affect significantly the reactivity, since it is unlikely to undergo 
oxidation. The result also underlines again that the difference produced by substituting 
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Figure 127. ABTS scavenging activity of alkyl linked tetramers. 
6.2.2.11 Hexamers Comparison 
 
Figure 128. Hexamers. 
The last group of compounds evaluated was the hexamers. These compounds 
bear six resorcinol units and, despite the halogen substituents, provide considerable 
ABTS+• scavenging activity (Figure 128, Figure 129). The activity at 10 minutes of 
both structures ranks among the non-halogenated tetramers, providing some of the best 
results. At 10 hours, compounds 217 and 218 are the second and third most active 
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Figure 129. ABTS scavenging activity of hexamers. 
6.2.2.12 SAR summary 
 The discussed reactivity with ABTS+• can be generalised and summarised as 
follows. For resorcinol dimers (Figure 130), the activity increases from benzophenone 
to bis-phenol. The activity of the bis-phenol is comparable to that of its analogues with 
an aromatic sidechain. 
 
Figure 130. Effect of the bridge substituent in resorcinol dimers. 
 The number of resorcinol units (Figure 131) is critical for the activity, which 
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Figure 131. Effect of the number of resorcinol units on the activity. 
 The halogen substituent (Figure 132) is important to the activity, with 
dihalogenated and fluorinated structures providing the lowest activity. A better profile 
is provided by chloro and bromo derivatives, having similar activities. Non-halogenated 
compounds are clearly superior to the previous in their scavenging activity. 
 
Figure 132. Effect of the halogen on the activity. 
 Geometry of the tetramers is relevant (although only at 10 hours), with the para 
substituted structures providing the best results, while meta and ortho have comparable 
activity (Figure 133). 
 
Figure 133. Effect of the geometry of tetramers on the activity. 
 Replacement of the phenyl ring of tetramers with biaryls or akyl-linked aryls 
does not result in enhanced scavenging activity (Figure 134). 
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Figure 134. Effect of the central linker on the activity of tetramers. 
6.3 Biological evaluation of protective activity 
 Although the previous assays provide a guideline about the ability of our 
compounds to scavenge specific radicals, the real protective effect in vivo cannot be 
simply correlated to the data available and requires evaluation in a biological system. 
For this purpose, the previously described MTS assay (Chapter 5) was adapted to 
measure the potential protective effect of a selected set of compounds. The method 
employed is based on approaches reported by Liu179 and Zhao.71 In Liu’s report, ARPE-
19 cells were treated with serial dilutions of the test compound, incubated for 24 hours, 
and then stressed with tert-butylhydroperoxide (tBuOOH) for 4 hours. After washing 
the cells, and an additional 20 hours of incubation, the proliferation was measured by 
MTT assay and compared with the control (untreated cells, 100% proliferation) and the 
reference (stressed cells without test compound). A similar approach, with HUVEC 
cells and hydrogen peroxide, was used by Zhao to test the protective effects of natural 
brominated phenols, as described in the introduction. 
In contrast to these methods, in our experiments the cancer cell line MCF7 was used as 
this had previously been used in proliferation experiments and allowed us to choose 
compounds with a proven, low antiproliferative effect. MCF7 are also adherent cells, 
which allows washing the cells after treatment. The second modification to the method 
is relative to the time of incubation with the sample compound before the stress event. 
In the published record by Liu,179 the activity of the compounds is related to the 
expression of antioxidant enzymes. In our case, the compounds are expected to be, first 
of all, direct antioxidants, due to their similarities with natural phenol-based 
antioxidants. For this reason, the incubation with the sample compound was reduced to 
4 hours, which appeared a reasonable amount of time to obtain through diffusion of the 
sample. The same incubation time was also used by Zhao71 for their assay with 
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brominated phenols. Finally, the reagent used was MTS, as previously employed with 
the initial proliferation assessment. 
 
Figure 135. Assay model. 
 To be able to identify a protective effect or an increased cytotoxicity caused by 
the combined effects of the pro-oxidant tBuOOH and the sample compound, an 
idoneous concentration of hydroperoxide has to be identified. As illustrated in Figure 
135, we aimed to identify a concentration which reduced the proliferation to about 40%. 
With this reference, it is possible to observe both a protective effect and a cytotoxic 
effect, with a slightly larger chromatic range for the first. 
 
Figure 136. Effect of different tBuOOH concentrations on proliferation. 
 To identify such a concentration, the IC50 of tBuOOH was initially measured 
(Figure 136). With an IC50 of 44 µM, initial assessment of protective effect was 
evaluated with a peroxide concentration of 50 µM. Unexpectedly, the proliferation 
versus the control was higher than before and measured 88%. The result may be a 
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changes in the cell line over time. For this reason, the execution time was reduced to a 
minimum, with all compounds tested on a single day, from the same stock of peroxide. 
The required concentration of peroxide was found at 70 µM, providing a proliferation 
of 48%, and a small set of compounds (Figure 137) was evaluated. These were chosen 
among those with poor antiproliferative effect against MCF7 and were tested at three 
different concentrations, to highlight potential concentration dependent trends. The 
basic 4-bromoresorcinol (116) was also tested as a reference. The results are 
summarised in Figure 138 and reported separately for each individual plate, instead of 
normalised, for clarity of information. 
 
Figure 137. Structures tested for protective effects. 
  Compound 136, a simple tetrabrominated bis-resorcinol, showed a protective 
effect at 10 µM and 20 µM, with an improvement in proliferation from 48% to 65% and 
88%, respectively. 
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Figure 138. Effect of different compounds (at three different concentrations, each one in triplicate), on 
MCF-7 cells treated with tBuOOH. Error expressed as standard deviation. 
 Unfortunately, all other compounds presented a lower proliferation compared to 
the reference peroxide. It is interesting to note how 194 displayed a strong synergistic 
effect with tBuOOH. As reported in Chapter 5, the proliferation in MCF7 treated with 
194 is 96% at 10 µM concentration. In the presence of tBuOOH, all tested 
concentrations including 5 µM, produced complete cell death. 
6.4 Conclusions 
 The library of compounds available was tested for its radical scavenging activity 
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 In both DPPH and ABTS radical scavenging assays, the compounds 
demonstrated a relatively slow reaction rate but higher activity compared to the 
reference, thus demonstrating potentially interesting as antioxidants. 
 On the other hand, the small set of compounds tested in vivo did not provide the 
desired results, with only one compound, 136, providing protection against oxidative 
stress. It would be interesting to evaluate additional analogues and more concentrations 
to identify more active compounds and potentially, a structure activity relationship to 
better understand the required functionalities. The compounds could also be tested after 
longer incubation times, to allow evaluation of potential changes in expression leading 
to different results. 
 Compound 194 may be an interesting compound to investigate further due to its 
interesting synergic effect with the oxidant, which is unexplained at present and might 
lead to a specific mechanism of action. 
Considering the similarity of some of the compounds in the library with the 
compounds tested by Zhao,71 the results are disappointing. Among his compounds, 99b 
and 96b (Figure 139), display considerable protective effects, with an EC50 of 0.4 µM 
and 0.8 µM, respectively. 
 
Figure 139. Lead compounds by Zhao.71 
 It is probably worth investigating a larger number of compounds and extend the 
trial to other types of cells, HUVEC (as in Zhao’s work) or ARPE-19, which are 
possibly more suitable for this type of investigation, compared to MCF-7. 
 Despite the poor results in vivo obtained to date, these compound may be also 
interesting as radical scavengers/antioxidants or photo resistant additives in 
materials.180 
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6.5 Experimental 
Chemicals and reference compounds were purchased from Sigma-Aldrich, 
Fisher Scientific and Alfa Aesar. UV-Vis measures were recorded on a Agilent 
Technologies Cary 60 UV-Vis with Quantum North West TC1 temperature controller 
for the DPPH assays, and on a Hitachi U3010 Spectrophotometer for the TEAC assays. 
Water solutions were prepared with Milli-Q water. 
6.5.1 DPPH assay 
 DPPH scavenging activity was determined as previously described by 
Balaydin,181 with minor modifications. Briefly, a 200 µM solution of DPPH was freshly 
prepared on the day and kept in the dark. Samples were prepared as 10 mM stocks in 
ethanol and diluted to working solutions at 80 µM concentration. For the measures, 250 
µL of sample, or ethanol for the reference, were added to 750 µL of DPPH and vortexed 
for 20 seconds. In the case of time-courses, the sample was transferred to a cuvette, 
sealed, and readings were started at 60 seconds. In the case of single time-point 
measures, the sample was kept in the dark and read at the appropriate time. Absorbance 
was recorded at 512 nm. 
6.5.2 TEAC assay 
 ABTS scavenging activity was recorded as previously described by Re,167 with 
minor modifications. ABTS stock solution was prepared by reaction of an aqueous 
solution of ABTS diammonium salt (14 µM) with an aqueous solution of potassium 
persulfate (4.90 µM) in 1:1 ratio for 16 hours. The stock solution was diluted to an 
absorbance of 0.7 with water. Samples were prepared in ethanol. For the measures, 1 
mL of ABTS working solution was equilibrated at 30 °C and then 10 µL of sample, or 
ethanol for the reference, were added and vortexed for 10 seconds. Samples were then 
incubated in the dark at 30 °C for the required amount of time. Absorbance was then 
read at 734 nm. 
6.5.3 Cell culture 
MCF-7 cell line was obtained from the European Collection of Cell Cultures. 
MCF-7 cells were cultured in DMEM High Glucose medium (HyClone 
Laboratories) supplemented with 10% Fetal Bovine Serum (PAA Laboratories), 2 mM 
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L-glutamine (HyClone Laboratories), 100 U/mL Penicillin and 100 μg/mL 
Streptomycin (HyClone Laboratories). 
Cells were maintained at 37 ºC in a humidified atmosphere with 5% CO2 and 
passaged at 1/10 dilution twice a week.153 
Cell counting was carried out using a 1/2 dilution of cells with 0.4% trypan blue 
solution (Sigma-Aldrich) and a Malassez haemocytometer. 
6.5.4 MTS with tert-butyl hydroperoxide 
96 well plates (Thermo-Scientific) were prepared with MCF-7 cells (10000 per 
well, 100 µL) in serum free media. After 24 hours, the cells were treated with serial 
dilutions of sample compounds or vehicle control and incubated for 4 hours. After 
treatment with tert-butyl hydroperoxide or vehicle control the cells were incubated for 
an additional 4 hours. The cells were washed twice with serum free media and incubated 
for 18 hours. The cells were then treated with 10 µL of CellTiter 96® AQueous One 
Solution Cell Proliferation Assay (MTS) (Promega) and incubated for 4 hours. 
Absorbance was measured using a POLARstar OPTIMA plate reader (BMG Labtech) 
at 492 nm. Data analysis was performed with Microsoft Excel and GraphPad Prism 
V6.0 (IC50 values). 
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7. Conclusions and future work 
A simple, efficient method for the synthesis and purification of resorcinol 
dimers, tetramers and hexamers have been developed and applied to the synthesis of a 
library of compounds. Further halogenation and dehalogenation methods have been 
identified to allow access to a wider variety of derivatives. All methods employed have 
been developed to be scalable and avoid chromatographic purification, allowing easy 
access to the required derivatives. Novel derivatives, in the form of tetramers and 
hexamers with different halogens (not only bromine as before) and a more varied 
number and combination of halogens are now available and more are accessible with 
the methods presented. 
A simplified set of structures, benzophenones, bis-phenols, xanthones and 
xanthenes have been prepared, adding new approaches to the previously described 
literature methods and novel structures. These structures add additional variations on 
the previously evaluated dimers. The absence of a side chain and the cyclic structure of 
xanthones contribute to the extent of the SAR evaluation. 
Among these compounds, tetramers and hexamers, a previously unreported 
class of compounds, and in particular their dehalogenated derivatives, constitute 
interesting starting points for the development of dendrimers. These are a novel class of 
“open resorcinarenes”. The functionalization of these structures have been presented 
with model compounds and tested for the synthesis of an octacalixarene with thirty two 
amines, a proof of concept for future work on DNA binding compounds and transfection 
agents. 
The compounds displayed interesting activities against DPPH and ABTS 
displaying notable activity, especially in scavenging the latter radical. Unfortunately, 
poor results have been obtained in vivo, with only one of the examples tested to date 
showing interesting, concentration dependent protection. On the other hand, a 
synergistic activity with tBuOOH have been identified for one of the derivatives, and 
may be worth further investigation. However, the model used may not be ideal and the 
cytoprotective activity will be further investigated in different cell lines. 
The activity of these compounds against mycobacterial isocitrate lyase is 
currently being investigated through a collaboration with Dr Eva Novotná, from the 
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Faculty of Pharmacy in Hradec Králové (Charles University) and Prof. Ho Ki-Bong 
from Seoul National University.
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